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FSP Section 11,000
Checklists and Illustrative Financial 
Statements for Health Care Organizations
Description
.01 Health care organizations may be classified by sponsorship or legal structure within the following 
broad categories:
Not-for-profit business-oriented: These are essentially self-sustaining from fees charged for goods and 
services. The fees charged by such organizations generally are intended to help the organization 
maintain its self-sustaining status rather than to maximize profits for the owner's benefit. Such 
organizations often are exempt from federal income taxes and may receive contributions of relatively 
small amounts from resource providers that do not expect commensurate or proportionate pecuniary 
returns.
Not-for-profit non-business-oriented: These are voluntary health and welfare organizations as defined 
in FASB Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements of Not-for- 
Profit Organizations. Such organizations are within the scope of the AICPA Audit and Accounting 
Guide Not-for-Profit Organizations, rather than that of the Health Care Organizations Guide.
Governmental: Often called public health care entities, the entities are owned and operated by federal, 
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned: These organizations operate as stock corporations, partnerships, or sole 
proprietorships.
.02 Health care organizations include, but are not limited to, the following:
• Clinics, medical group practices, individual practitioners and practice associations, and other ambu­
latory care organizations
• Continuing care retirement communities (CCRCs)
• Health maintenance organizations and similar prepaid health care plans
• Home health agencies
• Hospitals
• Nursing homes that provide skilled, intermediate, and less intensive levels of health care
• Parent companies, holding companies, and other organizations that primarily plan, organize, and 
oversee health care services
Applicability of This Checklist
.03 This checklist, and the illustrative financial statements included herein, follow the guidance con­
tained in the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of 
May 1, 2005), referred to as "the Guide." The checklist and illustrative financial statements should be used 
for not-for-profit business-oriented and investor-owned health care organizations. Not-for-profit health care
FSP §11,000.03
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providers that receive federal financial assistance may be required to have an audit conducted in accordance 
with Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and 
Non-Profit Organizations. FSP section 11,300 includes guidance for auditors' reports for audits performed 
under OMB Circular A-133.
.04 Although the Guide also applies to state and local government-owned health care providers, this 
checklist does not include disclosures or sample financial statements of government-owned providers. Chapter 
1 of the Guide discusses the application of generally accepted accounting principles (GAAP) to governmental 
health care providers.
.05 In addition, this checklist does not apply to not-for-profit non-business-oriented health care organiza­
tions. For these types of organizations, follow the guidance in the AICPA Audit and Accounting Guide 
Not-for-Profit Organizations, and the AICPA's disclosure checklist entitled Not-for-Profit Organizations.
Legislation and Regulation
.06 Significant aspects of health care organization operations are affected by government legislation and 
regulation with many states adopting laws governing the granting of licenses, as well as scope of services to 
be rendered. In addition, many independent organizations and governmental agencies, including Medicare 
and Medicaid, evaluate programs and services of health care organizations to determine compliance with 
set standards.
Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented organizations and investor-owned health 
care enterprises generally is consistent except for transactions that clearly are not applicable. For example, 
not-for-profit business-oriented organizations, by their nature, do not have shareholders' equity. On the 
other hand, investor-owned health care enterprises typically do not receive contributions. Throughout this 
checklist, disclosure/presentation questions are preceded by certain symbols. Not-for-profit business- 
oriented organizations should complete all disclosure items denoted with a star (★). Investor-owned health 
care enterprises should complete all disclosure items denoted with a diamond (♦).
.08 The basic financial statements of health care providers generally consist of a statement of financial 
position or balance sheet, a statement of activities or income statement or statement of operations, a statement 
of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The titles 
of the financial statements will depend upon the business form of the provider (i.e., not-for-profit, investor- 
owned, etc.). See the chart below.
Basic Financial Statements
Not-for-Profit 
Business-Oriented Organization Investor-Owned Organization
Balance Sheet/Statement of Financial Position Balance Sheet
Statement of Operations/Statement of Activities Statement of Operations/Income Statement
Statement of Changes in Net Assets* Statement of Changes in Equity*
Statement of Cash Flows Statement of Cash Flows
May be combined with the Statement of Operations.
Note: This publication was extracted from sections 11,000 through 11,500 of the AICPA Financial Statement 
Preparation Manual (FSP).
FSP §11,000.04
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FSP Section 11,100
Instructions
Purpose
.01 The checklists and illustrative financial statements included in this section have been developed by 
the staff of the Accounting and Auditing Publications Team of the AICPA as nonauthoritative technical 
practice aids to be used as a memory jogger to aid in the audit of financial statements of health care 
organizations. They have not been reviewed, approved, disapproved, or otherwise acted on by any senior 
technical committee or the AICPA and do not represent official positions or pronouncements of the AICPA.
The checklists have been updated to include relevant guidance in accounting and auditing 
pronouncements issued through June 30, 2005. This includes pronouncements issued up to 
and including the following:
• Financial Accounting Standards Board (FASB) Statement of Financial Accounting 
Standards (SFAS) No. 154, Accounting Changes and Error Corrections—a replacement of APB 
Opinion No. 20 and FASB Statement No. 3, and revised FASB Statements issued through 
June 30, 2005, including
• SFAS 123 (revised 2004), Share-Based Payment
• FASB Interpretation (FASBI) No. 47, Accounting for Conditional Asset Retirement 
Obligations—an interpretation of FASB Statement No. 143
• FASB Technical Bulletin (FTB) No. 01-1, Effective Date for Certain Financial Institutions of 
Certain Provisions of Statement 140 Related to the Isolation of Transferred Financial Assets
• FASB Emerging Issues Task Force (EITF) consensuses adopted through the June 2005 
EITF meeting
• FASB Staff Positions (FSP) issued through June 30, 2005
• AICPA Statement on Auditing Standards (SAS) No. 101, Auditing Fair Value Measurements 
and Disclosures
• AICPA Statement of Position (SOP) 04-2, Accounting for Real Estate Time-Sharing Transactions
• AICPA Practice Bulletin (PB) No. 15, Accounting by the Issuer of Surplus Notes
• AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes 
as of May 1, 2005)
• Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 3, 
Audit Documentation—And Amendment to Interim Auditing Standards
The checklists and illustrative financial statements should be modified, as appropriate, for 
subsequent pronouncements. In determining the applicability of a pronouncement, its 
effective date should also be considered.
Instructions
.02 The checklists consist of a number of questions or statements that are accompanied by references to 
the applicable authoritative pronouncements. The checklists provide for checking off or initialing each 
question or point to show that it has been considered. Users should check: "yes" if the disclosure has been 
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appropriately made, "no" if the disclosure has not been made, or "n/a" if the disclosure is not applicable to 
the organization. The auditor should consider the effect of a "no" answer on his/her report. A "no" answer 
that is material to the financial statements may warrant a departure from an unqualified opinion. (See 
paragraphs 20-63 of SAS No. 58, Reports on Audited Financial Statements, as amended [AICPA, Professional 
Standards, vol. 1, AU sec. 508.20-.63].) If a "no" answer is checked, the authors recommend that a note be 
made in the right margin to explain why the disclosure was not made (for example, if the disclosure was not 
made because it was not material to the financial statements, write "not material" in the right margin). The 
right margin may be used for other remarks or comments as appropriate, including cross-referencing to 
applicable workpapers where the support to a disclosure may be found. Use of the checklists requires the 
exercise of individual professional judgment and may likely require some modification based on the 
circumstances of individual engagements.
.03 This checklist is applicable to not-for-profit business-oriented and investor-owned health care organiza­
tions. While financial reporting for these types of organizations is generally consistent, there are requirements 
that apply to only not-for-profit business-oriented organizations and those that apply to only investor-owned 
enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements 
to these types of organizations. Not-for-profit business-oriented organizations should complete all disclosure 
items denoted with a star (★). Investor-owned organizations should complete all disclosure items denoted 
with a diamond (♦).
.04 The checklist is not a substitute for the authoritative pronouncements. Users of the checklists and 
illustrative financial statements are urged to refer directly to applicable authoritative pronouncements 
when appropriate. The checklists and illustrative financial statements do not include all disclosures and 
presentation items promulgated nor do they represent minimum requirements. Disclosures prescribed 
by pronouncements deemed remote for health care organizations are not included in this document. The 
checklists and illustrative financial statements are "tools" and in no way represent official positions or 
pronouncements of the AICPA.
.05 If you have further questions, call the AICPA Technical Hotline at 1-888-777-7077.
FSP §11,100.03
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FSP Section 11,200
Financial Statements and 
Notes Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid. The checklists and illustrative financial statements do not 
include all disclosures and presentation items required by GAAP; as a result, pronouncements deemed 
unlikely to be encountered in financial statements of health care providers are not included.
.02 Explanation of References:
★ = Disclosure applicable for not-for-profit organizations
♦ = Disclosure applicable for investor-owned organizations
AAG = AICPA Audit and Accounting Guide Health Care Organizations (with conform­
ing changes as of May 1, 2005)
AAG-SLA = AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits 
(with conforming changes as of May 1, 2005)
AC = Reference to section number in FASB Accounting Standards—Current Text
APB = Accounting Principles Board Opinion
ARB = Accounting Research Bulletin
AU = Reference to section number in AICPA Professional Standards (vol. 1)
EITF = FASB Emerging Issues Task Force consensus
FASBI = FASB Interpretation
FSP = FASB Staff Position
SAS = AICPA Statement on Auditing Standards
SFAS = FASB Statement of Financial Accounting Standards
SOP = AICPA Statement of Position
TB = FASB Technical Bulletin
.03 Checklist Questionnaire:
This checklist is organized into the sections listed below. Carefully review the topics listed and consider 
whether they represent potential disclosure items for the health care provider. Place a check mark by the 
topics or sections considered not applicable; these sections need not be completed. For example, if the entity 
does not have any extraordinary items, place a check by "Extraordinary Items" and skip this section when 
completing the checklist.
Place  by 
Sections Not Applicable
• General
A. Titles and References
B. Comparative Financial Statements
C. Consolidated Financial Statements
FSP §11,200.03
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Place    by 
Sections Not Applicable
• Statement of Financial Position/Balance Sheet
A. General
B. Cash and Cash Equivalents
C. Investments
D. Receivables and Loans
E. Beneficial Interests in Assets Held by Others
F. Property and Equipment, and Supplies
G. Deferred Income Tax Assets and Liabilities
H. Intangible Assets and Goodwill
I. Current Liabilities
J. Notes Payable and Other Debt
K. Other Liabilities and Deferred Credits
L. Net Assets/Shareholders' Equity
M. Restricted Resources
• Statement of Activities/Income Statement/Statement of
Operations/Statement of Changes in Net Assets
A. General
B. Revenue
C. Income Taxes
D. Extraordinary Items
E. Unusual or Infrequent Items
F. Advertising Costs
G. Donated or Contributed Services
H. Donated Materials and Facilities
I. Fund Raising
J. Contributions/Pledges
K. Expenses
L. Wills
M. Endowments
N. Earnings Per Share
O. Comprehensive Income
• Statement of Cash Flows
• Other Financial Statement Disclosures
A. Accounting Changes and Error Corrections
B. Accounting Policies
C. Business Combinations
D. Commitments and Contingencies
E. Exit or Disposal Activities
F. Derivative Instruments and Hedging Activities
G. Financial Instruments
H. Nonmonetary Transactions
I. Pension and Other Postretirement Benefit Plans
J. Related Organizations and Economic Dependency
K. Risks and Uncertainties
L. Segment Information
M. Subsequent Events
N. Stock-Based Compensation/Share-Based Payment
O. Transfers of Financial Assets
P. Long-Lived Assets and Disposal Groups to Be Disposed Of
FSP §11,200.03
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Place  by 
Sections Not Applicable
Q. Asset Retirement Obligations _________
R. Impaired Loans _________
S. Impairment of Long-Lived Assets to Be Held and Used _________
T. Lessor Leases _________
U. Lessee Leases _________
• Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees _________
B. Fees Refundable to Residents Only From Reoccupancy
Proceeds of a Contract Holder's Unit _________
C. Nonrefundable Advance Fees _________
D. Obligation to Provide Future Services and Use of Facilities
to Current Residents _________
E. Costs of Acquiring Initial Continuing-Care Contracts _________
F. Other _________
• OMB Circular A-133 Presentation Requirements _________
• Auditors' Reports _________
• Auditors' Reports on Audits Performed in Accordance With Government
Auditing Standards and Circular A-133 Checklist _________
Yes No N/A
General
A. Titles and References
1. Are the financial statements suitably titled? ____  ____  ____
[SFAS 62, par. 7 (AU 623.07); AAG, par. 1.05, fn. 3]
2. Does each statement include a general reference that the notes are an
integral part of the financial statement presentation? ____  ____  ____
[Generally Accepted]
★♦3. Do the basic financial statements of the health care organization 
include:
a. Statement of financial position (balance sheet)? ____  ____  ____
b. Statement of activities (statement of operations/income statement)? ____  ____  ____
c. Statement of cash flows? ____  ____  ____
d. Statement of changes in net assets (equity)? (Note: This statement
may be combined with the statement of activities.) ____  ____  ____
e. Notes to the financial statements? ____  ____  ____
[SFAS 117, pars. 1 and 6 (AC No5.104); AAG, par. 1.05]
B. Comparative Financial Statements
1. Has presentation of comparative statements been considered? ____  ____  ____
[SFAS 117, par. 69; ARB 43, Ch. 2A, pars. 1 and 2 (AC F43.101 and
.102)]
2. If comparative statements are presented, are the notes and other dis­
closures included in the financial statements of the preceding year(s) 
FSP §11,200.03
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repeated, or at least referred to, to the extent that they continue to be 
of significance?
[ARB 43, Ch. 2A, par. 2 (AC F43.102)]
3. If changes occurred in the manner of or basis for presenting corre­
sponding items for two or more periods, are appropriate explanations 
of the changes disclosed?
[ARB 43, Ch. 2A, par. 3 (AC F43.103)]
C. Consolidated Financial Statements
Yes No N/A
Note: EITF 97-2, Application of FASB Statement No. 94 and APB Opinion No.
16 to Physician Practice Management Entities and Certain Other Entities with 
Contractual Management Arrangements, provides guidance to assist physi­
cian practice management companies (PPMs) in applying SFAS 94 when 
PPMs acquire a physician practice.
★ ♦ 1. If the provider and another entity are related and they meet the criteria 
for consolidation, are consolidated financial statements presented? 
[AAG, pars. 11.10 and 11.11; ARB 51, as amended (AC C51); SFAS 94 
(AC C51)]
★♦2. If consolidated statements are presented:
a. Is the consolidation policy disclosed?
[ARB 51, par. 5 (AC C51.108); APB 22, par. 13 (AC A10.106)]
b. When the financial reporting periods of consolidated entities dif­
fer, is recognition given, by disclosure or otherwise, to the effect 
of intervening events that materially affect financial position or 
results of operations?
[ARB 51, par. 4 (AC C51.107)] J
Note: FASBI 46 (revised December 2003), Consolidation of Variable Interest 
Entities, an interpretation of ARB No. 51, replaces FASBI 46, Consolidation 
of Variable Interest Entities. FASBI 46 (revised December 2003) contains 
scope exceptions that should be considered in determining whether its 
provisions apply to a particular entity. FSP FIN 46-1, Applicability of FASB 
Interpretation No. 46, Consolidation of Variable Interest Entities, to Entities 
Subject to the AICPA Audit and Accounting Guide, Health Care Organiza­
tions, has been incorporated into the scope exceptions in paragraph 4(a) 
of FASBI 46 (revised December 2003). Special provisions apply to enter­
prises that have fully or partially applied FASBI 46 prior to issuance of 
FASBI 46 (revised December 2003). Refer to FASBI 46 (revised December 
2003) for effective date information.
♦ 3. Does the primary beneficiary of a variable interest entity disclose the 
following (unless the primary beneficiary also holds a majority voting 
interest):
a. The nature, purpose, size, and activities of the variable interest 
entity?
b. The carrying amount and classification of consolidated assets that 
are collateral for the variable interest entity's obligations?
c. Lack of recourse if creditors (or beneficial interest holders) of a 
consolidated variable interest entity have no recourse to the gen­
eral credit of the primary beneficiary?
[FASBI 46(R), par. 2 (AC C54.123)]
FSP §11,200.03
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Yes No N/A
♦ 4. Does an enterprise that holds a significant variable interest in a
variable interest entity but is not the primary beneficiary disclose:
a. The nature of its involvement with the variable interest entity and 
when that involvement began?
b. The nature, purpose, size, and activities of the variable interest 
entity?
c. The enterprise's maximum exposure to loss as a result of its 
involvement with the variable interest entity?
[FASBI 46(R), par. 24 (AC C54.124)]
♦ 5. Are the disclosures in paragraph 24 of FASBI 46(R) provided if a
reporting enterprise is not the primary beneficiary but holds a signifi­
cant implicit variable interest in a variable interest entity?
[FSP FIN 46(R)-5, par. 6 (AC C54.823)]
Note: FSP FIN 46(R)-5 shall be applied in the first reporting period 
beginning after March 3, 2005 for entities to which FASBI 46(R) has been 
applied. For entities to which FASBI 46(R) has not been applied, FSP FIN 
46(R)-5 is applied according to the effective date and transition provisions 
in FASBI 46(R).
[FSP FIN 46(R)-5, par. 7 (AC C54.824)]
♦ 6. Are disclosures required by SFAS 140 about a variable interest entity
included in the same note to the financial statements as the informa­
tion required by FASBI 46 (revised December 2003)?
[FASBI 46(R), par. 25 (AC C54.125)]
♦ 7. If an entity does not apply FASBI 46 (revised December 2003) to one
or more variable interest entities or potential variable interest entities 
because of the condition described in paragraph 4(g) of FASBI 46 
(revised December 2003), is the following information disclosed:
a. The number of entities to which that Interpretation is not being 
applied and the reason why the information required to apply that 
Interpretation is not available?
b. The nature, purpose, size (if available), and activities of the en- 
tity(ies) and the nature of the enterprise's involvement with the 
entity(ies)?
c. The reporting enterprise's maximum exposure to loss because of 
its involvement with the entity(ies)?
d. The amount of income, expense, purchases, sales, or other meas­
ure of activity between the reporting enterprise and the entity(ies) 
for all periods presented? (However, if it is not practicable to 
present that information for prior periods that are presented in the 
first set of financial statements for which this requirement applies, 
the information for those prior periods is not required.) 
[FASBI 46(R), par. 26 (AC C54.126)]
♦ 8. If it is reasonably possible that an enterprise will initially consolidate
or disclose information about a variable interest entity when FASBI 
46 (revised December 2003) becomes effective, does the enterprise 
disclose the following information in all financial statements initially 
issued after December 31, 2003, regardless of the date on which the 
variable interest entity was created:
FSP §11,200.03
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N/AYes No
a. The nature, purpose, size, and activities of the variable interest
entity? ____ ___
b. The enterprise's maximum exposure to loss as a result of its
involvement with the variable interest entity? ____  ___
[FASBI 46(R), par. 271
♦ 9. Is the effect of applying FASBI 46 (revised December 2003) to an entity
to which FASBI 46 had previously been applied reported as the
cumulative effect of an accounting change? ____  ___
[FASBI 46(R), par. 39]
Note: SFAS 154, Accounting Changes and Error Corrections, which super­
sedes APB 20, is effective for accounting changes made in fiscal years 
beginning after December 15, 2005. SFAS 154 does not change the transi­
tion provisions of any existing accounting pronouncements, including 
those in a transition phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]
♦ 10. Is the excess, if any, of (a) the fair value of the newly consolidated
assets and (b) the reported amount of assets transferred by the primary 
beneficiary to the variable interest entity over the sum of (1) the fair 
value of the consideration paid, (2) the reported amount of any 
previously held interests, and (3) the fair value of the newly consoli­
dated liabilities and noncontrolling interests allocated and reported 
as a pro rata adjustment of the amounts that would have been as­
signed to all of the newly consolidated assets as specified in para­
graphs 44 and 45 of SFAS 141, as if the initial consolidation had 
resulted from a business combination?
[FASBI 46(R), par. 21 (AC C54.121)]
♦ 11. Is the excess, if any, of the sum of (a) the fair value of the consideration
paid, (b) the reported amount of any previously held interests, and (c) 
the fair value of the newly consolidated liabilities and noncontrolling 
interests over (1) the fair value of the newly consolidated identifiable 
assets and (2) the reported amount of identifiable assets transferred 
by the primary beneficiary to the variable interest entity reported in 
the period in which the enterprise becomes the primary beneficiary 
as:
a. Goodwill, if the variable interest entity is a business?
b. An extraordinary loss, if the variable interest entity is not a busi­
ness?
[FASBI 46(R), par. 21 (AC C54.121)]
★♦ 12. For limited partnerships or similar entities in the scope of EITF 04-5, 
Determining Whether a General Partner, or the General Partners as a Group, 
Controls a Limited Partnership or Similar Entity When the Limited Partners 
Have Certain Rights, and if the guidance in EITF 04-5 is in effect or is 
applied:
a. If Transition Method A is used, (1) are prior year financial state­
ments presented as previously reported; (2) is any cumulative 
effect of adoption on retained earnings (or other appropriate 
components of equity or net assets) at the beginning of the period 
that the guidance is first applied, included in the opening balance 
of retained earnings (or other appropriate components of equity 
or net assets) in the period of change; (3) if early adoption in an
FSP §11,200.03
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Yes No N/A
interim period is elected, are the provisions of SFAS 3 applied, 
except a cumulative-effect-type adjustment is recognized in begin­
ning retained earnings (or other appropriate component of equity 
or net assets); and (4) is the effect of adoption on the opening 
balance sheet disclosed in the year of adoption?
b. If Transition Method B is used, is the guidance applied by retro­
spective application and are the disclosures required by para­
graph 17 of SFAS 154 presented?
[EITF 04-5, pars. 22-26]
Statement of Financial Position/Balance Sheet
A. General
★♦1. For classified statements of financial position/balance sheets, are 
assets and liabilities segregated into current and noncurrent classifi­
cations, with totals presented for current assets and current liabilities? ____
[ARB 43, Ch. 3A, pars. 2-8 (AC B05.103-.109); SFAS 78, pars. 5 and 13 
(AC B05.102-.109B); SFAS 6, par. 15 (AC B05.118); FASBI 8, par. 3 (AC 
B05.117); TB 79-3, par. 2 (AC B05.501-.503); SFAS 117, par. 12 (AC 
No5.110)]
2. Are assets not expected to be realized during the current operating 
cycle classified as noncurrent? ____
[ARB 43, Ch. 3A, pars. 5 and 6 (AC B05.106 and .107)]
★ 3. Does the statement of financial position/balance sheet report total
assets, liabilities, and net assets as well as separate amounts for each 
of three classes of net assets with captions used to describe their 
meaning as explained in SFAS 117? ____
[SFAS 117, pars. 10, 13, and 100 (AC No5.108, .111, and .131, fn. a)]
★ 4. Does the entity provide information about liquidity by one or more
of the following presentations:
a. Sequencing assets according to their nearness of conversion to
cash and sequencing liabilities according to the nearness of their 
maturity and resulting use of cash? ____
b. Classifying assets and liabilities as current and noncurrent? ____
c. Disclosing in notes to financial statements relevant information
about the liquidity or maturity of assets and liabilities, including 
restrictions on the use of particular assets? ____
[SFAS 117, par. 12 (AC No5.110)]
5. Are valuation allowances for assets shown as deductions from their 
related assets with appropriate disclosure? ____
[APB 12, par. 3 (AC V18.102)]
★♦6. Is the need for disclosure of the impact of a new FASB Statement, 
issued but not yet effective where restatement of prior periods is 
required, considered? ____
[SAS 1, secs. 9410.13-.18 (AU 9410.13-.18)]
B. Cash and Cash Equivalents
★♦1. Is restricted cash appropriately segregated from cash available for 
current operations? ____
[ARB 43, Ch. 3A, par. 6 (AC B05.107); AAG, par. 3.01]
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Yes No N/A
2. Are restrictions on cash (such as for plant acquisition, debt reduction 
or working capital maintenance) appropriately disclosed?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
3. Are personal funds of patients, residents and others under an agency 
arrangement reported as unrestricted assets and corresponding li­
abilities in the balance sheet/statement of financial position? 
[AAG, par. 3.02]
★♦4. If a concentration of credit risk arises from deposits in excess of 
federally insured limits, is it disclosed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A); AAG, 
par. 3.04]
5. If the organization has material bank overdrafts or a material balance 
of undelivered checks as of the statement-of-financial-position/ 
balance-sheet date, are:
a. Bank overdrafts presented as a separate caption within current 
liabilities?
b. Undelivered checks classified as accounts payable? 
[Generally Accepted]
6. Are internally designated funds reported separately from externally 
designated funds?
[AAG, par. 3.01]
C. Investments
1. Are investments reported as current or noncurrent assets in conform­
ity with GAAP?
[AAG, par. 4.16]
★♦2. Are the appropriate disclosures made for investments in common 
stock accounted for by the equity method?
[APB 18, par. 20 (AC I82.110)]
3. Are other investments (such as reed estate) reported at amortized cost, 
(subject to impairment considerations consistent with SFAS 144, Ac­
counting for the Impairment or Disposal of Long-Lived Assets)? 
[AAG, par. 4.02]
♦ 4. Are debt and equity securities classified as (a) held-to-maturity, (b)
available-for-sale, or (c) trading?
[SFAS 115, par. 6 (AC I80.103)]
♦ 5. For securities classified as available-for-sale, has the reporting entity
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value?
b. Total gains for securities with net gains in accumulated other 
comprehensive income?
c. Total losses for securities with net losses in accumulated other 
comprehensive income?
[SFAS 115, par. 19 (AC I80.118)]
♦ 6. For securities classified as held-to-maturity, has the reporting entity
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
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a. Aggregate fair value?
b. Gross unrecognized holding gains or losses?
c. Net carrying amount?
d. Gross gains and losses in accumulated other comprehensive in­
come for any derivatives that hedged the forecasted acquisition of 
the held-to-maturity securities?
[SFAS 115, par. 19 (AC I80.118)]
♦ 7. For investments in debt securities classified as available-for-sale or
held-to-maturity:
a. Is disclosure made about their contractual maturities as of the date 
of the latest balance sheet presented (maturity information may be 
combined in appropriate groupings)?
b. If securities not due at a single date (such as mortgage-backed 
securities) are allocated over several maturity groupings, is the 
basis for allocation disclosed?
[SFAS 115, par. 20 (AC I80.119)]
♦ 8. For each period for which an income statement is presented, are the
following disclosed:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses that have been included in earnings as a 
result of those sales?
b. The basis on which the cost of a security sold or the amount 
reclassified out of accumulated other comprehensive income into 
earnings was determined (i.e., specified identification, average 
cost, or other method used)?
c. The gross gains and losses included in earnings from transfers of 
securities from the available-for-sale category to the trading category?
d. The amount of the net unrealized holding gain or loss on available- 
for-sale securities for the period that has been included in accumu­
lated other comprehensive income and the amount of gains and 
losses reclassified out of accumulated other comprehensive in­
come into earnings for the period?
e. The portion of trading gains and losses for the period that relates 
to trading securities still held at the reporting date?
[SFAS 115, par. 21 (AC I80.120)]
♦ 9. For any sales of or transfers from securities classified as held-to-
maturity, are the following disclosed for each period for which an 
earnings statement is presented:
a. Net carrying amount of the sold or transferred security?
b. The net gain or loss in accumulated other comprehensive income 
for any derivative that hedged the forecasted acquisition of the 
held-to-maturity security?
c. Related realized or unrealized gain or loss?
d. The circumstances leading to the decision to sell or transfer the 
security?
[SFAS 115, par. 22 (AC I80.121)]
♦ 10. If an option that is not a derivative subject to SFAS 133 (to purchase
securities that will be accounted for under SFAS 115) is classified as 
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held-to-maturity or available-for-sale, is the accounting policy for the 
premium paid to acquire the option disclosed?
[EITF 96-11]
★♦ 11. For financial instruments, are significant concentrations of credit risk 
arising from concentrations of securities of a particular issuer dis­
closed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A)]
★ 12. Are realized gains and losses; unrealized gains and losses; dividend,
interest, and other similar investment income; and other than tempo­
rary impairment losses reported in the statement of activities as 
increases or decreases in unrestricted net assets or in temporarily 
restricted net assets or in permanently restricted net assets, depending 
on the existence of or lack of donor restrictions or law?
[SFAS 124, pars. 8 and 9 (AC No5.154 and .155); AAG, pars. 4.07 and 
4.08]
★ 13. Are realized gains and losses; dividend, interest and other similar invest­
ment income; and other than temporary impairment losses included in 
the performance indicator within the statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 14. Are unrealized gains and losses on trading securities (as defined in
SFAS 115) included in the performance indicator within the statement 
of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 15. Are unrealized gains and losses on other than trading securities
excluded from the performance indicator within the statement of 
activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 16. If a provider reports gains and investment income that are limited to
specific uses by donor-imposed restrictions as increases in unre­
stricted net assets because the restrictions are met in the same report­
ing period as the gains and income are recognized, does the provider:
a. Have a similar policy for reporting contributions received?
b. Report consistently from period to period?
c. Disclose its accounting policy?
[SFAS 124, par. 10 (AC No5.156); AAG, par. 4.09]
★ 17. For each period that a statement of activities is presented, are the
following disclosures made on the face of the financial statements or 
in the notes thereto:
a. The composition of investment return including, at a minimum, 
investment income, net realized gains or losses on investments 
reported at other than fair value, and net gains or losses on 
investments reported at fair value?
b. A reconciliation of investment return to amounts reported in the 
statement of activities, if investment return is separated into oper­
ating and nonoperating amounts?
c. A description of the policy used to determine the amount of invest­
ment return included in the measure of operations, if investment 
return is separated into operating and nonoperating amounts?
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d. A discussion of circumstances leading to a change, if any, in the 
policy referred to in Question 17c above? ____  ___
[SFAS 124, par. 14 (AC No5.161); AAG, par. 4.11]
★ 18. For each period for which a statement of financial position is pre­
sented, are the following disclosures made on the face of the financial 
statements or in the notes thereto:
a. The aggregate carrying amount of investments by major types
(e.g., equity securities, corporate debt securities, etc.)? ____  ___
b. The basis for determining the carrying amount for investments 
other than equity securities with readily determinable fair values
and all debt securities? ____  ___
c. The methods and assumptions used to estimate the fair values of
investments other than financial instruments, if those other invest­
ments are reported at fair value? ____  ___
d. The aggregate amount of the deficiencies for all donor-restricted 
endowment funds, for which the fair value of the assets at the 
reporting date is less than the level required by donor stipulations
or law? ____  ___
[SFAS 124, par. 15 (AC No5.162); AAG, par. 4.11]
★ 19. For the most recent period for which a statement of financial position
is presented, does the provider disclose the nature of and carrying 
amount for every individual investment or group of investments that 
represents a significant concentration of market risk (market risk may 
result from the nature of the investments, a lack of diversity of 
industry, currency, or geographic location)? ____  ___
[SFAS 124, pars. 16 and 86 (AC No5.163); AAG, par. 4.11]
20. Are significant net realized and net unrealized gains and losses that 
arose after the latest statement of financial position date, but before 
issuance of the financial statements, disclosed? ____  ___
[SAS 1, sec. 560, pars. 5 and 7 (AU 560.05 and .07)]
Note: EITF 03-1, The Meaning of Other-Than-Temporary Impairment and Its 
Application to Certain Investments, requires certain disclosures about unre­
alized losses that have not been recognized as other-than-temporary 
impairments. EITF 03-1 applies to debt and equity securities within the 
scope of SFAS 115, Accounting for Certain Investments in Debt and Equity 
Securities, and SFAS 124, Accounting for Certain Investments Held by Not-for- 
Profit Organizations (applicable to investments held by a not-for-profit 
health care organization in the scope of AAG). See EITF 03-1 for further 
information regarding investments within the scope of this Issue.
★♦21. For all investments in an unrealized loss position for which other- 
than-temporary impairments have not been recognized, do the an­
nual financial statements disclose:
a. Quantitative information as of each date for which a statement of 
financial position presented aggregated by each category of in­
vestment that the investor discloses in accordance with SFAS 115 
and SFAS 124 and cost method investments, in tabular form:
(1) The aggregate amount of unrealized losses (that is, the 
amount by which cost or amortized cost exceeds fair value), 
segregated by those investments that have been in a continu­
ous unrealized loss position for less than 12 months and those
FSP §11,200.03
16 Health Care Organizations
Yes No N/A
that have been in a continuous unrealized loss position for 12 
months or longer? ____  ____ ____
(2) The aggregate related fair value of investments with unreal­
ized losses, segregated by those investments that have been 
in a continuous unrealized loss position for less than 12 
months and those that have been in a continuous unrealized 
loss position for 12 months or longer? ____  ____  ____
b. Additional information in narrative form, as of the date of the most 
recent statement of financial position, that provides sufficient 
information to allow financial statement users to understand the 
quantitative disclosures and the information that the investor 
considered in reaching the conclusion that the impairments were 
not other than temporary? ____  ____  ____
[EITF 03-1, par. 21]
22. For cost method investments, is the following additional information 
disclosed in annual financial statements, if applicable, as of each date 
for which a statement of financial position is presented:
a. The aggregate carrying amount of all cost method investments? ____  ____  ____
b. The aggregate carrying amount of cost method investments that
the investor did not evaluate for impairment? ____  ____  ____
c. The fact that the fair value of a cost method investment is not 
estimated if there are no identified events or changes in circum­
stances that may have a significant adverse effect on the fair value 
of the investment and (1) the investor determined, in accordance 
with paragraphs 14 and 15 of SFAS 107 that it is not practicable to 
estimate the fair value of the investment, or (2) the investor is
exempt from estimating fair value under SFAS 126? ____  ____ ____
[EITF 03-1, par. 22]
D. Receivables and Loans
1. Are charity care revenue and receivables excluded from the financial 
statements? ____  ____  ____
[AAG, par. 5.03]
★♦2. Are differences between the estimates originally reported and sub­
sequent revisions, including final settlements:
a. Included in the statement of activities/income statement in the
period the revisions are made and disclosed, if material? ____  ____  ____
b. Reported in the current period unless they meet the criteria for
prior-period adjustments? ____  ____  ____
[AAG, par. 5.08; SFAS 16 (AC A35)]
3. Are amounts due from third-party payors for retroactive adjustments 
of items (such as final settlements or appeals) reported separately in 
the financial statements? ____  ____  ____
[AAG, par. 5.21]
★ 4. When displaying total assets and total liabilities, are interfund assets
and liabilities eliminated?1 ____  ____ ____
1 The display of interfund items in a statement of financial position is not prohibited by SFAS 117. However, since interfund items are 
not organizational assets or liabilities, those interfund items must be clearly labeled and arranged in the statement of financial position 
to eliminate their amounts when total assets and liabilities are displayed. [SFAS 117, par. 85, fn. 8 (AC No5.109, fn. 4)]
[AAG, par. 5.27] 1
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Note: Accounting for contributions is an issue primarily for not-for-profit 
organizations because contributions are a significant source of revenues 
for many of those organizations. However, SFAS 116 applies to all entities 
(not-for-profit and business enterprises) that receive or make contribu­
tions. [SFAS 116, par. 1 (AC C67.101)]
★ 5. Do entities that receive unconditional promises to give disclose the
following:
a. The amounts of promises receivable in less than one year, in one 
to five years, and in more than five years?
b. The amount of any allowance for uncollectible promises receivable? 
[SFAS 116, par. 24 (AC C67.121)]
★ 6. Do entities that receive conditional promises to give disclose the
following:
a. The total of the amounts promised?
b. A description and amount for each group of promises having 
similar characteristics (such as amount of promises conditioned 
on establishing new programs, completing a new building, and 
raising matching gifts by a specified date)?
[SFAS 116, par. 25 (AC C67.122)]
7. Are all receivables reported net of any related allowance for uncol­
lectible amounts, with appropriate disclosure?
[AAG, par. 5.21; APB 12, par. 3 (AC V18.102)]
★♦8. Are accounts and notes receivable from officers, employees, and 
affiliated organizations shown separately with appropriate disclosures? 
[ARB 43, Ch. 1A, par. 5 (AC R36.105)]
9. For financial instruments, are significant concentrations of credit risk 
arising from receivables disclosed?
[SFAS 107, as amended by SFAS 133, par. 531 (AC F25.116A)]
10. Are unearned discounts (other than cash or quantity discounts and 
the like), finance charges, and interest included in the face amounts of 
receivables shown as a deduction from the related receivables? 
[APB 6, par. 14 (AC B05.107A, note 3)]
★♦11. Does the summary of significant accounting policies include the 
following disclosures:
a. The basis of accounting for loans, trade receivables, and lease 
financings, including those classified as held for sale?
b. The method of determining the lower of cost or fair value of 
nonmortgage loans held for sale (that is, aggregate or individual 
asset basis)?
c. The classification and method of accounting for loans and other 
receivables that can be contractually prepaid or otherwise settled 
in a way that the holder would not recover substantially all of its 
recorded investment (applies to instruments within the scope of 
paragraph 14 of SFAS 140)?
d. The method for recognizing interest income on loan and trade 
receivables, including a statement about the entity's policy for 
treatment of related fees and costs, including the method of amor­
tizing net deferred fees or costs?
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e. A description of the accounting policies and methodology the 
entity used to estimate its allowance for loan losses, allowance for 
doubtful accounts, and any liability for off-balance sheet credit 
losses and related charges for loan, trade receivable or other credit 
losses, including a description of the factors that influenced man­
agement's judgment?
f. The policy for placing loans (and trade receivables if applicable) 
on nonaccrual status (or discontinuing accrual of interest) and 
recording payments received on nonaccrual loans (and trade re­
ceivables if applicable), and the policy for resuming accrual of 
interest?
g. The policy for charging off uncollectible loans and trade receiv­
ables?
h. The policy for determining past due or delinquency status (that is, 
whether past due status is based on how recently payments have 
been received or contractual terms?
[SOP 01-6, par. 13(a)-(c)]
12. Is the aggregate amount of gains or losses on sales of loans or trade 
receivables presented separately in the financial statements or dis­
closed in the notes?
[SOP 01-6, par. 13(d)]
13. Are loans and trade receivables held for sale presented as a separate 
balance sheet category?
[SOP 01-6, par. 13(e)]
14. Are major categories of loans and trade receivables presented sepa­
rately in the balance sheet or in the notes to the financial statements? 
[SOP 01-6, par. 13(e)]
15. Are the allowances for credit losses and doubtful accounts disclosed? 
[SOP 01-6, par. 13(e)]
16. Is the recorded investment in loans (and trade receivables, if applica­
ble), on nonaccrual status as of each balance-sheet date disclosed in 
the notes to the financial statements? (The recorded investment in 
loans, and if applicable, trade receivables, past due ninety days or 
more and still accruing should also be disclosed.)
[SOP 01-6, par. 13(g)]
17. Is the carrying amount of loans and trade receivables that serve as 
collateral for borrowings disclosed pursuant to paragraphs 18 and 19 
of SFAS 5?
[SOP 01-6, par. 13(i)]
18. Is a description of the accounting policies and methodology used to 
estimate the allowance for doubtful accounts, allowance for loan 
losses and any liability for off-balance-sheet credit losses and related 
charges for loan, trade receivable or other credit losses included in the 
notes to the financial statements? (Note: Such description should 
identify the factors that influenced management's judgment.) 
[SOP 01-6, par. 13(b)]
Note: SOP 03-3, Accounting for Certain Loans or Debt Securities Acquired in 
a Transfer, is effective for loans acquired in fiscal years beginning after 
December 15, 2004. Early application is encouraged.
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19. Do the notes to the financial statements describe how prepayments 
are considered in the determination of contractual cash flows and cash 
flows expected to be collected?
[SOP 03-3, par. 14]
20. Is information about loans meeting the scope criteria of paragraph 3 
of SOP 03-3 included in the disclosures required by paragraphs 20(a) 
and 20(b) of SFAS 114 if the condition in paragraph 16 of SFAS 115 or 
paragraph 8(a) of SFAS 5 is met?
[SOP 03-3, par. 15]
21. In addition to disclosures required by other GAAP principles, for each 
balance sheet presented, is the following information disclosed by an 
investor about loans within the scope of SOP 03-3:
a. Separately for both those loans that are accounted for as debt 
securities and those loans that are not accounted for as debt 
securities:
(1) The outstanding balance and the related carrying amount at 
the beginning and end of the period?
(2) The amount of accretable yield at the beginning and end of 
the period, reconciled for additions, accretion, disposal of 
loans, and reclassifications to or from nonaccretable differ­
ence during the period?
(3) For loans acquired during the period, the contractually re­
quired payments receivable, cash flows expected to be col­
lected, and fair value at the acquisition date?
(4) For those loans within the scope of SOP 03-3 for which the 
income recognition model in SOP 03-3 is not applied in accord­
ance with paragraph 6 of that SOP, the carrying amount at the 
acquisition date for loans acquired during the period and the 
carrying amount of all loans at the end of the period?
b. Further, for those loans that are not accounted for as debt securi­
ties, does an investor disclose:
(1) The amount of (a) any expense recognized pursuant to para­
graph 8(a) of SOP 03-3 and (b) any reductions of the allowance 
recognized pursuant to paragraph 8(b)(1) of SOP 03-3 for 
each period for which an income statement/statement of 
operations is presented?
(2) The amount of the allowance for uncollectible accounts at the 
beginning and end of the period?
[SOP 03-3, par. 16]
E. Beneficial Interests in Assets Held by Others
★ 1. If the organization transferred assets to another entity and specified 
itself or its affiliate as the beneficiary, has it disclosed the following 
for each period in which a statement of financial position is presented:
a. The identity of the recipient organization to which the transfer was 
made?
b. Whether variance power was granted to the recipient organization 
and, if so, a description of the terms of the variance power?
c. The terms under which amounts will be distributed to the organi­
zation or its affiliate?
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d. The aggregate amount recognized in the statement of financial 
position for those transfers and whether that amount is recorded 
as an interest in the net assets of the recipient organization or as 
another asset (such as a beneficial interest in assets held by others 
or as a refundable advance)?
[SFAS 136, par. 19 (AC No5.177)]
F. Property and Equipment, and Supplies
1. Are donor or legal restrictions on the proceeds from the disposition 
of donated property and equipment (or of property and equipment 
purchased with cash restricted for acquisition of long-lived assets) 
disclosed?
[AAG, par. 6.07]
2. For depreciable assets, do the financial statements or notes disclose:
a. Depreciation expense for each period?
b. Balances of major classes of depreciable assets by nature or function?
c. Accumulated depreciation, either by major classes of assets or in 
total?
d. The method or methods used in computing depreciation with 
respect to major classes of depreciable assets?
[APB 12, par. 5 (AC D40.105)]
3. Is the amount of interest cost incurred and charged to expense during 
the period disclosed for an accounting period in which no interest cost 
is capitalized?
[SFAS 34, par. 21a (AC I67.118)]
★♦4. Is the amount of interest cost incurred during the period and the 
amount that has been capitalized disclosed for an accounting period 
in which some interest cost is capitalized?
[SFAS 34, par. 21b (AC I67.118)]
5. Are material commitments for property expenditures disclosed? 
[SFAS 5, pars. 18 and 19 (AC C59.120)]
★♦6. For an existing property with an asbestos problem, are the costs 
incurred to treat the problem, if charged to expense, not classified as 
an extraordinary item?
[EITF 89-13]
7. Is the method of determining inventory cost disclosed?
[ARB 43, Ch. 3A, par. 9 (AC I78.120)]
Notes: If the provisions of SFAS 151, Inventory Costs, are in effect or are 
applied, see Question 8. SFAS 151, an amendment of ARB 43, Chapter 4, 
is effective for inventory costs incurred during fiscal years beginning after 
June 15, 2005. Early application is permitted for inventory costs incurred 
during fiscal years beginning after the date SFAS 151 was issued (Novem­
ber 2004).
[SFAS 151, par. 5]
SFAS 154, Accounting Changes and Error Corrections, which supersedes APB 
20, is effective for accounting changes made in fiscal years beginning after 
December 15, 2005. SFAS 154 does not change the transition provisions of 
(continued)
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any existing accounting pronouncements, including those in a transition 
phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]
★♦8. Are the disclosures required by paragraph 19(c) of APB 20 made if 
there are significant changes to an entity's inventory accounting as a 
result of adopting SFAS 151?
[SFAS 151, par. 4]
G. Deferred Income Tax Assets and Liabilities
♦ 1. In a classified balance sheet:
a. Are deferred tax assets and deferred tax liabilities classified as 
current or noncurrent based on the classification of the related 
asset or liability for financial reporting?
[SFAS 109, par. 41 (AC I27.140)]
b. Are deferred tax assets or liabilities not related to an asset or 
liability for financial reporting (including those related to carry­
forwards) classified according to the expected reversal date of the 
temporary difference pursuant to SFAS 37?
[SFAS 109, par. 41 (AC I27.140)]
c. Is the valuation allowance for a particular tax jurisdiction allocated 
between current and noncurrent deferred tax assets for that tax 
jurisdiction on a pro rata basis?
[SFAS 109, par. 41 (AC I27.140)]
d. Are the following items offset and presented as a single amount 
for a particular taxpaying component and within a particular 
taxpaying jurisdiction:
(1) All current deferred tax liabilities and assets?
(2) All noncurrent deferred tax liabilities and assets?
[SFAS 109, par. 42 (AC I27.141)]
♦ 2. Are the components of the net deferred tax liability or asset recog­
nized in the balance sheet disclosed as follows:
a. The total of all deferred tax liabilities (measured as described in 
paragraph 17b of SFAS 109)?
b. The total of all deferred tax assets (measured as described in 
paragraph 17c and 17d of SFAS 109)?
c. The total valuation allowance recognized for deferred tax assets 
(determined as described in paragraph 17e of SFAS 109)? 
[SFAS 109, par. 43 (AC I27.142)]
♦ 3. Is the net change during the year in the total valuation allowance
disclosed?
[SFAS 109, par. 43 (AC I27.142)]
♦ 4. If the reporting entity is a public enterprise, is the approximate tax
effect of each type of temporary difference and carryforward that 
gives rise to a significant portion of deferred tax liabilities and de­
ferred tax assets (before valuation allowances) disclosed?
[SFAS 109, par. 43 (AC I27.142)]
♦ 5. If the reporting entity is a nonpublic enterprise, are the types of
significant temporary differences and carryforwards disclosed? 
[SFAS 109, par. 43 (AC I27.142)]
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H. Intangible Assets and Goodwill
Note: Questions 1 through 16 apply if the provisions of SFAS 142, Good­
will and Other Intangible Assets, are applied to the financial statements. The 
provisions of SFAS 142 are required to be applied starting with fiscal years 
beginning after December 15, 2001. SFAS 142 is required to be applied at 
the beginning of an entity's fiscal year and to be applied to all goodwill 
and other intangible assets recognized in its financial statements at that 
date. The provisions of SFAS 142 should not be applied to goodwill and 
intangible assets acquired in a combination between not-for-profit organi­
zations or arising from the acquisition of a for-profit business entity by a 
not-for-profit organization until the FASB completes its project on those 
types of combinations. (Refer to paragraphs 48 through 61 of SFAS 142 for 
effective date and transition guidance.) If the provisions of APB 16 and 
APB 17 are applied, see Questions 13 and 14.
★♦1. At a minimum, are all intangible assets aggregated and presented as 
a separate line item in the statement of financial position? (This 
requirement does not preclude presentation of individual intangible 
assets or classes of intangible assets as separate line items.) 
[SFAS 142, par. 42 (AC G40.141)]
2. Are amortization expense and impairment losses for intangible assets 
presented in income statement line items within continuing opera­
tions as deemed appropriate for each entity?
[SFAS 142, par. 42 (AC G40.141)]
♦ 3. Is the aggregate amount of goodwill presented as a separate line item
in the statement of financial position?
[SFAS 142, par. 43 (AC G40.142)]
♦ 4. Is the aggregate amount of goodwill impairment losses presented as
a separate line item in the income statement before the subtotal income 
from continuing operations (or similar caption) unless a goodwill im­
pairment loss is associated with a discontinued operation?
[SFAS 142, par. 43 (AC G40.142)]
♦ 5. Is a goodwill impairment loss associated with a discontinued opera­
tion included (on a net-of-tax basis) within the results of discontinued 
operations?
[SFAS 142, par. 43 (AC G40.142)]
6. For intangible assets acquired either individually or with a group of 
assets, is the following information disclosed in the notes to the 
financial statements in the period of acquisition:
a. For intangible assets subject to amortization:
(1) The total amount assigned and the amount assigned to any 
major intangible asset class?
(2) The amount of any significant residual value, in total and by 
major intangible asset class?
(3) The weighted-average amortization period, in total and by 
major intangible asset class?
b. For intangible assets not subject to amortization, the total amount 
assigned and the amount assigned to any major intangible asset 
class?
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c. The amount of research and development assets acquired and 
written off in the period and the line item in the income statement 
in which the amounts written off are aggregated?
[SFAS 142, par. 44 (AC G40.143)]
7. Has the following information been disclosed in the financial state­
ments or the notes to the financial statements for each period for which 
a statement of financial position is presented:
a. For intangible assets subject to amortization:
(1) The gross carrying amount and accumulated amortization, in 
total and by major intangible asset class?
(2) The aggregate amortization expense for the period?
(3) The estimated aggregate amortization expense for each of the 
five succeeding fiscal years?
b. For intangible assets not subject to amortization, the total carrying 
amount and the carrying amount for each major intangible asset 
class?
♦ c. The changes in the carrying amount of goodwill during the period 
including:
(1) The aggregate amount of goodwill acquired?
(2) The aggregate amount of impairment losses recognized?
(3) The amount of goodwill included in the gain or loss on 
disposal of all or a portion of a reporting unit?
[SFAS 142, par. 44 (AC G40.144)]
♦ 8. If the entity reports segment information in accordance with SFAS
131, is the above information about goodwill provided in total and for 
each reportable segment and are any significant changes in the allo­
cation of goodwill by reportable segment disclosed?
[SFAS 142, par. 45 (AC G40.144)]
♦ 9. If any portion of goodwill has not yet been allocated to a reporting
unit at the date the financial statements are issued, is that unallocated 
amount and the reasons for not allocating that amount disclosed? 
[SFAS 142, par. 45 (AC G40.144)]
10. For each impairment loss recognized related to an intangible asset, is 
the following information disclosed in the notes to the financial 
statements that include the period in which the impairment loss is 
recognized:
a. A description of the impaired intangible asset and the facts and 
circumstances leading to the impairment?
b. The amount of the impairment loss and the method for determin­
ing fair value?
c. The caption in the income statement in which the impairment loss 
is aggregated?
d. If applicable, the segment in which the impaired intangible asset 
is reported under SFAS 131?
[SFAS 142, par. 46 (AC G40.145)]
♦ 11. For each goodwill impairment loss recognized, is the following infor­
mation disclosed in the notes to the financial statements that include 
the period in which the impairment loss is recognized:
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a. A description of the facts and circumstances leading to the impair­
ment?
b. The amount of the impairment loss and the method of determining 
the fair value of the associated reporting unit (whether based on 
quoted market prices, prices of comparable businesses, a present 
value or other valuation technique, or a combination thereof)?
c. If a recognized impairment loss is an estimate that has not yet been 
finalized (refer to SFAS 142, par. 22), that fact and the reasons 
therefore and, in subsequent periods, the nature and amount of 
any significant adjustments made to the initial estimate of the 
impairment loss?
[SFAS 142, par. 47 (AC G40.146)]
♦ 12. Are effects on a goodwill impairment charge resulting from the 
application of EITF 04-1 reported in operating income?
[EITF 04-1, par. 9]
Note: EITF 04-1, Accounting for Preexisting Relationships between the Parties 
to a Business Combination, should be applied to business combinations 
consummated and goodwill impairment tests performed in reporting 
periods beginning after October 13, 2004. Early application permitted in 
periods for which financial statements have not been issued.
[EITF 04-1, pars. 9-101
13. Do disclosures relating to intangible assets include the method and 
period of amortization?
[APB 16, par. 95e (AC B50.164e); APB 17, par. 30 (AC I60.111); APB 
22, par. 13 (AC A10.106)]
★ 14. Do disclosures relating to intangible assets include the reason for any 
unusual reduction of the value and future benefits of intangible assets 
recognized during the period?
[APB 17, par. 31 (AC I60.112)]
I. Current Liabilities
★♦1. For classified balance sheets and classified statements of financial 
position, do current liabilities include:
a. Obligations for items that entered the operating cycle?
b. Collections received in advance of the performance of services?
c. Debts that arise from operations directly related to the operating 
cycle?
d. Other liabilities whose regular and ordinary liquidation is likely 
to occur within a relatively short time period?
e. Obligations that, by their terms, are due on demand or will be due 
within one year (or operating cycle, if longer) from the balance- 
sheet date, even though liquidation may not be expected within 
that period?
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109); SFAS 78, par. 
5 (AC B05.109A)]
2. Do current liabilities exclude short-term obligations that the provider 
intends to refinance on a long-term basis, provided the provider has
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demonstrated the ability to consummate the long-term financing? 
[SFAS 6, pars. 8-14 (AC B05.113-.116); FASBI 8, pars. 2-4 (AC B05.117, 
.138, and .139)]
3. In classified statements of financial position and in classified balance 
sheets, are current portions of debt obligations presented as current 
liabilities?
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109)]
Note: Current liabilities may include notes payable to banks; the current 
portion of long-term debt; accounts payable; advances from and amounts 
payable to third-party payors for estimated and final reimbursement 
settlements; refunds to and deposits from patients and others; deferred 
revenue; accrued salaries and payroll taxes; and other accruals.
[AAG, par. 7.01]
J. Notes Payable and Other Debt
★♦1. Is there adequate disclosure of interest rates, maturities, and other 
terms and conditions provided in loan agreements and bond inden­
tures (such as assets pledged as collateral, and covenants to reduce 
debt, and maintain working capital)?
[SFAS 5, par. 18 (AC C59.120)]
2. Are the combined aggregate amounts of maturities and sinking fund 
requirements for all long-term borrowings disclosed for each of the 
five years following the date of the latest balance sheet presented? 
[SFAS 47, par. 10b (AC C32.105b)]
3. For unconditional purchase obligations that have been recorded in 
accordance with SFAS 47, paragraph 6, is the amount of payments 
due in the aggregate and for every year during the five years following 
the date of the latest statement of financial position/ balance sheet 
presented disclosed?
[SFAS 47, par. 10a (AC C32.105a)]
4. If a note is non-interest-bearing or has an inappropriate stated interest 
rate:
a. Is the discount or premium presented as a deduction from or 
addition to the face amount of the note?
b. Does the disclosure include the effective interest rate and face 
amount of the note?
c. Is amortization of the discount or premium reported as interest?
d. Are issue costs reported in the balance sheet/statement of finan­
cial position as deferred charges?
[APB 21, par. 16 (AC I69.109)]
★♦5. Are debt conversion features (such as rates and pertinent dates) 
disclosed?
[APB 14 (AC D10)]
6. If a short-term obligation is to be excluded from current liabilities in 
a classified balance sheet/statement of financial position, do disclo­
sures include:
a. General description of the financing agreement?
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b. Terms of any new obligation incurred or expected to be incurred, 
or equity securities issued or expected to be issued as a result of 
the refinancing?
[SFAS 6, par. 15 (AC B05.118)]
7. For a troubled debt restructuring occurring during the current period, 
do disclosures include:
a. Description of the principle changes in terms and/or the major 
features of settlement?
b. Aggregate gain on restructuring of payables?
c. Aggregate net gain or loss on transfers of assets recognized during 
the period?
d. Per-share amount, if applicable, of the aggregate gain on restruc­
turing of payables?
[SFAS 15, par. 25, as amended by SFAS 145 (AC D22.121)]
8. For periods after a troubled debt restructuring, do disclosures include:
a. Extent to which amounts contingently payable are included in the 
carrying amount of restructured payables?
b. Total amounts contingently payable, if applicable, and conditions 
under which those amounts would become payable or forgiven? 
[SFAS 15, par. 26 (AC D22.122)]
★♦9. If debt was considered to be extinguished under the provisions of 
SFAS 76 prior to the effective date of SFAS 125, do disclosures include:
a. A general description of the transaction?
b. The amount of debt that is considered extinguished at the end of 
the period as long as the debt remains outstanding?
[SFAS 140, par. 17b (AC L35.109)]
10. If assets are set aside after the effective date of SFAS 125 solely for 
satisfying scheduled payments of a specific obligation, is disclosure 
made describing the nature of restrictions placed on those assets? 
[SFAS 140, par. 17c (AC L35.109)]
Note: SOP 02-2, Accounting for Derivative Instruments and Hedging Activi­
ties by Not-for-Profit Health Care Organizations, and Clarification of the Per­
formance Indicator, addresses the reporting by not-for-profit health care 
organizations of gains or losses on hedging derivative instruments under 
SFAS 133, as amended, and requires that not-for-profit health care organi­
zations apply the provisions of SFAS 133, including the provisions per­
taining to cash flow hedge accounting, in the same manner as for-profit 
enterprises. The provisions of SOP 02-2 are effective for fiscal years 
beginning after June 15, 2003. Earlier application is encouraged but per­
mitted only as of the beginning of any fiscal quarter that begins after 
issuance of SOP 02-2. See paragraphs 10 and 11 of SOP 02-2 for additional 
effect date and transition information.
♦ 11. If the reclassification to earnings of the amount in accumulated com­
prehensive income resulting from a cash flow hedge of debt is re­
quired under SFAS 133 when the debt is extinguished, is the 
reclassified amount not classified as extraordinary?
[EITF 00-9]
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★♦ 12. Are long-term obligations that are or will be callable by the creditor, 
either because the debtor's violation of the debt agreement at the 
balance-sheet/statement-of-financial-position date makes the obliga­
tion callable, or because the violation (if not cured within a specified 
grace period) will make the obligation callable, classified as current 
unless one of the following conditions is met:
a. The creditor waives or subsequently loses the right to demand 
repayment for more than one year (or operating cycle, if longer)
from the balance-sheet date? ____  ___
b. The obligation contains a grace period within which the debtor
may cure the violation and it is probable that the violation will be 
cured within that period, thus preventing the violation from be­
coming callable? ____ ___
[SFAS 78, par. 5 (AC B05.109A)]
13. If an obligation under Question 12b above is included in long-term 
liabilities (or in the case of an unclassified balance sheet is included as 
a long-term liability in the disclosure of debt maturities), are the 
circumstances disclosed? ____  ___
[SFAS 78, par. 5 (AC B05.118); see also EITF 86-301
★ 14. Does the not-for-profit provider report tax-exempt obligations that
were issued for its benefit as liabilities if the provider is responsible 
for repayment? ____  ___
[AAG, par. 7.17]
★♦15. Are disclosures appropriate regarding the provider's tax-exempt 
status and any other significant tax matters? ____  ___
[AAG, par. 7.12]
K. Other Liabilities and Deferred Credits
★♦ 1. If the reporting entity has not accrued compensated absences (SFAS 
43) because the amount cannot be reasonably estimated, is that fact 
disclosed? ____  ___
[SFAS 43, par. 6 (AC C44.104)]
★♦ 2. If an obligation for postemployment benefits is not accrued in accord­
ance with SFAS 5 or SFAS 43 only because the amount cannot be 
reasonably estimated, is the fact that the benefits have not been 
accrued disclosed in the financial statements? ____  ___
[SFAS 112, par. 7 (AC P32.105)]
L. Net Assets/Shareholders' Equity
★ 1. Are the equity accounts of investor-owned providers presented in a
similar fashion as other investor-owned businesses? ____  ___
[AAG, par. 9.01]
★♦ 2. Is the nature of restrictions on donor-restricted resources disclosed? ____ ___
[AAG, par. 9.06]
★ 3. Are limits on the use of unrestricted net assets (such as loan covenants
and board-designated endowments) and information about the na­
ture and amounts of different types of permanent and temporary 
restrictions disclosed? ____  ___
[SFAS 117, par. 16 (AC No5.114); AAG, pars. 9.03 and 9.04]
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★ 4. Are net assets released from restriction, such as those related to the
fufillment of time or purpose restrictions, reported separately in the 
financial statements or disclosed in the notes?
[AAG, par. 10.08]
♦ 5. Shareholders' equity (corporations):
a. For each class of stock, do disclosures include the number of shares 
authorized, issued and outstanding, and par or stated value per 
share and changes therein?
[Generally Accepted]
b. Are classes of capital stock presented in order of priority in liqui­
dation?
[Generally Accepted]
c. Do the financial statements include a description, in summary 
form, sufficient to explain the pertinent rights and privileges of the 
various securities outstanding, (e.g., dividend and liquidation 
preferences, participation rights, call prices and dates, conversion 
or exercise prices or rates and pertinent dates, sinking fund re­
quirements, unusual voting rights, significant terms of contracts 
to issue additional shares)?
[SFAS 129, par. 4 (AC C24.102)]
d. Do disclosures include the number of shares issued upon conver­
sion, exercise, or satisfaction of required conditions during at least 
the most recent annual fiscal period and any subsequent interim 
period presented?
[SFAS 129, par. 5 (AC C24.103)]
e. Are the following disclosed on the face of the statement of financial 
position or in the notes:
(1) The aggregate or per-share amounts at which preferred stock 
may be called or is subject to redemption through sinking- 
fund operations or otherwise?
(2) The aggregate and per-share amounts of arrearages in cumu­
lative preferred dividends?
[SFAS 129, par. 7 (AC C24.105)]
f. For preferred stock that has a preference in involuntary liquida­
tion considerably in excess of par or stated value of the shares, is 
the liquidation preference disclosed? (Note: Disclosure shall be 
made in the equity section of the statement of financial position in 
the aggregate, either parenthetically or "in short," rather than on 
a per-share basis or through disclosure in the notes.)
[SFAS 129, par. 6 (AC C24.104)]
g. For redeemable stock, do disclosures include the amount of re­
demption requirements, separately by issue or combined, for all 
issues of capital stock that are redeemable at fixed or determinable 
prices on fixed or determinable dates in each of the five years follow­
ing the date of the latest statement of financial position presented? 
[SFAS 129, par. 8 (AC C24.106)]
h. Are significant terms of the conversion features of contingently 
convertible securities disclosed to enable users of financial state­
ments to understand the circumstances of the contingency and the 
potential impact of conversion?
[FSP FAS 129-1, par. 3 (AC C24.804)]
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i. Do disclosures indicate whether the shares that would be issued 
if the contingently convertible securities were converted are in­
cluded in the calculation of diluted earnings per share, and the 
reasons why or why not?
[FSP FAS 129-1, par. 4 (AC C24.805)]
Note: Disclosures of information about derivative transactions entered 
into in connection with the issuance of the contingently convertible secu­
rities may be useful in terms of fully explaining the potential impact of the 
contingently convertible securities.
[FSP FAS 129-1, par. 5 (AC C24.806)]
j. Are applicable disclosures required by SFAS 129 made for instru­
ments within the scope of EITF 05-2?
[EITF 05-2, par. 10]
Note: EITF 05-2, The Meaning of "Conventional Convertible Debt Instrument" 
in EITF Issue No. 00-19, "Accounting for Derivative Financial Instruments 
Indexed to, and Potentially Settled in, a Company's Own Stock," should be 
applied to new instruments entered into and instruments modified in 
periods beginning after June 29, 2005.
[EITF 05-2, pars. 11-12]
k. Are any appropriations of retained earnings for loss contingencies 
clearly identified and included in stockholders' equity?
[SFAS 5, par. 15 (AC R70.103)]
l. Are restrictions on payment of dividends disclosed? 
[SFAS 5, pars. 18 and 19 (AC C59.120)]
m. Are receivables for stock issued or subscribed appropriately iden­
tified and presented as a deduction from capital or, if presented as 
an asset, stated separately, clearly labeled, and their status clearly 
described to distinguish them from any other type of assets?
n. Are the carrying basis, the cost and the number of shares disclosed 
for treasury stock?
[Generally Accepted]
o. After completion of a quasi-reorganization, is a new retained 
earnings account established and dated with the date being dis­
closed in subsequent financial statements until it is no longer 
deemed significant?
[ARB 43, Ch. 7A, par. 10; ARB 46, par. 2 (AC Q15.111)]
p. If state laws relating to acquisition of stock restrict the availability 
of retained earnings for payment of dividends or other significant 
effects, is appropriate disclosure made?
[APB 6, par. 13 (AC C23.104)]
♦ 6. If interim financial reports contain an adjustment related to prior 
interim periods of the current fiscal year, do disclosures include:
a. The effect on income from continuing operations, net income, and 
related per share amounts for each prior interim period of the 
current fiscal year?
b. Income from continuing operations, net income, and related per 
share amounts for each prior interim period restated?
[SFAS 16, par. 15 (AC A35.111)]
FSP §11,200.03
30 Health Care Organizations
Yes No N/A
♦ 7. If the reporting entity is a publicly traded company and if interim 
financial data and disclosures are not separately reported for the 
fourth quarter, are accounting changes made during the fourth quar­
ter, disposals of components of an entity, extraordinary, unusual or 
infrequently occurring items recognized in the fourth quarter, and the 
aggregate effect of year-end adjustments that are material to the 
results of the quarter disclosed in a note to the annual financial 
statements?
[APB 28, par. 31 (AC I73.147)1
Note: If the provisions of SFAS 154, Accounting Changes and Error Correc­
tions, are in effect or are applied, delete Question 8 and refer to "Other 
Financial Statement Disclosures, Section A—Accounting Changes and 
Error Corrections." SFAS 154 supersedes SFAS 3. SFAS 154 is effective 
for accounting changes made in fiscal years beginning after December 
15, 2005. Early adoption is permitted for accounting changes made in 
fiscal years beginning after the date SFAS 154 is issued (May 2005). 
[SFAS 154, par. 27]
♦ 8. If the reporting entity is a publicly traded company, is disclosure 
about the effect of accounting changes on interim periods that are 
required by paragraphs 23-26 of APB 28 or by paragraphs 9-13 of 
SFAS 3 included in a note to the financial statements for the fiscal year 
in which the change is made?
[SFAS 3, par. 14]
9. Changes in net assets/shareholders' equity:
a. When both financial position and results of operations are presented:
(1) Are changes in the separate accounts of equity disclosed? 
[APB 12, par. 10 (AC C08.102)]
(2) Are changes in the number of shares of equity securities 
disclosed for at least the latest year and any subsequent 
interim periods presented (for-profit only)?
[APB 12, par. 10 (AC C08.102)]
b. If prior-period adjustments have been recorded during the current 
year, are their resulting effects (both gross and net of applicable 
income taxes and including the amounts of income tax applicable 
to the prior period adjustments) appropriately disclosed?
(1) For single-period statements, does the disclosure indicate the 
effects of such restatement on the balance of retained earn­
ings/net assets at the beginning of the period and on the net 
income/change in net assets of the immediately preceding 
period?
(2) If financial statements of more than one period are presented, 
does disclosure include the effects for each of the periods 
presented in the statements?
[APB 9, par. 26 (AC A35.107)]
Note: If the provisions of SFAS 154, Accounting Changes and Error Correc­
tions, are in effect or are applied, delete Question 9c and refer to "Other 
Financial Statement Disclosures, Section A—Accounting Changes and 
(continued)
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Error Corrections." SFAS 154 supersedes APB 20. SFAS 154 is effective for 
corrections of errors made in fiscal years beginning after December 15, 
2005. Early adoption is permitted for corrections of errors made in fiscal 
years beginning after the date SFAS 154 is issued (May 2005).
[SFAS 154, par. 271
c. Is the correction of an error in the financial statements of a prior 
period discovered subsequent to their issuance reported as a prior 
period adjustment, with disclosure of the following in the period 
in which the error was discovered and corrected:
(1) Nature of the error in previously issued financial statements? ____
(2) Effect of its correction on income before extraordinary items,
net income, and related per-share amounts, if applicable? ____
[APB 20, par. 37 (AC A35.105)]
M. Restricted Resources
★ 1. Are cash or other assets received with a donor-imposed restriction
that limits their use to long-term purposes reported separately from 
assets that are unrestricted and available for current use? ____
[SFAS 117, par. 11 (AC No5.109)]
★ 2. Does the entity provide information about the nature and amounts of
different types of permanent restrictions and temporary restrictions 
by reporting their amounts on the face of the statement of financial 
position or by including relevant details in notes to financial statements? ____
[SFAS 117, par. 14 (AC No5.112)]
★ 3. Is property and equipment that is donor-restricted reported as tem­
porarily or permanently restricted assets? ____
[SFAS 116, par. 14 (AC No5.143)]
Statement of Activities/Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General
★ 1. Does the statement of activities/operations or statement of changes
in net assets report the amount of change in net assets for the period 
for the provider as a whole (using a descriptive term such as "change 
in net assets" or "change in equity"), and does that amount articulate 
to the net assets reported in the statement of financial position? ____
[SFAS 117, par. 18 (AC No5.116)]
★ 2. Does the statement of activities/operations or the statement of
changes in net assets report the amount of change in permanently 
restricted net assets, temporarily restricted net assets, and unre­
stricted net assets for the period? ____
[SFAS 117, par. 19 (AC No5.117)]
★ 3. Does the statement of activities/operations report the following:
a. Revenues as increases in unrestricted net assets unless the use of
the assets received is limited by donor-imposed restrictions? ____
b. Expenses as decreases in unrestricted net assets? ____
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c. Events that simultaneously increase one class of net assets and 
decrease another (reclassifications), including expiration of donor- 
imposed restrictions, separately from revenues, expenses, gains, 
and losses?
d. Gains and losses as increases or decreases in unrestricted net assets 
unless a donor or law temporarily or permanently restrict their use? 
[SFAS 117, pars. 19, 20, and 22 (AC No5.117, .118, and .119); SFAS 
116, par. 17 (AC No5.147)]
★ 4. Are revenues and expenses (arising from ongoing activities associated
with health care services) displayed as gross amounts?
[SFAS 117, par. 24 (AC No5.121)]
★ 5. If the provider elects to report investment revenues net of related
expenses, does the provider disclose the amount of expenses, either 
on the face of the statement of activities or in the notes to the financial 
statements?
[SFAS 117, par. 24 (AC No5.121)]
★ 6. If the entity reports an intermediate measure of operations (for exam­
ple, excess or deficit of operating revenues over expenses), is this 
intermediate measure reported only in a financial statement that, at a 
minimum, reports the change in unrestricted net assets for the period? 
[SFAS 117, par. 23 (AC No5.120)]
★ 7. If the entity's use of the term operations is not apparent from the details
provided on the face of the statement of activities, does a note to 
financial statements describe the nature of the reported measure of 
operations or the items excluded from operations?
[SFAS 117, par. 23 (AC No5.120)]
★ 8. If the entity reports net gains and losses on its statement of activi­
ties/ operations, do these net amounts result from peripheral or inci­
dental transactions or from events largely beyond the control of the 
entity and its management?
[SFAS 117, pars. 25 and 138 (AC No5.122)]
9. Is management's policy for providing charity care, as well as the level 
of charity care provided, disclosed?
[AAG, par. 10.28]
★ 10. Does the statement of activities/operations include a performance
indicator that reports results of operations and that is clearly labeled 
with a descriptive term such as revenues over expenses, revenues and 
gains over expenses and losses, earned income, or performance earnings? 
[AAG, par. 10.20]
★ 11. Do the notes to the financial statements include a description of the
nature and composition of the performance indicator?
[AAG, par. 10.20]
★ 12. Does the not-for-profit provider report the performance indicator in
a statement that also presents the total changes in unrestricted net 
assets? (Note: Other changes in net assets may be presented sepa­
rately or in the same statement.)
[AAG, par. 10.20]
★ 13. Does the organization report the following items separately from the
performance indicator:
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a. Transactions with owners acting in that capacity?
b. Equity transfers involving other entities that control the reporting 
entity, are controlled by the reporting entity, or are under common 
control with the reporting entity?
c. Receipt of restricted contributions, including temporary restric­
tions (such as time or purpose) or permanent restrictions?
d. Contributions of (and assets released from donor restrictions re­
lated to) long-lived assets?
e. Items that are required to be reported in or reclassified from other 
comprehensive income, such as minimum pension liabilities in 
accordance with paragraph 37 of SFAS 87; foreign currency trans­
lation adjustments and the effective portion of the gain or loss on 
derivative instruments designated and qualifying as cash flow 
hedging instruments?
f. Items that are required to be reported separately under specialized 
not-for-profit standards. These include extraordinary items, the effect 
of discontinued operations, and the cumulative effect of accounting 
changes pursuant to the provisions of SFAS 117; and unrealized 
gains and losses on investments not restricted by donors or by law 
(except for those investments classified as trading securities) and 
investment returns restricted by donors or by law, as required by 
paragraphs 4.07 through 4.10 of this Guide?
[SOP 02-2; AAG, par. 10.211
Note: SFAS 154, Accounting Changes and Error Corrections, changes the 
requirements for reporting changes in accounting principle. SFAS 154 is 
effective for accounting changes made in fiscal years beginning after 
December 15, 2005. Early adoption is permitted for accounting changes 
made in fiscal years beginning after the date SFAS 154 was issued (May 
2005).
[SFAS 154, pars. 1, 7, and 27]
★♦14. For investments in common stock accounted for by the equity 
method, is the investor's share of earnings shown as a single amount 
except for investee extraordinary items and prior-period adjustments 
that are material to the investor?
[APB 18, pars. 19c and d (AC I82.109c and d)]
★♦ 15. Are total research and development costs charged to expenses dis­
closed for each period for which a statement of activities/income 
statement is presented?
[SFAS 2, pars. 12 and 13 (AC R50.108 and .109); FASBI 4, par. 5 (AC 
B50.152) (AC B51.145); FASBI 6, par. 8 (AC R50.117); SFAS 86, par. 3 
(AC Co2.102)]
★♦ 16. If the provider accounts for its obligation under a research and devel­
opment arrangement as a contract to perform research and develop­
ment for others, is there disclosure of:
a. The terms of significant agreements under the research and develop­
ment arrangement as of the date of each balance sheet presented?
b. The amount of compensation earned or costs incurred under such 
contracts for each period for which a statement of revenues and 
expenses (statement of operations) is presented?
[SFAS 68, par. 14 (AC R55.112)]
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♦ 17. Are the following excluded from the determination of net income or
results of operations under all circumstances:
a. Adjustments or charges or credits resulting from transactions in
the provider's own capital stock? ____  ___
b. Transfers to and from accounts properly designated as appropri­
ated retained earnings? ____  ___
c. Adjustments made pursuant to a quasi-reorganization? ____  ___
[APB 9, par. 28 (AC C08.101)]
♦ 18. Are net assets released from restriction, such as those related to the
fulfillment of time or purpose restrictions, reported separately in the 
financial statements or disclosed in the notes? ____  ___
[AAG, par. 10.08]
B. Revenue
1. Is revenue classified based on the type of service (such as patient or 
resident) rendered or contracted to be rendered? ____  ___
[AAG, par. 10.04]
★♦2. Are gains, losses, and interest earned properly classified and reported? ____ ___
[AAG, par. 10.08]
3. Is patient service revenue reported net of provisions for contractual
and other adjustments? ____  ___
[AAG, par. 10.26]
4. Do disclosures include methods of revenue recognition? ____  ___
[AAG, par. 10.26]
5. With regard to contractual adjustments and third-party settlements, 
does the provider identify and explain the estimated amounts payable
or receivable? ____ ___
[AAG, par. 10.26]
6. Is significant revenue earned under capitation arrangements reported
separately? ____  ___
[AAG, par. 10.26]
C. Income Taxes
♦ 1. Are the following significant components of income tax expense
attributable to continuing operations for each year presented dis­
closed in the financial statements or notes thereto:
a. Current tax expense or benefit? ____  ___
b. Deferred tax expense or benefit (exclusive of the effects of other
components listed below)? ____  ___
c. Investment tax credits? ____  ___
d. Government grants (to the extent recognized as a reduction of
income tax expense)? ____  ___
e. The benefits of operating loss carryforwards? ____  ___
f. Tax expense that results from allocating certain benefits, either
directly to contributed capital or to reduce goodwill or other 
noncurrent intangible assets of an acquired entity? ____  ___
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g. Adjustments of a deferred tax liability or asset for enacted changes 
in tax laws or rates or a change in the tax status of the provider?
h. Adjustments of the beginning-of-the-year balance of a valuation 
allowance because of a change in circumstances that causes a 
change in judgment about the realizability of the related deferred 
tax asset in future years?
[SFAS 109, par. 45 (AC I27.144)]
♦ 2. Is the amount of income tax expense or benefit allocated to continuing
operations and the amounts separately allocated to other items dis­
closed for each year for which those items are presented? 
[SFAS 109, pars. 35-39 and 46 (AC I27.134-.138 and .145)]
♦ 3. If the reporting entity is a public enterprise, is a reconciliation in both
percentages and dollars of the reported amount of income tax expense 
attributable to continuing operations for the year to the amount of 
income tax expense that would result from applying domestic federal 
statutory rates to pretax income from continuing operations? 
[SFAS 109, par. 47 (AC I27.146)]
♦ 4. If the reporting entity is a nonpublic enterprise, is there disclosure of
the nature of significant items required to reconcile the reported 
amount of income tax expense attributable to continuing operations 
for the year to the amount of income tax expense that would result 
from applying domestic federal statutory tax rates to pretax income 
from continuing operations?
[SFAS 109, par. 47 (AC I27.146)]
♦ 5. Are the amounts and expiration dates of operating loss and tax credit
carryforwards for tax purposes disclosed?
[SFAS 109, par. 48 (AC I27.147)]
♦ 6. Is the amount of any portion of the valuation allowance for deferred
tax assets for which subsequently recognized tax benefits will be 
allocated to reduce goodwill or other noncurrent intangible assets of 
an acquired entity or directly to contributed capital disclosed? 
[SFAS 109, par. 48 (AC I27.147)]
♦ 7. If the provider is a member of a group that files a consolidated tax
return, are the following items disclosed in its separately-issued finan­
cial statements:
a. The aggregate amount of current and deferred tax expense for 
each statement of earnings presented, and the amount of any 
tax-related balances due to or from affiliates as of the date of each 
balance sheet presented?
b. The principal provisions of the method by which the consolidated 
amount of current and deferred tax expense is allocated to mem­
bers of the group and the nature and effect of any changes in that 
method (and in determining related balances to or from affiliates) 
during the years for which the disclosures in Question 7a above 
are presented?
[SFAS 109, par. 49 (AC I27.148)]
♦ 8. Are the income taxes applicable to extraordinary events disclosed on
the face of the income statement or in related notes?
[APB 30, par. 11 (AC I17.102)]
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D. Extraordinary Items
1. Are extraordinary items segregated and shown (including applicable
income taxes) following income before extraordinary items and be­
fore net income? ____  ___
[APB 30, par. 11 (AC I17.102)]
2. Are descriptive captions and amounts (including applicable income
taxes) presented for individual extraordinary events or transactions, 
preferably on the face of the statement of operations/income state­
ment, if practicable? ____  ___
[APB 30, par. 11 (AC I17.102)]
3. Do disclosures include descriptions of extraordinary events or trans­
actions and the principal items entering into determination of extraor­
dinary gains or losses? ____  ___
[APB 30, par. 11 (AC I17.102)]
4. For an adjustment of an extraordinary item reported in a prior period 
(except for correction of an error):
a. Is the adjustment classified separately as an extraordinary item in
the current period? ____  ___
b. Are the nature, year of origin, and amount of the item disclosed? ____  ___
[SFAS 16, par. 16(c) (AC I17.119)]
E. Unusual or Infrequent Items
1. Are material events or transactions that are either unusual in nature 
or of infrequent occurrence, but not both (and therefore not meeting 
criteria for extraordinary items):
a. Reported as a separate component of income from continuing
operations? ____  ___
b. Accompanied by disclosure of the nature and financial effects of
each event? ____  ___
[APB 30, par. 26 (AC I22.101)]
F. Advertising Costs
1. Do disclosures for advertising costs include:
a. The accounting policy selected from the two alternatives in the 
beginning of paragraph 26 of SOP 93-7 for reporting advertising, 
indicating whether such costs are expensed as incurred or the first
time the advertising takes place? ____  ___
b. A description of the direct-response advertising reported as assets
(if any), the accounting policy for it, and the amortization period? ____ ___
c. The total amount charged to advertising expense for each state­
ment of activities/income statement presented, with separate dis­
closure of amounts, if any, representing a write-down of the
capitalized advertising costs to net realizable value? ____  ___
d. The total amount of advertising reported as assets in each balance
sheet/statement of financial position presented? ____  ___
[SOP 93-7, par. 49]
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G. Donated or Contributed Services
★ 1. If the provider receives contributed services, does it disclose the
following:
a. A description of the programs or activities for which those services 
were used, including the nature and extent of contributed services 
received for the period and the amount recognized as revenues for 
the period?
b. The fair value of contributed services received but not recognized, 
if practicable (optional)?
c. Nonmonetary information such as the number and trends of 
donated hours received or service outputs provided by volunteer 
efforts (optional)?
d. Dollar amount of contributions raised by volunteers (optional)? 
[SFAS 116, pars. 10 and 123 (AC C67.110)]
H. Donated Materials and Facilities
★ 1. If donated materials merely pass through the organization to its
charitable beneficiaries, and the organization is only an agent or 
intermediary for the donors, has that donation been excluded from 
contribution revenues?
[SFAS 116, pars. 52 and 53; SFAS 136, pars. 8 and 11 (AC C67.161 and 
.164)]
I. Fund Raising
★ 1. Do financial statement disclosures include:
a. The types of activities for which joint costs have been incurred?
b. A statement that such costs have been allocated?
c. The total amount allocated during the period and the portion 
allocated to each functional expense category?
[SOP 98-2, par. 18]
Note: SOP 98-2 encourages, but does not require, that the amount of joint 
costs for each kind of joint activity be disclosed, if practical. [SOP 98-2, 
par. 19]
★ 2. If the organization includes within its financial statements a ratio of
fundraising expenses to amounts raised, has it disclosed how that 
ratio was computed? ____
[SFAS 136, par. 20 (AC No5.125A)]
J. Contributions/Pledges
★ 1. Does the provider distinguish between contributions received with per­
manent restrictions, those received with temporary restrictions, and 
those received without donor-imposed restrictions, so that they are 
reported as support increasing permanently restricted net assets, tempo­
rarily restricted net assets, or unrestricted net assets, respectively? ____
[SFAS 116, par. 14 (AC No5.143)]
★ 2. If donor-restricted contributions whose restrictions are met in the
same reporting period are reported as unrestricted support, is such 
treatment consistent from period to period and is the policy disclosed? ____
[SFAS 117, par. 21; SFAS 116, par. 14 (AC No5.143)]
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★ 3. Does the provider report receipt of unconditional promises to give
with payments due in future periods as restricted support, unless 
explicit donor stipulations or circumstances surrounding the receipt 
of the promise make clear that the donor intended the contribution to 
be used to support activities of the current period?
[SFAS 116, par. 15 (AC No5.144)]
★ 4. Does an entity that receives gifts of long-lived assets without donor
stipulation about how long the donated asset must be used:
a. Disclose its accounting policy of implying or not implying a time 
restriction that expires over the useful life of the asset?
b. Report such support as restricted if it is the provider's policy to 
imply a time restriction that expires over the useful life of the 
donated asset?
c. Report such support as unrestricted in the absence of such a 
policy?
[SFAS 116, par. 16 (AC No5.145)]
★ 5. Does a provider that receives unconditional promises to give, in
which cash promised will be received in future periods, measure the 
fair value of the contribution as the present value of estimated future 
cash flows, using a discount rate commensurate with the risks in­
volved, and report subsequent accruals of the interest element as 
contribution income increasing either the temporarily or permanently 
restricted class of net assets if the underlying promise to give is donor 
restricted?
[SFAS 116, par. 20 (AC C67.116)]
6. Are unrestricted pledges/contributions reported in the statement of 
operations?
[AAG, par. 10.09]
K. Expenses
★ 1. Does the provider provide information about expenses reported by
their functional classification (such as major classes of program serv­
ices and supporting services) either in the statement of activities or in 
notes to financial statements?
[SFAS 117, par. 26 (AC No5.123)]
2. For deferred compensation agreements, are estimated amounts to be 
paid properly accrued?
[APB 12, pars. 6 and 7 (AC C38.101A and .102)]
3. At a minimum, is the following information disclosed in the notes to 
the financial statements in all periods affected by the September 11, 
2001 attacks:
a. A description of the nature and amounts of losses and costs 
recognized as a result of the September 11 events and the amount 
of related insurance recoveries (if any) recognized?
b. A description of contingencies resulting from the September 11 
events that have not yet been recognized in the financial state­
ments but that are reasonably expected to impact the entity's 
financial statements in the near term?
c. Applicable disclosures pursuant to SOP 94-6?
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d. Applicable disclosures about environmental obligations (and re­
coveries) pursuant to SOP 96-1? ____  ___
[EITF 01-10]
★♦4. Are losses and costs incurred as a result of the September 11, 2001 
attacks classified as part of income from continuing operations? ____  ___
[EITF 01-10]
★♦5. If the losses and costs incurred as a result of the September 11, 2001 
attacks meet the criteria for disclosure of unusual or infrequently 
occurring items, are they reported as a separate component of income 
from continuing operations, either on the face of the statement of 
operations or in the notes to the financial statements? ____  ___
[EITF 01-10]
★♦6. Is the following information disclosed in the notes to the financial 
statements in the period(s) in which business interruption insurance 
recoveries are recognized:
a. Nature of the event resulting in business interruption losses? ____  ___
b. Aggregate amount of business interruption insurance recoveries 
recognized during the period and the line item(s) in the statement 
of operations in which those recoveries are classified (including
amounts reported as extraordinary pursuant to APB 30)? ____  ___
[EITF 01-13]
L. Wills
★♦1. If the entity receives a promise to give conditioned on a future 
uncertain event that is contained in a will and the will has been 
declared valid by the probate court, has the provider disclosed the 
conditional promise to give? ____  ___
[SFAS 116, par. 208 (AC C67.160)]
M. Endowments
★ 1. If the governing board determines that the relevant law requires the
organization to retain permanently some portion of gains on invest­
ment assets of endowment funds, is that amount reported as an 
increase in permanently restricted net assets? ____  ___
[SFAS 117, par. 22 (AC No5.119)]
★ 2. In the absence of such a law or a donor's explicit or clear implicit
permanent restriction is net appreciation reported as unrestricted if 
the endowment's income is unrestricted or temporarily restricted if 
the endowment's income is temporarily restricted by the donor? ____  ___
[SFAS 117, par. 129 (AC No5.119)]
N. Earnings Per Share
Note: SFAS 128, Earnings per Share, applies only to entities with publicly 
held common stock or potential common stock.
♦ 1. Are earnings per share (EPS) data presented for all periods for which 
an income statement or summary of earnings is presented?
[SFAS 128, par. 38 (AC E11.133)]
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♦ 2. If diluted EPS data are reported for at least one period, are they
reported for all periods presented, even if they are the same amounts 
as basic EPS?
[SFAS 128, par. 38 (AC E11.133)]
♦ 3. For entities with only common stock outstanding, are basic EPS
amounts for income from continuing operations and for net income 
presented on the face of the income statement?
[SFAS 128, par. 36 (AC E11.131)]
♦ 4. For entities with other than a simple capital structure, are basic and
diluted EPS amounts for income from continuing operations and for 
net income presented on the face of the income statement with equal 
prominence?
[SFAS 128, par. 36 (AC E11.131)]
♦ 5. If discontinued operations, extraordinary items, or the cumulative
effect of accounting changes are reported in a period, are the basic and 
diluted per share amounts for those line items presented on the face 
of the income statement or in the notes?
[SFAS 128, par. 37 (AC E11.132)]
Note: SFAS 154, Accounting Changes and Error Corrections, is effective for 
accounting changes made in fiscal years beginning after December 15, 
2005. Early adoption is permitted for accounting changes made in fiscal 
years beginning after the date SFAS 154 is issued (May 2005). After the 
effective date of SFAS 154, voluntary changes in accounting principle will 
no longer be reported as a cumulative-effect adjustment through the 
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC E11.132, fn. 24a)]
♦ 6. If per share amounts not required to be presented by SFAS 128 are
disclosed, are they disclosed only in the notes and do the disclosures 
indicate whether the per share amounts are pretax or net of tax? 
[SFAS 128, par. 37 (AC E11.132)]
♦ 7. Are the following disclosed for each period for which an income
statement is presented:
a. A reconciliation of the numerators and denominators of the basic 
and diluted per share computations for income from continuing 
operations?
b. The effect that has been given to preferred dividends in arriving at 
income available to common stockholders in computing basic EPS?
c. Securities (including those issuable pursuant to contingent stock 
agreements) that could potentially dilute basic EPS in the future 
that were not included in the computation of diluted EPS because 
to do so would have been antidilutive for the period(s) presented? 
[SFAS 128, par. 40 (AC E11.135)]
♦ 8. For the latest period for which an income statement is presented, do
disclosures include a description of any transaction that occurs after 
the end of the most recent period but before issuance of the financial 
statements that would have changed materially the number of com­
mon shares or potential common shares outstanding at the end of the 
period if the transaction had occurred before the end of the period? 
[SFAS 128, par. 41 (AC E11.136)]
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Notes: EITF 03-6, Participating Securities and the Two-Class Method under 
FASB Statement No. 128, Earnings per Share, has transition guidance 
stating prior period earnings per share amounts presented for compara­
tive purposes should be restated to conform to consensus guidance. EITF 
03-6 is effective for fiscal periods beginning after March 31, 2004.
[EITF 03-6, pars. 23-24]
EITF 04-8, The Effect of Contingently Convertible Instruments on Diluted 
Earnings per Share, has transition guidance requiring restatement of prior­
period diluted earnings per share to conform to consensus guidance for 
comparative purposes. EITF 04-8 is effective for reporting periods ending 
after December 15, 2004.
[EITF 04-8, pars. 6-11]
O. Comprehensive Income
Practice Tip
A listing of items of other comprehensive income under current accounting standards can be found in section 
C49.106 of the FASB Current Text.
♦ 1. Are all components of comprehensive income reported in the finan­
cial statements in the period in which they are recognized? 
[SFAS 130, par. 14 (AC C49.108)]
♦ 2. Is a total for comprehensive income displayed in the financial statement
where the components of other comprehensive income are reported? 
[SFAS 130, par. 14 (AC C49.108)]
♦ 3. Is an amount for net income displayed and included as a component
of comprehensive income?
[SFAS 130, pars. 15 and 22 (AC C49.109 and .116)]
♦ 4. Are items included in other comprehensive income classified sepa­
rately into foreign currency items, minimum pension liability adjust­
ments, and unrealized gains and losses on certain investments in debt 
and equity securities?
[SFAS 130, par. 17 (AC C49.111)]
♦ 5. Are reclassification adjustments presented on the face of the financial
statement in which comprehensive income is reported or disclosed in 
the notes?
[SFAS 130, par. 20 (AC C49.114)]
♦ 6. Are the components of other comprehensive income and total
comprehensive income displayed below the total for net income? 
(Encouraged, but not required.) 
[SFAS 130, par. 23 (AC C49.117)]
♦ 7. Are the components of other comprehensive income displayed either
net of related tax effects, or before related tax effects with one amount 
shown for the aggregate tax effect related to the total of other compre­
hensive income items?
[SFAS 130, par. 24 (AC C49.118)]
♦ 8. Is the amount of income tax expense or benefit allocated to each
component of other comprehensive income (including reclassification
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adjustments) disclosed either on the face of the statement in which 
those components are displayed or in the notes?
[SFAS 130, par. 25 (AC C49.119)]
♦ 9. Is the total of other comprehensive income for a period transferred to
a component of equity that is displayed separately from retained 
earnings and additional paid-in-capital in a statement of financial 
position with a descriptive title such as accumulated other comprehensive 
income?
[SFAS 130, par. 26 (AC C49.120)]
♦ 10. Are accumulated balances for each classification within accumulated
other comprehensive income disclosed on the face of the statement of 
financial position, in a statement of changes in equity, or in the notes? 
[SFAS 130, par. 26 (AC C49.120)]
♦ 11. Has the enterprise reported a total for comprehensive income in
condensed financial statements of interim periods?
[SFAS 130, par. 27 (AC C49.121)]
♦ 12. Are unrealized holding gains and losses for available-for-sale securi­
ties, including those classified as current assets, reported in other 
comprehensive income until realized except as indicated in para­
graph 13 of SFAS 115?
[SFAS 115, par. 13, as amended by SFAS 130 and SFAS 133 (AC 
I80.110)]
♦ 13. If an additional pension liability is required to be recognized and
exceeds unrecognized prior service cost, is the excess (which would 
represent a net loss not yet recognized as net periodic pension cost) 
reported in other comprehensive income net of any tax benefits that 
result from considering such losses as temporary differences? 
[SFAS 87, par. 37, as amended by SFAS 130 (AC P16.131)]
♦ 14. Has the entity displayed as a separate classification within other
comprehensive income the net gain or loss on derivative instruments 
designated and qualifying as cash flow hedging instruments that are 
reported in comprehensive income pursuant to paragraphs 30 and 41 
of SFAS 133?
[SFAS 133, par. 46 (AC D50.143)]
♦ 15. As part of the disclosures of accumulated other comprehensive in­
come, pursuant to paragraph 26 of SFAS 130, Reporting Comprehensive 
Income, has the entity separately disclosed the beginning and ending 
accumulated derivative gain or loss, the related net change associated 
with current period hedging transactions, and the net amount of any 
reclassification into earnings?
[SFAS 133, par. 47 (AC D50.144)]
Statement of Cash Flows
1. Is a statement of cash flows presented as a basic financial statement for 
each period for which both a statement of financial position/balance 
sheet and a statement of activities/income statement is presented? 
[SFAS 95, par. 3, as amended by SFAS 117, par. 30a (AC C25.101); 
AAG, par. 1.07]
2. Does the statement of cash flows show the change in cash and cash 
equivalents?
[SFAS 95, par. 7 (AC C25.105)]
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3. Is the policy for defining cash equivalents disclosed? 
[SFAS 95, par. 10 (AC C25.108)]
Note: Any change in policy for determining which items are treated as cash 
equivalents is a change in accounting principle.
[SFAS 95, par. 10 (AC C25.108)]
4. If the direct method is used, is a separate schedule provided to reconcile 
net income of an investor-owned provider or change in net assets of a 
not-for-profit provider to net cash flow from operating activities? 
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
5. If the indirect method is used:
a. Is the same amount for net cash flow from operating activities 
reported indirectly by adjusting net income of an investor-owned 
provider or change in net assets of a not-for-profit provider to 
reconcile it to net cash flow from operating activities?
[SFAS 95, par. 28, as amended by SFAS 117, par. 30f (AC C25.126)]
b. Is the reconciliation of net income of an investor-owned provider 
or change in net assets of a not-for-profit provider to net cash flows 
from operating activities reported, either within the statement of 
cash flows or provided in a separate schedule, with the statement 
of cash flows reporting only the net cash flow from operating 
activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
6. Are cash receipts and cash payments from operating activities shown 
separately on the statement of cash flows?
[SFAS 95, par. 27 (AC C25.125)]
Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect 
or are applied, replace Question 7e with Question 7i. SFAS 123(R) amends 
SFAS 95. The provisions of SFAS 123(R) are effective (a) for public entities 
that do not file as small business issuers—as of the beginning of the first 
interim or annual reporting period that begins after June 15,2005; (b) for 
public entities that file as small business issuers—as of the beginning of 
the first interim or annual reporting period that begins after December 15, 
2005; and (c) for nonpublic entities—as of the beginning of the first annual 
reporting period that begins after December 15, 2005. See paragraphs 69 
through 85 of SFAS 123(R) for further effective date and transition infor­
mation. Early adoption for interim or annual periods for which financial 
statements or interim reports have not been issued is encouraged. 
[SFAS 123(R), pars. 68-85]
7. Are cash receipts and cash payments for the following transactions 
classified as cash flows from operating activities:
a. Interest received on loans?
b. Insurance proceeds except those directly related to investing or 
financing activities?
c. Interest paid to creditors?
d. Payments to suppliers and employees?
e. Payments to governments for taxes, duties, fines, and other fees 
or penalties?
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f. Payments to settle lawsuits?
g. Contributions to charities?
[SFAS 95, pars. 22 and 23 (AC C25.120 and .121)]
h. Cash flows from purchases, sales, and maturities of trading 
securities?
[SFAS 115, par. 18 (AC I80.117); AAG, par. 4.17; SFAS 95, pars. 22 
and 23 (AC C25.120 and .121)]
i. Payments to governments for taxes, duties, fines, and other fees 
or penalties and the cash that would have been paid for income 
taxes if increases in the value of equity instruments issued under 
share-based payment arrangements that are not included in the 
cost of goods or services recognizable for financial reporting pur­
poses also had not been deductible in determining taxable in­
come?
[SFAS 95, par. 23, as amended by SFAS 123(R) (AC C25.121)]
8. Are cash receipts and cash payments for the following transactions 
classified as cash flows from investing activities:
a. Receipts from collections or sales of loans?
b. Receipts from sales of property?
c. Loans to others?
d. Payments to acquire property?
e. Purchases of and proceeds from sales of available-for-sale securities?
f. Receipts from sales of equity instruments of other enterprises 
exclusive of those carried in the trading account and from returns 
of investment in those instruments?
g. Payments to acquire equity instruments of other enterprises, ex­
clusive of those carried in the trading account?
h. Proceeds from maturities of available for sale and held-to-maturity 
securities?
i. Purchases of held-to-maturity securities?
[SFAS 95, pars. 16 and 17 (AC C25.114 and .115); SFAS 115, par. 18 
(AC I80.117)]
★♦9. Except for items described in paragraphs 12 and 13 of SFAS 95, are 
cash receipts and cash payments from investing and financing activi­
ties shown separately on the statement of cash flows?
[SFAS 95, pars. 12,13, and 31 (AC C25.110, .111, and .129)]
Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect 
or are applied, also see Question 10/. SFAS 123(R) amends SFAS 95. The 
provisions of SFAS 123(R) are effective (a) for public entities that do not 
file as small business issuers—as of the beginning of the first interim or 
annual reporting period that begins after June 15, 2005; (b) for public 
entities that file as small business issuers—as of the beginning of the first 
interim or annual reporting period that begins after December 15, 2005; 
and (c) for nonpublic entities—as of the beginning of the first annual 
reporting period that begins after December 15,2005. See paragraphs 69 
through 85 of SFAS 123(R) for further effective date and transition infor­
mation. Early adoption for interim or annual periods for which financial 
statements or interim reports have not been issued is encouraged. 
[SFAS 123(R), pars. 68-85]
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10. Are cash receipts and cash payments for the following transactions 
classified as cash flows from financing activities:
a. Proceeds from issuing debt?
b. Repayments for amounts borrowed?
c. Proceeds from issuing equity instruments?
d. Payment of dividends or other distributions to owners?
e. Other principal payments to creditors who have extended long-term 
debt?
[SFAS 95, pars. 19 and 20 (AC C25.117 and .118]
f. Cash payments for debt issue costs?
[EITF 95-13]
g. Proceeds received (whether at inception or over the term of the 
derivative instrument) from derivative instruments that include 
financing elements (other than a financing element inherently 
included in an at-the-market derivative instrument with no pre­
payments) at inception?
h. Distributions (whether at inception or over the term of the deriva­
tive instrument) to counterparties of derivative instruments that 
include financing elements (other than a financing element inher­
ently included in an at-the-market derivative instrument with no 
prepayments) at inception?
[SFAS 95, pars. 19 and 20 (C25.117-118), as amended by SFAS 149]
i. Cash retained as a result of the tax deductibility of increases in the 
value of equity instruments issued under share-based payment 
arrangements that are not included in the cost of goods or services 
that is recognizable for financial reporting purposes? (Note: For 
this purpose, excess tax benefits shall be determined on an indi­
vidual award (or a portion thereof) basis.)
[SFAS 95, par. 19, as amended by SFAS 123(R) (AC C25.117)]
★♦11. Are investing and financing activities that affect recognized assets or 
liabilities but that do not result in cash receipts or cash payments in 
the period disclosed?
[SFAS 95, par. 32, as amended by SFAS 117, par. 30g (AC C25.134)]
★ 12. In its statement of cash flows, does the organization include in cash 
flows from financing activities any amounts received with donor- 
imposed stipulations that they must be used for long-term purposes? 
[SFAS 117, par. 30c (AC C25.116)]
Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect 
or are applied, replace Question 13k with Question 13k. SFAS 123(R) 
amends SFAS 95. The provisions of SFAS 123(R) are effective (a) for public 
entities that do not file as small business issuers—as of the beginning of 
the first interim or annual reporting period that begins after June 15, 2005; 
(b) for public entities that file as small business issuers—as of the begin­
ning of the first interim or annual reporting period that begins after 
December 15, 2005; and (c) for nonpublic entities—as of the beginning of 
the first annual reporting period that begins after December 15, 2005. See 
paragraphs 69 through 85 of SFAS 123(R) for further effective date and 
transition information. Early adoption for interim or annual periods for 
which financial statements or interim reports have not been issued is 
encouraged.
[SFAS 123(R), pars. 68-85]
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13. Are the following classes of operating cash receipts and payments for 
providers using the direct method, at a minimum, separately disclosed:
a. Cash received from service recipients?
b. Cash received from contributors?
c. Interest and dividends received?
d. Cash collected on contributions receivable?
e. Other operating cash receipts, if any?
f. Cash paid to employees and suppliers?
g. Interest paid?
h. Income taxes paid?
i. Grants paid?
j. Other operating cash payments, if any?
[SFAS 95, par. 27, as amended by SFAS 117, par. 30e (AC C25.125)]
k. Income taxes paid and, separately, the cash that would have been 
paid for income taxes if increases in the value of equity instru­
ments issued under share-based payment arrangements that are 
not recognizable as a cost of goods or services for accounting 
purposes also had not been deductible in determining taxable 
income?
[SFAS 95, par. 27, as amended by SFAS 123(R) (AC C25.125)]
Note: SFAS 95 encourages enterprises to provide further breakdowns of 
operating cash receipts and payments that they consider meaningful and 
feasible.
[SFAS 95, par. 27 (AC C25.125)]
14. Is the reconciliation of net income or change in net assets to net cash 
flow from operating activities, including separate reporting of all 
major classes of reconciling items, presented?
[SFAS 95, par. 29, as amended by SFAS 117, par. 30 (AC C25.127)]
★♦15. If the indirect method of reporting net cash flow from operating 
activities is used, are amounts of interest paid (net of amounts capi­
talized) and income taxes paid during the period provided in related 
disclosures?
[SFAS 95, par. 29 (AC C25.127)]
★♦ 16. Does the statement of cash flows report net cash provided or used by 
operating, investing, and financing activities and the net effect of those 
flows on cash and cash equivalents during the period in a manner that 
reconciles beginning and ending cash and cash equivalents? 
[SFAS 95, par. 26 (AC C25.124)]
★ 17. Are cash receipts from contributions and investment income that by 
donor stipulation are restricted for the purposes of acquiring, con­
structing, or improving property, plant, equipment, or other long- 
lived assets or establishing or increasing a permanent endowment or 
term endowment classified as cash flows from financing activities? 
[SFAS 117, par. 30(d) (AC C25.117)]
★♦18. Are cash payments made to settle an asset retirement obligation 
classified in the statement of cash flows as an operating activity? 
[EITF 02-6]
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Other Financial Statement Disclosures
A. Accounting Changes and Error Corrections
Note: If the provisions of SFAS 154, Accounting Changes and Error Correc­
tions, are in effect or are applied, replace Questions 1 through 9 with 
Questions 10 through 25. SFAS 154 supersedes APB 20 and SFAS 3, and 
supersedes or amends other pronouncements. SFAS 154 is effective for 
accounting changes and corrections of errors made in fiscal years begin­
ning after December 15, 2005. Early adoption is permitted for accounting 
changes and corrections of errors made in fiscal years beginning after the 
date SFAS 154 is issued (May 2005).
[SFAS 154, par. 27]
1. For changes in accounting principle, does disclosure in the period of 
the change include:
a. Nature of the change?
b. Justification for the change, including a clear explanation of why 
the newly adopted principle is preferable?
c. Effect on income?
[APB 20, par. 17 (AC A06.113)]
2. For all changes in accounting principle except those described in para­
graphs 27 through 30, 34, and 35 of APB 20 regarding a change in entity:
a. Are financial statements for prior periods included for compara­
tive purposes presented as previously reported?
b. Is the cumulative effect of changing to a new accounting principle 
on the amount of retained earnings/net assets at the beginning of the 
period in which the change is made included in net income/change 
in net assets of the period of change, between the captions "extraor­
dinary items" and "net income/change in net assets"?
c. Is the effect on income/change in net assets before extraordinary 
items and on net income/change in net assets (and the related per 
share amounts, if applicable) of the period of change disclosed?
d. Is income/change in net assets before extraordinary items and net 
income/change in net assets computed on a pro forma basis 
shown on the face of the income statement/statement of opera­
tions for all periods presented as if the newly adopted accounting 
principle had been applied during all periods affected?
[APB 20, par. 19 (AC A06.115)]
♦ 3. For the cumulative effect of a change in accounting principle, are 
per-share amounts presented either on the face of the income state­
ment or in the related notes?
[APB 20, par. 20, as amended by SFAS 128, par. 163(a) (AC A06.116)]
4. If pro forma amounts cannot be computed or reasonably estimated 
for individual prior periods, although the cumulative effect on re­
tained earnings/net assets at the beginning of the period of change 
can be determined, is the reason for not showing the pro forma 
amounts by periods explained?
[APB 20, par. 25 (AC A06.121)]
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5. If computing the effect on retained earnings/net assets at the begin­
ning of the period of change is considered impossible, are disclosures 
limited to showing the effect of the change on results of net in­
come/ operations of the period of change (including per share data if 
applicable) and explaining the reason for omitting accounting for the 
cumulative effect and disclosure of pro forma amounts for prior years? 
[APB 20, par. 26 (AC A06.122)]
6. For changes in accounting principle that are required to be accounted 
for by restating prior period financial statements:
a. Are all financial statements of prior periods presented restated? 
[APB 20, par. 27 (AC A06.123)]
b. Is the nature and justification for a change in accounting principle 
disclosed in the financial statements for the period the change was 
adopted?
[APB 20, par. 28 (AC A06.124)]
c. Is the effect on income/change in net assets before extraordinary 
items and net income/change in net assets (and related per share 
amounts if applicable) for all prior periods presented disclosed? 
[APB 20, par. 28 (AC A06.124)]
★♦7. For accounting changes that are changes in estimates that affect 
several future periods that are not ordinary course of business ac­
counting, is the effect on income/change in net assets before extraor­
dinary items, net income/change in net assets, and related per share 
amounts, if applicable, of the current period disclosed? (Note: Disclo­
sure of the effect of a change in estimate that is in the ordinary course 
of business is recommended if the effect of such changes is material.) 
[APB 20, par. 33 (AC A06.132)]
★♦8. For changes in accounting principles that are in effect changes in 
reporting entity, are the following disclosed:
a. Nature of the change?
b. The reason for the change?
c. The effect of the change on income/change in net assets before 
extraordinary items, net income/change in net assets, and related 
per share amounts, if applicable, for all periods presented? 
[APB 20, par. 35]
9. Is the correction of an error in the financial statements of a prior period 
discovered subsequent to their issuance reported as a prior period 
adjustment, with disclosure of the following in the period in which 
the error was discovered and corrected:
a. Nature of the error in previously issued financial statements?
b. Effect of its correction on revenue and gains in excess of expenses 
and losses (income) before extraordinary items and net revenue 
and gains in excess of expenses and losses (net income) (and 
related per share amounts if applicable)?
[APB 20, par. 37]
Change in Accounting Principle
 10. Are changes in accounting principle reported through retrospective 
application of the new principle to all prior periods unless impracti­
cable?
[SFAS 154, par. 7 (AC A07.106)]
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★♦11. Does retrospective application include any direct effects of the change 
in accounting principle, including any related income tax effects? ____  ___
[SFAS 154, par. 10 (AC A07.109)]
★♦ 12. In the retrospective application, are the indirect effects of a change in 
accounting principle actually incurred and recognized not included 
in retrospective application but reported in the period in which the 
accounting change is made? ____  ___
[SFAS 154, par. 10 (AC A07.109)]
★♦13. If it is impracticable to determine the period-specific effects of a 
change in accounting principle on all prior periods presented, but the 
cumulative effect of applying the change to the new principle to all 
prior periods can be determined:
a. Is the cumulative effect of the change applied to the carrying 
amounts of assets and liabilities as of the beginning of the earliest
period to which the new accounting principle can be applied? ____  ___
b. Is any offsetting adjustment made to the opening balance of re­
tained earnings or other appropriate components of equity/net
assets for that period? ____  ___
[SFAS 154, par. 8 (AC A07.107)]
★♦ 14. If it is impracticable to determine the cumulative effect of applying a 
change in accounting principle to any prior period, is the new account­
ing principle applied as if the change was made prospectively as of 
the earliest date practicable? ____  ___
[SFAS 154, par. 9 (AC A07.108)]
♦ 15. Are changes in accounting principle made in an interim period re­
ported by retrospective application in accordance with paragraphs 7 
through 10 of SFAS 154? (Note: The impracticability exception in 
paragraph 11 of SFAS 154 may not be applied to prechange interim 
periods of the fiscal year in which the change is made.) ____  ___
[SFAS 154, par. 15 (AC A07.115)]
★♦16. For changes in accounting principle, are the following disclosed in the 
fiscal period in which a change in accounting principle is made:
a. The nature of and reason for the change in accounting principle, 
including an explanation of why the newly adopted accounting
principle is preferable? ____  ___
b. The method of applying the change and:
(1) A description of the prior-period information that has been
retrospectively adjusted if any? ____  ___
(2) The effect of the change on income from continuing opera­
tions, net income (or other appropriate captions of changes in 
the applicable net assets or performance indicator), any other 
affected financial statement line item, and any affected per 
share amounts for the current period and any prior periods 
retrospectively adjusted? (Note: Presentation of the effect on 
financial statement subtotals and totals other than income 
from continuing operations and net income (or other appro­
priate captions of changes in the applicable net assets or 
performance indicator) is not required.) ____  ___
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(3) The cumulative effect of the change on retained earnings or 
other components of equity or net assets in the statement of 
financial position as of the beginning of the earliest period
presented? ____  ___
(4) If retrospective application to all periods is impracticable, the 
reasons therefor, and a description of the alternative method
used to report the change? ____  ___
c. If indirect effects of a change in accounting principle are recog­
nized:
(1) A description of the indirect effects including amounts recog­
nized in the current period and related per share amounts, if
applicable? ____ ___
(2) Unless impracticable, the amount of the total recognized 
indirect effects of the accounting change and the related per- 
share amounts, if applicable, attributable to each prior period
presented? ____ ___
d. If a change in accounting principle has no material effect in the 
period of change but is reasonably certain to have material effect 
in later periods are the disclosures in Question 16a provided 
whenever the financial statements of the period of change are
presented? ____  ___
[SFAS 154, par. 17 (AC A07.117)]
♦ 17. If interim financial statements are issued, are the required disclosures 
provided in the financial statements of both the interim period of the 
change and the annual period of the change? ____  ___
[SFAS 154, par. 17, fn. 5 (AC A07.117, fn. 4)]
Note: Financial statements of subsequent periods do not have to repeat
the disclosures required in paragraph 17 of SFAS 154.
[SFAS 154, par. 17 (AC A07.117)]
♦ 18. If a public company that regularly reports interim information makes 
an accounting change during the fiscal year fourth quarter and does 
not report data specified in paragraph 30 of APB 28, in a separate 
fourth-quarter report or its annual report, do the notes to the annual 
financial statements in the fiscal year in which the change is made 
disclose the effects of the change on interim-period results as required 
by paragraph 17 of SFAS 154? ____
[SFAS 154, par. 16 (AC A07.116)]
19. In the fiscal year in which a new accounting principle is adopted does 
the financial information reported for interim periods after the date 
of adoption disclose the effect of the change on income from continu­
ing operations, net income (or other appropriate captions of changes 
in applicable net assets or performance indicator) and related per-
share amounts, if applicable, for those post-change interim periods? ____
[SFAS 154, par. 18 (AC A07.118)]
Change in Accounting Estimate
20. For changes in accounting estimate:
a. Is the effect on income from continuing operations, net income (or 
other appropriate captions of changes in the applicable net assets 
or performance indicator), and any related per-share amounts of
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the current period disclosed for a change in estimate that effects 
several future periods? (Note: Not necessary for estimates made 
in ordinary course of accounting for items such as uncollectible 
accounts, inventory obsolescence.)
b. Are material effects of changes in estimate disclosed?
c. If an entity effects a change in accounting estimate by changing an 
accounting principle, are the disclosures in Questions 16, 17, and 
19 presented?
d. If a change in estimate does not have a material effect in the period 
of change but is reasonably certain to have material effect in later 
periods is a description of that change in estimate disclosed when­
ever the financial statements of the period of change are pre­
sented?
[SFAS 154, par. 22 (AC A07.122)]
♦ e. For reporting of interim financial information, do disclosures for 
the effects of changes in accounting estimate conform with para­
graph 22 of SFAS 154?
[APB 28, par. 26, as amended by SFAS 154 (AC I73.133)]
Change in the Reporting Entity
21. For accounting changes that in effect result in financial statements of 
a different reporting entity, are changes applied retrospectively to the 
financial statements of all prior periods presented, and is previously 
issued interim financial information presented on a retrospective 
basis?
[SFAS 154, par. 23 (AC A07.123)]
22. For changes in reporting entity:
a. Do the financial statements of the period of change describe the 
nature of the change and the reason for it?
b. Is the effect of the change on income before extraordinary items, 
net income (or other appropriate captions of changes in the appli­
cable net assets or performance indicator), other comprehensive 
income, and any related per-share amounts disclosed for all peri­
ods presented?
c. If a change in reporting entity does not have a material effect in 
the period of change but is reasonably certain to have material 
effect in later periods is the nature of and reason for the change 
disclosed whenever the financial statements of the period of 
change are presented?
[SFAS 154, par. 24 (AC A07.124)]
Correction of an Error in Previously Issued Financial Statements
★♦23. Are corrections of errors in previously issued financial statements 
reported as prior period adjustments by restating prior-period finan­
cial statements?
[SFAS 154, par. 25 (AC A07.125)]
24. For corrections of errors in previously issued financial statements:
a. Does the entity disclose that its previously issued financial state­
ments have been restated along with a description of the nature of 
the error?
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b. Is the effect of the correction on each financial statement line item 
and any per-share amounts affected for each prior period pre­
sented disclosed?
c. Is the cumulative effect of the change on retained earnings or other 
appropriate components of equity or net assets in the statement of 
financial position as of the beginning of the earliest period pre­
sented disclosed?
d. Are disclosures of prior-period adjustments and restatements re­
quired by paragraph 26 of APB 9 presented?
[SFAS 154, par. 26 (AC A07.126)]
♦ 25. If interim financial statements are issued, are the required disclosures 
provided in the financial statements of both the interim period of the 
change and the annual period of the change?
[SFAS 154, par. 26, fn. 8 (AC A07.126, fn. 7)]
Note: Financial statements of subsequent periods do not have to repeat 
the disclosures required in paragraph 26 of SFAS 154.
[SFAS 154, par. 26 (AC A07.126)]
B. Accounting Policies
1. Is a description of all significant accounting policies of the provider 
presented as an integral part of the financial statements?
[APB 22, pars. 8 and 9 (AC A10.102 and .103)]
★♦2. Does the disclosure of accounting policies identify and describe all 
significant accounting principles followed by the reporting entity and the 
methods of applying those principles that materially affect the determi­
nation of financial position, cash flows, and results of operations? 
[APB 22, par. 12 (AC A10.105)]
3. Does disclosure of significant accounting policies encompass impor­
tant judgments as to the appropriateness of principles concerning 
recognition of revenue and allocation of asset costs to current and 
future periods?
[APB 22, par. 12 (AC A10.105)]
4. Does the disclosure of accounting policies encompass those account­
ing principles and methods that involve either:
a. A selection from existing acceptable alternatives?
b. Principles and methods peculiar to the industry in which the 
reporting entity operates, even if such principles and methods are 
predominantly following in that industry?
c. Unusual or innovative applications of GAAP? 
[APB 22, par. 12 (AC A10.105)]
5. Does disclosure of significant accounting policies include appropriate 
reference to details presented elsewhere (in the statements and notes 
thereto) so duplication of details is avoided?
[APB 22, par. 14 (AC A10.107)]
C. Business Combinations
Notes: Questions 4 through 13 in this section apply to business combina­
tions that are accounted for following the provisions of SFAS 141, Business 
(continued) 
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Combinations. SFAS 141 does not apply to combinations between not-for- 
profit organizations, nor does it apply to the acquisition of a for-profit 
business entity by a not-for-profit organization. If the provisions of SFAS 
141 are not applicable, refer to Questions 1 through 3 in this section.
EITF 97-2, Application of FASB Statement No. 94 and APB Opinion No. 16 to 
Physician Practice Management Entities and Certain Other Entities with Con­
tractual Management Arrangements, provides guidance to assist PPMs in 
applying APB 16 when PPMs acquire a physician practice.
★ 1. If a business combination occurred during the period and met the 
specified conditions for a pooling-of-interests, do the statements and 
notes include the required disclosures?
[APB 16, pars. 63-65 (AC B50.122-.124)]
Note: Not-for-profit organizations are, under certain circumstances, per­
mitted to use the pooling-of-interests method, even though they generally 
do not issue common stock.
[AAG, pars. 1.49 and 1.50]
★ 2. If a business combination occurred during the period and is to be
accounted for under the purchase method, do the statements and 
notes include the required disclosures?
[APB 16, par. 95 (AC B50.164); SFAS 38, par. 10 (AC B50.166)]
★ 3. If, as part of a business combination accounted for as a purchase, a
material liability is recognized by the combined company for costs 
incurred to (a) exit an activity, (b) involuntarily terminate employees of 
an acquired company, or (c) relocate employees of an acquired company:
a. Are the following disclosures made for the period in which a 
purchase business combination occurs:
(1) If the plans to exit an activity or involuntarily terminate 
(relocate) employees of the acquired company are not final as 
of the balance sheet date, a description of any unresolved 
issues, the types of additional liabilities that may result in an 
adjustment to the purchase price allocation, and how any 
adjustment will be reported?
(2) A description of the type and amount of liabilities assumed 
in the purchase price allocation for costs to exit an activity or 
involuntary terminate (relocate) employees?
(3) A description of the major actions comprising the plan to exit 
an activity or involuntarily terminate (relocate) employees of 
an acquired company?
(4) A description of activities of the acquired company that will 
not be continued, including the method of disposition, and 
the anticipated date of completion and description of em­
ployee group(s) to be terminated (relocated)?
b. Are the following disclosures made for all periods presented 
subsequent to the acquisition date in which a purchase business 
combination occurred, until a plan to exit an activity or involun­
tarily terminate or relocate employees of an acquired company is 
fully executed:
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(1) A description of the type and amount of exit costs, involun­
tary employee termination costs, and relocation costs paid 
and charged against the liability?
(2) The amount of any adjustment to the liability account and 
whether the corresponding entry was an adjustment of the 
costs of the acquired company or included in the determina­
tion of net income for the period?
[EITF 95-31
♦ 4. Do the notes to the financial statements of a combined entity disclose
the following information in the period in which a material business 
combination is completed:
a. The name and a brief description of the acquired entity and the 
percentage of voting equity interests acquired?
b. The primary reasons for the acquisition, including a description of 
the factors that contributed to a purchase price that results in 
recognition of goodwill?
c. The period for which the results of operations of the acquired entity 
are included in the income statement of the combined entity?
d. The cost of the acquired entity and, if applicable, the number of 
shares of equity interests (such as common shares, preferred 
shares, or partnership interests) issued or issuable, the value as­
signed to those interests, and the basis for determining that value?
e. A condensed balance sheet disclosing the amount assigned to each 
major asset and liability caption of the acquired entity at the 
acquisition date?
f. Contingent payments, options, or commitments specified in the 
acquisition agreement and the accounting treatment that will be 
followed should any such contingency occur?
g. The amount of purchased research and development assets ac­
quired and written off in the period (refer to paragraph 42 of SFAS 
141) and the line item in the income statement in which the 
amounts written off are aggregated?
h. For any purchase price allocation that has not been finalized, that 
fact and the reasons therefore?
i. In subsequent periods, the nature and amount of any material 
adjustments made to the initial allocation of the purchase price? 
[SFAS 141, par. 51 (AC B51.164)]
♦ 5. Is the following information disclosed in the notes to the financial
statements in the period in which a material business combination is 
completed if the amounts assigned to goodwill or to other intangible 
assets acquired are significant in relation to the total cost of the 
acquired entity:
a. For intangible assets subject to amortization:
(1) The total amount assigned and the amount assigned to any 
major intangible asset class?
(2) The amount of any significant residual value, in total and by 
major intangible asset class?
(3) The weighted-average amortization period, in total and by 
major intangible asset class?
FSP §11,200.03
Financial Statements and Notes Checklist 55
Yes No N/A
b. For intangible assets not subject to amortization the total amount 
assigned and the amount assigned to any major intangible asset class?
c. For goodwill:
(1) The total amount of goodwill and the amount that is expected 
to be deductible for tax purposes?
(2) The amount of goodwill by reportable segment (if the com­
bined entity is required to disclose segment information in 
accordance with SFAS 131), unless not practicable?
[SFAS 141, par. 52 (AC B51.165)]
♦ 6. If a series of individually immaterial business combinations completed
during the period are material in the aggregate, is the following disclosed:
a. The number of entities acquired and a brief description of those 
entities?
b. The aggregate cost of the acquired entities, the number of equity 
interests, (such as common shares, preferred shares, or partnership 
interests) issued or issuable, and the value assigned to those interests?
c. The aggregate amount of any contingent payments, options, or 
commitments and the accounting treatment that will be followed 
should any such contingency occur (if potentially significant in 
relation to the aggregate cost of the acquired entities)?
d. The information described in Question 5 above, if the aggregate 
amount assigned to goodwill or to other intangible assets acquired is 
significant in relation to the aggregate cost of the acquired entities? 
[SFAS 141, par. 53 (AC B51.166)]
♦ 7. If the combined entity is a public business enterprise, is the following
supplemental information on a pro forma basis for the period in 
which a material business combination occurs (or for the period in 
which a series of individually immaterial business combinations oc­
cur that are material in the aggregate) disclosed:
a. Results of operations for the current period as though the business 
combination or combinations had been completed at the begin­
ning of the period unless the acquisition was at or near the begin­
ning of the period?
b. Results of operations for the comparable prior period as though the 
business combination or combinations had been completed at the 
beginning of that period if comparative financial statements are 
presented?
[SFAS 141, par. 54 (AC B51.167)]
♦ 8. Does the supplemental pro forma information display revenue, in­
come before extraordinary items and the cumulative effect of account­
ing changes, net income, and earnings per share at a minimum? (Note: 
In determining the pro forma amounts, income taxes, interest ex­
pense, preferred share dividends, and depreciation and amortization 
of assets shall be adjusted to the accounting base recognized for each 
in recording the combination. Pro forma information related to results 
of operations of periods prior to the combination shall be limited to 
the results of operations for the immediately preceding period.) 
[SFAS 141, par. 55 (AC B51.168)]
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Note: SFAS 154, Accounting Changes and Error Corrections, is effective for 
accounting changes made in fiscal years beginning after December 15, 
2005. Early adoption is permitted for accounting changes made in fiscal 
years beginning after the date SFAS 154 is issued (May 2005). After the 
effective date of SFAS 154, voluntary changes in accounting principle will 
no longer be reported as a cumulative-effect adjustment through the 
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC B51.168, fn. 25a)]
♦ 9. Does the supplemental pro forma information disclose the nature and
amount of material, nonrecurring items included in the reported pro 
forma results of operations, if any?
[SFAS 141, par. 55 (AC B51.168)]
♦ 10. In the period in which an extraordinary gain is recognized related to
a business combination, do the notes to the financial statements 
disclose the information required by paragraph 11 of APB 30? 
[SFAS 141, par. 56 (AC B51.169)]
♦ 11. If a material business combination is completed after the balance sheet
date but before the financial statements are issued, is the information 
required by Questions 4 and 5 above disclosed if practicable? 
[SFAS 141, par. 57 (AC B51.170)]
Interim Financial Information
♦ 12. For summarized interim financial information of a public business
enterprise is the following information disclosed if a material business 
combination is completed during the current year up to the date of 
the most recent interim statement of financial position presented:
a. The name and a brief description of the acquired entity and the 
percentage of voting equity interests acquired?
b. The primary reasons for the acquisition, including a brief descrip­
tion of the factors that contributed to a purchase price that results 
in recognition of goodwill?
c. The period for which the results of operations of the acquired entity 
are included in the income statement of the combined entity?
d. The cost of the acquired entity and, if applicable, the number of 
shares of equity interests (such as common shares, preferred 
shares, or partnership interests) issued or issuable, the value as­
signed to those interests, and the basis for determining that value?
e. Supplemental pro forma information that discloses the results of 
operations for the current interim period and the current year up 
to the date of the most recent interim statement of financial posi­
tion presented (and for the corresponding periods in the preceding 
year) as though the business combination had been completed as 
of the beginning of the period reported on?
f. The nature and amount of any material, nonrecurring items in­
cluded in the reported pro forma results of operations?
g. Do the pro forma information disclosures in Question e above 
display at a minimum, revenue, income before extraordinary 
items and the cumulative effect of accounting changes (including 
those on an interim basis), net income and earnings per share? 
[SFAS 141, par. 58 (AC B51.171)]
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Note: SFAS 154, Accounting Changes and Error Corrections, is effective for 
accounting changes made in fiscal years beginning after December 15, 
2005. Early adoption is permitted for accounting changes made in fiscal 
years beginning after the date SFAS 154 is issued (May 2005). After the 
effective date of SFAS 154, voluntary changes in accounting principle will 
no longer be reported as a cumulative-effect adjustment through the 
income statement of the period of change.
[SFAS 154, pars. 27 and C19 (AC B51.171, fn. 25b)]
♦ 13. If, as part of a business combination accounted for as a purchase, a
material liability is recognized by the combined company for costs 
incurred to (a) exit an activity, (b) involuntarily terminate employees of 
an acquired company, or (c) relocate employees of an acquired company:
a. Are the following disclosures made for the period in which a 
purchase business combination occurs:
(1) If the plans to exit an activity or involuntarily terminate 
(relocate) employees of the acquired company are not final as 
of the balance sheet date, a description of any unresolved 
issues, the types of additional liabilities that may result in an 
adjustment to the purchase price allocation, and how any 
adjustment will be reported?
(2) A description of the type and amount of liabilities assumed 
in the purchase price allocation for costs to exit an activity or 
involuntarily terminate (relocate) employees?
(3) A description of the major actions comprising the plan to exit 
an activity or involuntarily terminate (relocate) employees of 
an acquired company?
(4) A description of activities of the acquired company that will 
not be continued, including the method of disposition, and 
the anticipated date of completion and description of em­
ployee group(s) to be terminated (relocated)?
b. Are the following disclosures made for all periods presented 
subsequent to the acquisition date in which a purchase business 
combination occurred, until a plan to exit an activity or involun­
tarily terminate or relocate employees of an acquired company is 
fully executed:
(1) A description of the type and amount of exit costs, involun­
tary employee termination costs, and relocation costs paid 
and charged against the liability?
(2) The amount of any adjustment to the liability account and 
whether the corresponding entry was an adjustment of the 
costs of the acquired company or included in the determina­
tion of net income for the period?
[EITF 95-3]
♦ 14. Are the following disclosures made for business combinations be­
tween parties with a preexisting relationship:
a. The nature of the preexisting relationship?
b. The measurement of the amount of the settlement of the preexist­
ing relationship, if any, and the valuation method used to deter­
mine the settlement amount?
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c. The amount of any settlement gain or loss recognized and its 
classification in the statement of operations?
[EITF 04-1, par. 8]
Note: EITF 04-1, Accounting for Preexisting Relationships between the Parties 
to a Business Combination, should be applied to business combinations 
consummated in reporting periods beginning after October 13, 2004. Early 
application permitted in periods for which financial statements have not 
been issued.
[EITF 04-1, pars. 9-10]
D. Commitments and Contingencies
1. Uninsured medical malpractice claims:
★♦a. If a minimum amount of a probable loss (usually associated with 
litigating or settling malpractice claims) is accrued, is there disclo­
sure as to a reasonable possibility of an additional potential loss 
in excess of the amount accrued?
[AAG, par. 8.07; SFAS 5 (AC C59)]
b. If a range of loss cannot be reasonably estimated, is a contingency 
disclosed?
[AAG, par. 8.11; SFAS 5 (AC C59)]
c. Is the program of medical malpractice coverage and basis for loss 
accruals disclosed?
[AAG, par. 8.11]
d. If the provider discounts accrued malpractice claims, are the fol­
lowing disclosed:
(1) The carrying amount of the claims?
(2) The interest rates or other rates used to discount the claims? 
[AAG, par. 8.12]
2. Retrospectively rated premiums:
a. If the provider cannot estimate losses from asserted or unasserted 
malpractice claims, is the existing contingency disclosed? 
[AAG, par. 8.14; SFAS 5 (AC C59)]
b. Does the provider disclose that it is insured under a retrospec­
tively rated policy?
[AAG, par. 8.15]
c. Does the provider disclose that premiums are accrued based on 
the ultimate cost of the experience to date of a group of entities? 
[AAG, par. 8.15]
3. Medical malpractice claims insured with captive insurance compa­
nies (controlled by a parent entity for the main purpose of providing 
insurance for the parent):
a. Does the provider disclose that it is insured under a retrospec­
tively rated policy of a multiprovider captive?
[AAG, par. 8.18]
b. Does the provider disclose that premiums are accrued based on 
the captive's experience to date?
[AAG, par. 8.18]
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c. Is the provider's ownership percentage in the captive disclosed? 
[AAG, par. 8.19]
d. Is the method of accounting for its investment in and the opera­
tions of the captive disclosed?
[AAG, par. 8.19]
e. If the provider cannot make the necessary estimates of losses 
from asserted or unasserted claims, does it disclose the existing 
contingency?
[AAG, par. 8.19; SFAS 5 (AC C59)]
4. Trust funds:
a. If trust funds (revocable or irrevocable) are included in the 
provider's financial statements:
(1) Is a portion of the funds (the amount of assets expected to be 
liquidated to pay malpractice claims classified as current 
Eabilities) classified as a current asset in a classified balance 
sheet/statement of financial position?
[AAG, par. 8.20]
(2) Is the balance of the funds, if any, classified as a noncurrent 
asset in a classified balance sheet/statement of financial 
position?
[AAG, par. 8.20]
(3) Are trust fund revenue and administrative expenses included 
in the statement of activities (statement of operations)? 
[AAG, par. 8.20]
(4) Are estimated losses from asserted and unasserted claims 
reported?
[AAG, par. 8.21]
(5) Is the existence of trust funds and whether they are irrevoca­
ble disclosed?
[AAG, par. 8.22]
5. Prepaid health care services:
a. Health care costs:
(1) Is the basis for accruing health care costs disclosed?
(2) Are significant business and contractual arrangements 
with hospitals, physicians, and other associated entities 
disclosed?
[AAG, par. 13.04]
b. Stop-loss insurance:
(1) Are receivables representing amounts recoverable from in­
surers reported as assets net of any valuation allowance?
(2) Are the nature, amounts, and effects of significant stop-loss 
insurance contracts disclosed?
[AAG, par. 13.08]
c. Loss contracts:
(1) Are losses recognized, in accordance with SFAS 5, when it is 
probable that expected future health care costs and mainte­
nance costs under a group of existing contracts will exceed 
FSP §11,200.03
60 Health Care Organizations
Yes No N/A
anticipated future premiums and stop-loss insurance on 
those contracts?
[AAG, par. 13.06]
d. Contract acquisition costs:
(1) Are acquisition costs of providers of prepaid health care serv­
ices, other than costs of advertising, expensed as incurred? 
[AAG, par. 13.11]
6. Guarantees:
a. Are the nature and amount of guarantees disclosed (for example, 
of indebtedness of others)?
[SFAS 5, par. 12 (AC C59.113); FASBI 45, pars. 17 and 18 (AC 
C59.114)]
b. Is the following information disclosed by a guarantor about each 
guarantee, or each group of similar guarantees, even if the likeli­
hood of the guarantor's having to make any payments under the 
guarantee is remote:
(1)
(2)
The nature of the guarantee, including the approximate term, 
how the guarantee arose, and the events or circumstances that 
would require the guarantor to perform under the guarantee? 
The maximum potential amount of future payments (undis­
counted) the guarantor could be required to make under the 
guarantee?
(3) If the terms of the guarantee provide for no limitation to the 
maximum potential future payments under the guarantee, is 
that fact disclosed?
(4) The reasons why the guarantor cannot estimate the maxi­
mum potential amount of future payments under its guaran­
tee, if the guarantor is unable to develop an estimate?
(5) The current carrying amount of the liability, if any, for the 
guarantor's obligations under the guarantee, including the 
amount, if any, recognized under SFAS 5, paragraph 8, re­
gardless of whether the guarantee is freestanding or embed­
ded in another contract?
(6) The nature of—
(i) Any recourse provisions that would enable the guaran­
tor to recover from third parties any of the amounts paid 
under the guarantee?
(ii) Any assets held either as collateral or by third parties 
that, upon the occurrence of any triggering event or 
condition under the guarantee, the guarantor can obtain 
and liquidate to recover all or a portion of the amounts 
paid under the guarantee?
(7) If estimable, the approximate extent to which the proceeds 
from liquidation of those assets would be expected to cover 
the maximum potential amount of future payments under 
the guarantee?
[FASBI 45, par. 13 (AC G80.112)]
c. For product warranties and other guarantee contracts, collectively 
referred to as product warranties, is the following information 
disclosed if the guarantor is not required to disclose the maximum
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potential amount of future payments, as provided in FASBI 45, 
paragraph 14:
(1) The guarantor's accounting policy and methodology used in 
determining its liability for product warranties?
(2) A tabular reconciliation of the changes in the guarantor's aggre­
gate product warranty liability for the reporting period?
(3) Does the tabular reconciliation present—
(i) The beginning balance of the aggregate product war­
ranty liability?
(ii) The aggregate reductions in that liability for payments 
made in cash or in kind under the warranty?
(iii) The aggregate changes in the liability for accruals related 
to product warranties issued during the reporting period, 
and the aggregate changes in the liability for accruals 
related to preexisting warranties, including adjustments 
related to changes in estimates?
(iv) The ending balance of the aggregate product warranty 
liability?
[FASBI 45, par. 14 (AC G80.113)]
7. Other disclosures:
a. Is disclosure made of the nature of estimated loss contingencies 
accrued when (a) information available prior to issuance of the 
financial statements indicates that it is probable that an asset has 
been impaired or liability incurred at the date of the financial 
statements and (b) the amount of the loss can be reasonably 
estimated?
[SFAS 5, pars. 8 and 9 (AC C59.105 and .108)]
b. If necessary to keep the financial statements from being mislead­
ing, are the amounts of contingencies accrued as described in 
Question 7a above disclosed?
[SFAS 5, pars. 8 and 9 (AC C59.105 and .108)]
c. For loss contingencies not accrued because one or both of the 
conditions in paragraph 8 of SFAS 5 are not met, or if an exposure 
to loss exists in excess of the amount accrued, when there is at least 
a reasonable possibility that a loss or an additional loss may have 
been incurred, do disclosures indicate the:
(1) Nature of the contingency?
(2) Estimate of the possible loss or range of loss (or a statement 
that such an estimate cannot be made)?
[SFAS 5, par. 10 (AC C59.109)]
d. Are gain contingencies adequately disclosed with care to avoid 
any misleading implications about likelihood of realization? 
[SFAS 5, par. 17 (AC C59.118)]
e. Is there adequate disclosure of commitments such as those for 
plant acquisition or an obligation to reduce debts, maintain work­
ing capital, or restrict dividends?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
f. For long-term unconditional purchase obligations that are not 
recorded in the purchaser's balance sheet, are the following 
disclosed:
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(1) Nature and term of the obligations?
(2) Amount of the fixed and determinable portion of the obliga­
tions as of the date of the latest balance sheet presented in the 
aggregate and, if determinable, for each of the next five years?
(3) Nature of any variable components of the obligation?
(4) Amounts purchased under the obligations for each period 
for which an income statement/statement of operations is 
presented?
[SFAS 47, par. 7 (AC C32.102)]
8. Postemployment benefits:
★♦a. If an obligation for postemployment benefits (for example, sal­
ary continuation, supplemental unemployment benefits, sever­
ance benefits, disability-related benefits, job training and 
counseling, and continuation of health and insurance coverage) is 
not accrued in accordance with SFAS 5 (AC C59) or SFAS 43 (AC 
C44) only because the amount cannot reasonably be estimated, 
is the fact of nonaccrual disclosed in the financial statements? 
[SFAS 112, par. 7 (AC P32.105)]
9. Environmental remediation liabilities:
a. Are environmental remediation obligations reported and dis­
closed in accordance with SOP 96-1?
[SOP 96-1]
E. Exit or Disposal Activities
Note: SFAS 146, Accounting for Costs Associated with Exit or Disposal Activi­
ties, nullifies EITF 94-3. The provisions of EITF 94-3 shall continue to apply 
for an exit activity initiated under an exit plan that met the criteria of EITF 
94-3 prior to SFAS 146's initial application. For the purposes of applying 
SFAS 146, an exit or disposal activity is initiated when management, 
having the authority to approve the action, commits to an exit or disposal 
plan or otherwise disposes of a long-lived asset (disposal group) and, if 
the activity involves the termination of employees, the criteria for a plan 
of termination in paragraph 8 of SFAS 146 are met.
1. If a material liability is recognized for certain employee termination 
benefits in accordance with Section A of EITF 94-3, Liability Recognition 
for Certain Employee Termination Benefits and Other Costs to Exit an 
Activity (including Certain Costs Incurred in a Restructuring), are the 
following disclosures made in all periods until the plan of termination 
is completed:
a. The amount of termination benefits accrued and charged to ex­
pense and the classification of those costs in the income statement/ 
statement of activities?
b. The number of employees to be terminated?
c. A description of the employee group(s) to be terminated?
d. The amount of actual termination benefits paid and charged 
against the liability and the number of employees actually termi­
nated as a result of the plan to terminate employees?
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e. The amount of any adjustment(s) to the liability?
[EITF 94-3, Section A]
★♦2. If management commits to an exit plan that meets the criteria in 
Section B of EITF 94-3, are the following reporting requirements 
followed:
a. Reporting the income statement effect of recognizing a liability at 
the commitment date in income from continuing operations and 
not on the face of the income statement net of taxes?
b. No disclosure made on the face of the income statement for 
earnings per share effect?
c. Revenue and related costs and expenses of activities that will not 
be continued should not be combined and reported as a separate 
component of income?
[EITF 94-3, Section B]
3. If the activities that will not be continued are significant to the enter­
prise's revenue or operating results, or if the exit costs recognized at 
the commitment date are material, are the following disclosures made 
in all periods until the exit plan is completed:
a. A description of the major actions comprising the exit plan, activi­
ties that will not be continued, including the method of disposi­
tion, and the anticipated date of completion?
b. A description of the type and amount of exit costs recognized as 
liabilities and the classification of those costs in the income 
statement/statement of activities?
c. A description of the type and amount of exit costs paid and 
charged against the liability?
d. The amount of any adjustment(s) to the liability?
e. For all periods presented, the revenue and net operating income 
or losses from activities that will not be continued if those activities 
have separately identifiable operations?
[EITF 94-3, Section B]
4. Is the following information disclosed in notes to the financial state­
ments that include the period in which an exit or disposal activity is 
initiated and any subsequent period until the activity is completed:
a. A description of the exit or disposal activity, including the facts 
and circumstances leading to the expected activity and the ex­
pected completion date?
b. For each major type of cost associated with the activity (for exam­
ple, one-time termination benefits, contract termination costs, and 
other associated costs):
(1) The total amount expected to be incurred in connection with 
the activity, the amount incurred in the period, and the cu­
mulative amount incurred to date?
(2) A reconciliation of the beginning and ending liability bal­
ances showing separately the changes during the period at­
tributable to costs incurred and charged to expense, costs 
paid or otherwise settled, and any adjustments to the liability 
with an explanation of the reason(s) therefor?
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c. The line item(s) in the income statement or the statement of 
activities in which the costs in Question 4b are aggregated?
d. For each reportable segment:
(1) The total amount of costs expected to be incurred in connec­
tion with the activity?
(2) The amount incurred in the period?
(3) The cumulative amount incurred to date, net of any adjust­
ments to the liability with an explanation of the reason(s) 
therefor?
e. If a liability for a cost associated with the activity is not recognized 
because fair value cannot be reasonably estimated, that fact and 
the reasons therefor?
[SFAS 146, par. 20 (AC L32.120)]
♦ 5. Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing 
operations before income taxes in the income statement?
[SFAS 146, par. 18 (AC L32.118)]
★ 6. Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing 
operations in the statement of activities?
[SFAS 146, par. 18 (AC L32.118)]
7. Are costs associated with an exit or disposal activity that involves a 
discontinued operation included in the results of discontinued opera­
tions?
[SFAS 146, par. 18 (AC L32.118)]
8. If an event or circumstance occurs that discharges or removes an entity's 
responsibility to settle a liability for a cost associated with an exit or 
disposal activity recognized in a prior period, is the liability reversed? 
[SFAS 146, par. 19 (AC L32.119)]
★♦9. Are the related costs reversed through the same line item(s) in the 
income statement (statement of activities) used when those costs were 
recognized initially?
[SFAS 146, par. 19 (AC L32.119)]
F. Derivative Instruments and Hedging Activities
1. If an entity holds or issues derivative instruments (or nonderivative 
instruments that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42 of SFAS 133) has disclosure been 
made of its objectives for holding or issuing those instruments, the 
context needed to understand those objectives, and its strategies for 
achieving those objectives?
[SFAS 133, par. 44 (AC D50.141)]
★♦2. Does the description distinguish between derivative instruments 
(and nonderivative instruments) designated as fair value hedging 
instruments, derivative instruments designated as cash flow hedg­
ing instruments, derivative instruments (and nonderivative instru­
ments) designated as hedging instruments for hedges of the foreign
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currency exposure of a net investment in a foreign operation, and all 
other derivatives?
[SFAS 133, par. 44 (AC D50.141)]
3. Does the description also indicate the entity's risk management policy 
for each of those types of hedges, including a description of the items 
or transactions for which risks are hedged?
[SFAS 133, par. 44 (AC D50.141)]
★♦4. For derivative instruments not designated as hedging instruments, 
does the description indicate the purpose of the derivative activity? 
[SFAS 133, par. 44 (AC D50.141)]
5. Qualitative disclosures about an entity's objectives and strategies for 
using derivative instruments may be more meaningful if such objec­
tives and strategies are described in the context of an entity's overall 
risk management profile. If appropriate, an entity is encouraged, but 
not required, to provide such additional qualitative disclosures. Have 
such disclosures been made?
[SFAS 133, par. 44 (AC D50.141)]
Note: SOP 02-2, Accounting for Derivative Instruments and Hedging Activi­
ties by Not-for-Profit Health Care Organizations, and Clarification of the Per­
formance Indicator, paragraph 8, requires not-for-profit health care 
organizations to provide disclosures that are analogous to those required 
by paragraph 45 of SFAS 133, Accounting for Derivative Financial Instru­
ments and Hedging Activities, for for-profit enterprises, including the dis­
closure of anticipated reclassifications into the performance indicator of 
gains and losses that have been excluded from that measure and reported 
in accumulated derivative gain or loss as of the reporting date. The provisions 
of SOP 02-2 are effective for fiscal years beginning after June 15, 2003. Earlier 
application is encouraged but permitted only as of the beginning of any fiscal 
quarter that begins after issuance of SOP 02-2. See paragraphs 10 and 11 of 
SOP 02-2 for additional effect date and transition information. If the provi­
sions of SOP 02-2 are applied, see Questions 8, 9 and 10 for disclosures 
required for the transition to the provisions of SOP 02-2.
6. Do the entity's disclosures for every reporting period for which a com­
plete set of financial statements is presented also include the following:
Fair Value Hedges
a. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, that have been designated and have qualified as 
fair value hedging instruments and for the related hedged items:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance?
(2) The amount of net gain or loss recognized in earnings when 
a hedged firm commitment no longer qualifies as a fair value 
hedge?
[SFAS 133, par. 45a (AC D50.142)]
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Cash Flow Hedges
b. For derivative instruments that have been designated and have 
qualified as cash flow hedging instruments and for the related 
hedged transactions:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance?
(2) A description of the transactions or other events that will 
result in the reclassification into earnings of gains and losses 
that are reported in accumulated other comprehensive in­
come, and the estimated net amount of the existing gains or 
losses at the reporting date that is expected to be reclassified 
into earnings within the next 12 months?
(3) The maximum length of time over which the entity is hedging 
its exposure to the variability in future cash flows for fore­
casted transactions excluding those forecasted transactions 
related to the payment of variable interest on existing finan­
cial instruments?
(4) The amount of gains and losses reclassified into earnings as 
a result of the discontinuance of cash flow hedges because it 
is probable that the original forecasted transactions will not 
occur by the end of the originally specified time period (as 
documented at the inception of the hedging relationship) or 
within additional two-month period of time thereafter? 
[SFAS 133, par. 45b, as amended by SFAS 138, par. 4r (AC 
D50.142)]
Hedges of the Net Investment in a Foreign Operation
c. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, that have been designated and have qualified 
as hedging instruments for hedges of the foreign currency ex­
posure of a net investment in a foreign operation, the net amount 
of gains or losses included in the cumulative translation adjust­
ment during the reporting period?
[SFAS 133, par. 45c (AC D50.142)]
★♦7. The quantitative disclosures about derivative instruments may be 
more useful, and less likely to be perceived to be out of context or 
otherwise misunderstood, if similar information is disclosed about 
other financial instruments or nonfinancial assets and liabilities to 
which the derivative instruments are related by activity. Accordingly, in 
such situations, has the entity presented a more complete picture of its 
activities by disclosing that information? (Encouraged, but not required.) 
[SFAS 133, par. 45 (AC D50.142)]
★ 8. Are any derivative gains and losses excluded from the performance 
indicator in the financial statements issued for periods ended before 
the initial date of application of SOP 02-2 that did not meet the cash 
flow hedging criteria of SFAS 133:
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a. Not reclassified and included as a component of the performance 
indicator in any period subsequent to the initial date of application 
of SOP 02-2?
b. Not included in the disclosure of the accumulated derivative gain 
or loss as described in paragraph 8 of SOP 02-2?
[SOP 02-2, par. 10]
★ 9. To the extent that derivative gains or losses on cash flow hedges
qualifying under SFAS 133 had been reported in a manner consistent 
with the provisions of SOP 02-2 in financial statements for periods 
prior to the initial date of application of SOP 02-2, are such amounts 
included in the disclosure of derivative gain or loss as described in 
paragraph 8 of SOP 02-2 and reclassified and included in the perform­
ance indicator when the hedged transaction affects the performance 
indicator?
[SOP 02-2, par. 10]
★ 10. When the financial statements of the year of adoption are presented
separately or included in comparative financial statements do the 
notes to the financial statements disclose:
a. The fact that SOP 02-2 has been adopted and the effective date of 
the adoption?
b. The nature of any differences in accounting principles or financial 
statement presentation applicable to the financial statements pre­
sented that resulted from adoption of SOP 02-2 (disclosure of pro 
forma amounts is not required)?
[SOP 02-2, par. 10]
G. Financial Instruments
Disclosures About Fair Value of Financial Instruments
1. Has the entity disclosed, either in the body of the financial statements 
or in the accompanying notes, the fair value of financial instruments 
(except for those excluded in paragraphs 8 and 13 of SFAS 107) for 
which it is practicable to estimate fair value?
[SFAS 107, par. 10 (AC F25.115C)]
Note: If disclosed in more than a single note, one of the notes shall include 
a summary table. The summary table shall contain the fair value and 
related carrying amounts and cross-references to the location(s) of the 
remaining disclosures required by SFAS 107 as amended.
[SFAS 107, par. 10, fn. * (AC F25.115C fn. 16a)]
2. Has the fair value disclosed in the notes been presented together with 
the related carrying amount in a form that makes it clear whether the 
fair value and carrying amount represent assets or liabilities and how 
the carrying amounts relate to what is reported in the statement of 
financial position?
[SFAS 107, par. 10 (AC F25.115C)]
3. Are the methods and significant assumptions used to estimate the fair 
value of financial instruments disclosed?
[SFAS 107, par. 10 (AC F25.115C)]
4. In disclosing the fair value of a financial instrument, has the entity 
taken care not to net that fair value with the fair value of other 
financial instruments—even if those financial instruments are of 
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the same class or are otherwise considered to be related, for example, 
by a risk management strategy—except to the extent that the offset­
ting of carrying amounts in the statement of financial position is 
permitted under the general principle in paragraphs 5 and 6 of FASBI 
39, Offsetting of Amounts Related to Certain Contracts, or the exceptions 
for master netting arrangements in paragraph 10 of FASBI 39 and 
for amounts related to certain repurchase and reverse repurchase 
agreements in paragraphs 3 and 4 of FASBI 41, Offsetting of Amounts 
Related to Certain Repurchase and Reverse Repurchase Agreements? 
[SFAS 107, par. 14 (AC F25.115I)]
5. If it is not practicable to estimate the fair value of a financial instru­
ment or a class of financial instruments, are the following dis­
closed:
a. Information pertinent to estimating the fair value of that financial 
instrument or class of financial instruments, such as the carrying 
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value? 
[SFAS 107, par. 14 (AC F25.115J)]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial 
Instruments for Certain Nonpublic Entities, makes the disclosures about fair 
values of financial instruments prescribed in SFAS 107 optional for report­
ing entities that:
• Are nonpublic entities,
Have total assets of less than $100 million on the date of the financial 
statements, and
Have no instrument that, in whole or in part, is accounted for as a 
derivative instrument under SFAS 133, Accounting for Derivative In­
struments and Hedging Activities, other than commitments related to 
the origination of mortgage loans to be held for sale during the report­
ing period.
[SFAS 126, par. 2, as amended by SFAS 149 (AC F25.105J)]
Disclosure About Concentrations of Credit Risk of AU Financial Instruments
6. Except as indicated in paragraph 15B of SFAS 107, has the entity 
disclosed all significant concentrations of credit risk arising from 
all financial instruments, whether from an individual counter­
party or groups of counterparties (Group concentrations of credit risk 
exist if a number of counterparties are engaged in similar economic 
characteristics that would cause their ability to meet contractual 
obligations to be similarly affected by changes in economic or other 
conditions)?
[SFAS 107, par. 15A (AC F25.116A)]
Note: SFAS 107, paragraph 15B provides that these disclosure require­
ments do not apply to the following financial instruments, whether writ­
ten or held:
a. Financial instruments of a pension plan, including plan assets, when 
subject to the accounting and reporting requirements of SFAS 87 
(Financial instruments of a pension plan, other than the obligations 
for pension benefits, when subject to the accounting and reporting 
requirements of SFAS 35, Accounting and Reporting by Defined Benefit 
Pension Plans, are subject to the reporting of paragraph 15A).
(continued)
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b. The financial instruments described in paragraphs 8(a), 8(c), 8(e), 
and 8(f) of SFAS 107, as amended by SFAS 112, Employers' Accounting 
for Postemployment Benefits, SFAS 123, Accounting for Stock-Based 
Compensation, except for reinsurance receivables and prepaid rein­
surance premiums.
[SFAS 107, par. 15B (AC F25.116B)]
7. Has the entity made the following disclosures about each significant 
concentration:
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration?
b. The maximum amount of loss due to credit risk that, based on the 
gross fair value of the financial instrument, the entity would incur 
if parties to the financial instruments that make up the concentra­
tion failed completely to perform according to the terms of the 
contracts and the collateral or other security, if any, for the amount 
due proved to be of no value to the entity?
c. The entity's policy of requiring collateral or other security to 
support financial instruments subject to credit risk, information 
about the entity's access to that collateral or other security, and the 
nature and a brief description of the collateral or other security 
supporting those financial instruments?
d. The entity's policy of entering into master netting arrangements 
to mitigate the credit risk of financial instruments, information 
about the arrangements for which the entity is a party, and a brief 
description of the terms of those arrangements, including the 
extent to which they would reduce the entity's maximum amount 
of loss due to credit risk?
[SFAS 107, par. 15A (AC F25.116A)]
8. Has the entity disclosed quantitative information about the market 
risks of financial instruments that is consistent with the way it man­
ages or adjusts those risks? (Encouraged, but not required.)
[SFAS 107, par. 15C (AC F25.116C)]
Note: Appropriate ways of reporting the quantitative information en­
couraged will differ for different entities and will likely evolve over 
time as management approaches and measurement techniques evolve. 
Possibilities include disclosing (a) more details about current positions 
and perhaps activity during the period, (b) the hypothetical effects on 
comprehensive income (or net assets), or annual income, of several 
possible changes in market prices, (c) a gap analysis of interest rate 
repricing or maturity dates, (d) the duration of the financial instru­
ments, or (e) the entity's value at risk from derivatives and from other 
positions at the end of the reporting period and the average value at 
risk during the year. This list is not exhaustive, and an entity is encour­
aged to develop other ways of reporting quantitative information. 
[SFAS 107, par. 15D (AC F25.116D)]
9. Are the classification guidelines and disclosures under EITF 00-19, 
Accounting for Derivative Financial Instruments Indexed to, and Potentially 
Settled in, a Company's Own Stock, followed for freestanding contracts 
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that are indexed to, and potentially settled in, the company's own 
stock?
[EITF 00-191
10. Is disclosure made of the primary geographic sources of patients? 
[AAG, par. 5.24]
♦ Disclosures About Certain Financial Instruments With Characteristics of 
Both Liabilities and Equity
Note: Depending upon whether an entity is a nonpublic entity, a public 
entity, or an SEC registrant, FSP FAS 150-3 defers the effective date for 
applying the provisions of SFAS 150. Refer to SFAS 150 and FSP FAS 150-3 
for effective date information on applying the provisions of SFAS 150.
11. For items within the scope of SFAS 150, are they presented as liabilities 
(or assets in some circumstances), and not between the liabilities 
section and the equity section of the statement of financial position? 
[SFAS 150, par. 18 (AC F41.116)]
12. If the entity has no equity instruments outstanding but has financial 
instruments in the form of shares, all of which are mandatorily re­
deemable financial instruments required to be classified as liabilities:
a. Are they described in statements of financial position as "shares 
subject to mandatory redemption"?
b. Are payments to holders of such instruments and related accruals 
presented separately from payments to and interest due to other 
creditors in statements of cash flows and income?
[SFAS 150, pars. 19 and 28 (AC F41.117 and .126)]
13. Do the entities referred to in Question 12 above disclose the compo­
nents of the liability that would otherwise be related to shareholders' 
interest and other comprehensive income, if any, subject to the re­
demption feature? (For example, par value and other paid-in amounts 
of mandatorily redeemable instruments should be disclosed sepa­
rately from the amount of retained earnings or accumulated deficit.) 
[SFAS 150, par. 28 (AC F41.126)]
14. For issuers of financial instruments within the scope of SFAS 150:
a. Are the nature and terms of the financial instruments and the 
rights and obligations embodied in those instruments disclosed?
b. Does that disclosure include information about settlement alter­
natives, if any, in the contract and identify the entity that controls 
the settlement alternatives?
[SFAS 150, par. 26 (AC F41.124)]
15. For all outstanding financial instruments within the scope of SFAS 150 
and for each settlement alternative, do issuers disclose:
a. The amount that would be paid, or the number of shares that 
would be issued and their fair value, determined under the con­
ditions specified in the contract if the settlement were to occur at 
the reporting date?
b. How changes in the fair value of the issuer's equity shares would 
affect those settlement amounts?
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c. The maximum amount that the issuer could be required to pay to 
redeem the instrument by physical settlement, if applicable?
d. The maximum number of shares that could be required to be 
issued, if applicable?
e. That a contract does not limit the amount that the issuer could be 
required to pay or the number of shares that the issuer could be 
required to issue, if applicable?
f. For a forward contract or an option indexed to the issuer's equity 
shares, the forward price or option strike price, the number of 
issuer's shares to which the contract is indexed, and the settlement 
date or dates of the contract, as applicable?
[SFAS 150, par. 27 (AC F41.125)]
16. Are mandatorily redeemable financial instruments classified as li­
abilities unless the redemption is required to occur only upon the 
liquidation or termination of the reporting entity?
[SFAS 150, par. 9 (AC F41.107)]
17. Are financial instruments, other than an outstanding share, that at 
inception, (a) embodies an obligation to repurchase the issuer's equity 
shares or is indexed to such an obligation, and (b) requires or may 
require the issuer to settle the obligation by transferring assets, clas­
sified as liabilities (or assets in some circumstances)?
[SFAS 150, par. 11 (AC F41.109)]
18. Are financial instruments that embody an unconditional obligation, 
or financial instruments other than an outstanding share that embod­
ies a conditional obligation, that the issuer must or may settle by 
issuing a variable number of its equity shares, classified as liabilities 
(or assets in some circumstances) if, at inception, the monetary value 
of the obligation is based solely or predominantly on any one of the 
items indicated in paragraph 12 of SFAS 150?
[SFAS 150, par. 12 (AC F41.110)]
Mandatorily Redeemable Shares Requiring Redemption by Payment of 
an Amount That Differs from Book Value
19. Are the cumulative transition adjustment and any subsequent adjust­
ments reported as an excess of liabilities over assets (a deficit) and 
changes thereto even though the mandatorily redeemable shares are 
reported as a liability?
[FSP FAS 150-2 (AC F41.810)]
20. If the redemption price of mandatorily redeemable shares is less than 
the book value of those shares, is the excess of that book value over 
the liability reported for the mandatorily redeemable shares as an 
excess of assets over liabilities (equity)?
[FSP FAS 150-2 (AC F41.811)]
SFAS 150 Effective Date Deferral
21. Although the disclosure requirements of SFAS 150 do not apply for 
those mandatorily redeemable instruments of certain nonpublic com­
panies while application of the provisions of SFAS 150 to those 
instruments is deferred, are the capital structure disclosure require­
ments in SFAS 129 still provided, in particular: 
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a. Information required in paragraph 4 about the pertinent rights 
and privileges of the various securities outstanding, including 
mandatory redemption requirements?
b. Disclosure required in paragraph 8 of the amount of redemption 
requirements for all issues of stock that are redeemable at fixed or 
determinable prices on fixed or determinable dates in each of the 
next five years?
[FSP FAS 150-3 (AC F41.819)]
22. During the deferral period, if the entity is a public entity or a nonpub­
lic entity that is an SEC registrant, are the disclosure requirements in 
paragraphs 26 and 27 of SFAS 150 as well as disclosures required by 
other applicable guidance complied with?
[FSP FAS 150-3 (AC F41.822)]
H. Nonmonetary Transactions
1. Do disclosures include:
a. Nature of the transactions?
b. Basis of accounting for the assets transferred?
c. Gains or losses recognized on the transfers? 
[APB 29, par. 28 (AC C11.102 and N35.120)]
♦ 2. Is the amount of gross operating revenue recognized as a result of 
nonmonetary transactions addressed by EITF 00-8, Accounting by a 
Grantee for an Equity Instrument to Be Received in Conjunction with 
Providing Goods or Services, disclosed in each period's financial state­
ments?
[EITF 00-8]
I. Pension and Other Postretirement Benefit Plans
★♦1. If an employer sponsors one or more defined benefit pension plans or 
one or more defined benefit postretirement plans, do disclosures 
include (separately for pension plans and other postretirement benefit 
plans):
a. A reconciliation of beginning and ending balances of the benefit 
obligation showing separately, if applicable, the effects during the 
period attributable to each of the following: service cost, interest 
cost, contributions by plan participants, actuarial gains and losses, 
foreign currency exchange rate changes, benefits paid, plan 
amendments, business combinations, divestitures, curtailments, 
settlements, and special termination benefits?
b. A reconciliation of beginning and ending balances of the fair value 
of plan assets showing separately, if applicable, the effects during 
the period attributable to each of the following: actual return on 
plan assets, foreign currency exchange rate changes, contributions 
by the employer, contributions by plan participants, benefits paid, 
business combinations, divestitures, and settlements?
c. The funded status of the plans, the amounts not recognized in the 
statement of financial position, and the amounts recognized in the 
statement of financial position, including:
(1) The amount of any unamortized prior service cost?
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(2) The amount of any unrecognized net gain or loss (including 
asset gains and losses not yet reflected in market-related 
value)?
(3) The amount of any remaining unamortized, unrecognized 
net obligation or net asset existing at the initial date of appli­
cation of SFAS 87 or SFAS 106?
(4) The net pension or other postretirement benefit prepaid as­
sets or accrued liabilities?
(5) Any intangible asset and the amount of accumulated other 
comprehensive income (net assets) recognized pursuant to 
paragraph 37 of SFAS 87, as amended?
d. Information about plan assets:
(1) For each major category of plan assets, which shall include, 
but is not limited to, equity securities, debt securities, real 
estate, and all other assets, the percentage of the fair value of 
total plan assets held as of the measurement date used for 
each statement of financial position presented?
(2) A narrative description of investment policies and strategies, 
including target allocation percentages or range of percent­
ages for each major category of plan assets presented on a 
weighted-average basis as of the measurement date(s) of the 
latest statement of financial position presented, if applicable, 
and other factors that are pertinent to an understanding of the 
policies or strategies such as investment goals, risk manage­
ment practices, permitted and prohibited investments in­
cluding the use of derivatives, diversification, and the 
relationship between plan assets and benefit obligations?
(3) A narrative description of the basis used to determine the 
overall expected long-term rate-of-return-on-assets assump­
tion, such as the general approach used, the extent to which 
the overall rate-of-return-on-assets assumption was based on 
historical returns, the extent to which adjustments were made 
to those historical returns in order to reflect expectations of 
future returns, and how those adjustments were determined?
(4) Disclosure of additional asset categories and additional infor­
mation about specific assets within a category? (Note: En­
couraged if that information is expected to be useful in 
understanding the risks associated with each asset category 
and the overall expected long-term rate of return on assets.)
e. For defined benefit pension plans, the accumulated benefit obli­
gation?
f. The benefits (as of the date of the latest statement of financial 
position presented) expected to be paid in each of the next five 
fiscal years, and in the aggregate for the five fiscal years thereafter? 
(Note: The expected benefits should be estimated based on the 
same assumptions used to measure the company's benefit obliga­
tion at the end of the year and should include benefits attributable 
to estimated future employee service.)
g. The employer's best estimate, as soon as it can reasonably be 
determined, of contributions expected to be paid to the plan 
during the next fiscal year beginning after the date of the latest 
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statement of financial position presented? (Note: Estimated con­
tributions may be presented in the aggregate combining (1) con­
tributions required by funding regulations or laws, (2) 
discretionary contributions, and (3) noncash contributions.)
h. The amount of net periodic benefit cost recognized, showing 
separately the service cost component, the interest cost compo­
nent, the expected return on plan assets for the period, the amor­
tization of the unrecognized transition obligation or transition 
asset, the amount of recognized gains or losses, the amount of 
prior service cost recognized, and the amount of gains or losses 
recognized due to a settlement or curtailment?
i. The amount included within other comprehensive income 
(change in net assets) for the period arising from a change in the 
additional minimum pension liability recognized pursuant to 
paragraph 37 of SFAS 87, as amended?
j. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rates, rates of 
compensation increase (for pay-related plans), and expected long­
term rates of return on plan assets specifying, in a tabular format, 
the assumptions used to determine the benefit obligation and the 
assumptions used to determine net benefit cost?
k. The measurement date(s) used to determine pension and other 
postretirement benefit measurements for the pension plans and 
other postretirement benefit plans that make up at least the major­
ity of plan assets and benefit obligations?
l. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to 
be achieved?
m. The effect of a one-percentage-point increase and the effect of a 
one-percentage-point decrease in the assumed health care cost trend 
rates on (1) the aggregate of the service and interest cost components 
of net periodic postretirement health care benefit costs and (2) the 
accumulated postretirement benefit obligation for health care bene­
fits? (For purposes of this disclosure, all other assumptions shall be 
held constant, and the effects shall be measured based on the sub­
stantive plan that is the basis for the accounting.)
n. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
o. If applicable, any alternative method used to amortize prior serv­
ice amounts or unrecognized net gains and losses pursuant to 
paragraphs 26 and 33 of SFAS 87 or paragraphs 53 and 60 of SFAS 
106?
p. If applicable, any substantive commitment, such as past practice 
or a history of regular benefit increases, used as the basis for 
accounting for the benefit obligation?
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q. If applicable, the cost of providing special or contractual termina­
tion benefits recognized during the period and a description of the 
nature of the event?
r. An explanation of any significant change in the benefit obligation 
or plan assets not otherwise apparent in the other disclosures 
required by SFAS 132?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]
2. Are amounts related to the employer's results of operations disclosed 
for each period for which an income statement/statement of opera­
tions is presented?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]
3. Are amounts related to the employer's statement of financial position, 
unless otherwise stated, disclosed as of the measurement date used 
for each statement of financial position presented?
[SFAS 132(R), par. 5 (AC P16.150 and P40.169)]
Employers With Two or More Plans
★♦4. Are the disclosures required by SFAS 132 (revised 2003) aggregated 
for all of an employer's defined benefit pension plans and for all of an 
employer's other defined benefit postretirement plans unless disag­
gregating in groups is considered to provide useful information or is 
otherwise required by paragraphs 6 and 7 of SFAS 132 (revised 2003)? 
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
5. Unless otherwise stated, are disclosures as of the measurement date 
for each statement of financial position presented?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
6. Does the disclosure of amounts recognized in the statement of finan­
cial position present prepaid benefit costs and accrued benefit liabili­
ties separately?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
Note: Disclosures about pension plans with assets in excess of the accu­
mulated benefit obligation generally may be aggregated with disclosures 
about pension plans with accumulated benefit obligations in excess of 
assets. The same aggregation is permitted for other postretirement benefit 
plans.
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
7. If aggregate disclosures are presented, does the employer disclose:
a. The aggregate benefit obligation and aggregate fair value of plan 
assets for plans with benefit obligations in excess of plan assets as 
of the measurement date of each statement of financial position 
presented?
b. The aggregate pension accumulated benefit obligation and aggre­
gate fair value of plan assets for pension plans with accumulated 
benefit obligations in excess of plan assets?
[SFAS 132(R), par. 6 (AC P16.153 and P40.172)]
8. Are disclosures about pension or other postretirement benefit plans 
outside the United States separate from those for U.S. plans when the 
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plans outside the United States have benefit obligations that are 
significant relevant to the total benefit obligation and use significantly 
different assumptions?
[SFAS 132(R), par. 7 (AC P16.153A and P40.173)]
Reduced Disclosure Requirements for Nonpublic Entities
9. A nonpublic entity is not required to disclose the information required 
by paragraphs 5(a)-(c), 5(h), 5(m), and 5(o)-(r) of SFAS 132 (revised 
2003). If a nonpublic entity that sponsors one or more defined benefit 
pension plans or one or more other defined benefit postretirement 
plans elects the reduced disclosure requirements, has the following 
information been disclosed, separately for pension plans and other 
postretirement benefit plans:
a. The benefit obligation, fair value of plan assets, and funded status 
of the plan?
b. Employer contributions, participant contributions, and benefits 
paid?
c. Information about plan assets:
(1) For each major category of plan assets which shall include, 
but is not limited to, equity securities, debt securities, real 
estate, and all other assets, the percentage of the fair value of 
total plan assets held as of the measurement date used for 
each statement of financial position presented?
(2) A narrative description of investment policies and strategies, 
including target allocation percentages or range of percent­
ages for each major category of plan assets presented on a 
weighted-average basis as of the measurement date(s) of the 
latest statement of financial position presented, if applicable, 
and other factors that are pertinent to an understanding of the 
policies or strategies such as investment goals, risk manage­
ment practices, permitted and prohibited investments in­
cluding the use of derivatives, diversification, and the 
relationship between plan assets and benefit obligations?
(3) A narrative description of the basis used to determine the 
overall expected long-term rate-of-return-on-assets assump­
tion, such as the general approach used, the extent to which 
the overall rate-of-return-on-assets assumption was based on 
historical returns, the extent to which adjustments were made 
to those historical returns in order to reflect expectations of 
future returns, and how those adjustments were determined?
Note: Disclosure of additional asset categories and additional informa­
tion about specific assets within a category is encouraged if that informa­
tion is expected to be useful in understanding the risks associated with 
each asset category and the overall expected long-term rate of return on 
assets.
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
d. For defined benefit pension plans, the accumulated benefit obli­
gation?
e. The benefits (as of the date of the latest statement of financial 
position presented) expected to be paid in each of the next five 
fiscal years, and in the aggregate for the five fiscal years thereafter?
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(The expected benefits should be estimated based on the same 
assumptions used to measure the company's benefit obligation at 
the end of the year and should include benefits attributable to 
estimated future employee service.)
f. The employer's best estimate, as soon as it can reasonably be 
determined, of contributions expected to be paid to the plan 
during the next fiscal year beginning after the date of the latest 
statement of financial position presented? (Estimated contribu­
tions may be presented in the aggregate combining (1) contribu­
tions required by funding regulations or laws, (2) discretionary 
contributions, and (3) noncash contributions.)
g. The amounts recognized in the statements of financial position, 
including net pension and other postretirement benefit prepaid 
assets or accrued liabilities and any intangible asset and the 
amount of accumulated other comprehensive income (net assets) 
recognized pursuant to paragraph 37 of SFAS 87, as amended?
h. The amount of net periodic benefit cost recognized and the 
amount included within other comprehensive income (change in 
net assets) arising from a change in the minimum pension liability 
recognized pursuant to paragraph 37 of SFAS 87, as amended?
i. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rates, rates of 
compensation increase (for pay-related plans), and expected long­
term rates of return on plan assets specifying, in a tabular format, 
the assumptions used to determine the benefit obligation and the 
assumptions used to determine net benefit cost?
j. The measurement date(s) used to determine pension and other 
postretirement benefit measurements for the pension plans and 
other postretirement benefit plans that make up at least the major­
ity of plan assets and benefit obligations?
k. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to 
be achieved?
l. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
m. The nature and effect of significant nonroutine events, such as 
amendments, combinations, divestitures, curtailments, and 
settlements?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
10. Are amounts related to the employer's results of operations disclosed 
for each period for which a statement of income/statement of opera­
tions is presented?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
FSP §11,200.03
78 Health Care Organizations
Yes No N/A
11. Are amounts related to the employer's statement of financial position 
disclosed as of the measurement date used for each statement of 
financial position presented?
[SFAS 132(R), par. 8 (AC P16.150A and P40.169A)]
Disclosures in Interim Financial Reports
 12. If the entity is a publicly traded entity, does it disclose the following 
information in its interim financial statements that include a statement 
of income:
a. The amount of net periodic benefit cost recognized, for each period 
for which a statement of income/operations is presented, showing 
separately the service cost component, the interest cost compo­
nent, the expected return on plan assets for the period, the amor­
tization of the unrecognized transition obligation or transition 
asset, the amount of recognized gains or losses, the amount of 
prior service cost recognized, and the amount of gain or loss 
recognized due to a settlement or curtailment?
b. The total amount of the employer's contributions paid, and ex­
pected to be paid, during the current fiscal year, if significantly 
different from amounts previously disclosed pursuant to para­
graph 5(g) of SFAS 132 (revised 2003)? (Estimated contributions 
may be presented in the aggregate combining (1) contributions 
required by funding regulations or laws, (2) discretionary contri­
butions, and (3) noncash contributions.)
[SFAS 132(R), par. 9; APB 28, par. 30, as amended by SFAS 132(R), 
par. 15 (AC I73.146)]
13. If the entity is a nonpublic entity, does it disclose in interim periods, 
for which a complete set of financial statements is presented, the total 
amount of the employer's contributions paid, and expected to be paid, 
during the current fiscal year, if significantly different from amounts 
previously disclosed pursuant to paragraph 8(f) of SFAS 132 (revised 
2003)? (Estimated contributions may be presented in the aggregate 
combining (a) contributions required by funding regulations or laws, 
(b) discretionary contributions, and (c) noncash contributions.) 
[SFAS 132(R), par. 10 (AC P16.150B and P40.169B)]
Defined Contribution Plans
14. Does the employer disclose the amount of cost recognized for defined 
contribution pension plans and for other defined contribution postre­
tirement benefit plans for all periods presented separately from the 
amount of cost recognized for defined benefit plans?
[SFAS 132(R), par. 11 (AC P16.162 and P40.198)]
15. Do disclosures include a description of the nature and effect of any 
significant changes during the period affecting comparability, such as 
a change in the rate of employer contributions, a business combina­
tion, or a divestiture?
[SFAS 132(R), par. 11 (AC P16.162 and P40.198)]
Multiemployer Plans
16. Has the employer disclosed the amount of contributions to multiem­
ployer plans for each annual period for which a statement of income/
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statement of operations is presented? (An employer may disclose total 
contributions to multiemployer plans without disaggregating the 
amounts attributable to pension plans and other postretirement bene­
fit plans.)
[SFAS 132(R), par. 12 (AC P16.166 and P40.178)]
★♦17. Is a description of the nature and effect of any changes affecting 
comparability, such as a change in the rate of employer contributions, 
a business combination, or a divesture, disclosed?
[SFAS 132(R), par. 12 (AC P16.166 and P40.178)]
★♦18. In some situations, withdrawal from a multiemployer plan may result 
in an employer having an obligation to the plan for a portion of the 
unfunded benefit obligation of the pension plans and other postretire­
ment benefit plans:
a. If withdrawal under circumstances that would give rise to an 
obligation is either probable or reasonably possible, have the 
provisions of SFAS 5 been applied? (See also Question 7 in "Other 
Financial Statement Disclosures, Section D—Commitments and 
Contingencies.")
[SFAS 132(R), par. 13; SFAS 87, par. 70 (AC P16.167)]
b. If it is either probable or reasonably possible that (a) an employer 
would withdraw from the plan under circumstances that would 
give rise to an obligation or (b) an employer's contribution to the 
fund would be increased during the remainder of the contract 
period to make up a shortfall in the funds necessary to maintain 
the negotiated level of benefit coverage (a "maintenance of bene­
fits" clause), has the employer applied the provisions of SFAS 5? 
(See also Question 7 in "Other Financial Statement Disclosures, 
Section D—Commitments and Contingencies.")
[SFAS 132(R), par. 13; SFAS 106, par. 83 (AC P40.179)]
Disclosure Requirements Related to the Medicare Prescription Drug, 
Improvement and Modernization Act of 2003
Note: FSP FAS 106-1 permits a sponsor of a postretirement health care 
plan that provides a prescription drug benefit to make a one-time election 
to defer recognizing the effects of the Act in accounting for its plan under 
SFAS 106 and providing disclosures related to the plan required by SFAS 
132 (revised 2003) until authoritative guidance on the accounting for the 
federal subsidy is issued, or certain other events occur. See Questions 22 
through 24 for disclosures required by FSP FAS 106-2.
★♦19. If the entity that sponsors a postretirement health care plan that 
provides prescription drug benefits and elects the deferral provided 
by FSP FAS 106-1, is the following disclosed in annual or interim 
financial statements:
a. The existence of the Act and the fact that, in accordance with FSP 
FAS 106-1, any measures of the accumulated postretirement bene­
fit obligation or net periodic postretirement benefit cost in the 
financial statements or accompanying notes do not reflect the 
effects of the Act on the plan?
b. The fact that specific authoritative guidance on the accounting for 
the federal subsidy is pending and that guidance, when effective, 
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could require the sponsor to change previously reported informa­
tion? ____  ___
[FSP FAS 106-1, par. 10 (AC P40.863)]
Note: A plan sponsor that elects the deferral is also encouraged to disclose 
additional information that it believes is appropriate for the reader to 
understand the Act's possible economic consequences including whether 
the sponsor would need to amend the plan (regardless of whether the 
sponsor intends to do so) in order to benefit from the new legislation. 
[FSP FAS 106-1, par. 10 (AC P40.863)]
20. If a plan sponsor does not elect the deferral provided by FSP 106-1, 
do the annual or interim financial statements disclose:
a. The effects, if any, of the Act on the reported measure of the
accumulated postretirement benefit obligation? ____
b. How that effect has been, or will be reflected, in the net postretire­
ment benefit costs of current or subsequent periods? ____
c. The effects of any changes in estimates of participation rates or per
capita claims costs as a result of the Act? ____
d. The fact that specific authoritative guidance on the accounting for
the federal subsidy is pending and that guidance, when effective, 
could require the sponsor to change previously reported informa­
tion? ____
e. To the extent a plan sponsor's accounting recognizes the effect of
the federal subsidy, the basis for concluding that its plan is at least 
"actuarially equivalent" (as defined in the Act) to Medicare Part D? ____
[FSP FAS 106-1, par. 11 (AC P40.864)]
★♦21. If a plan sponsor does not elect the deferral provided by FSP FAS 
106-1, and the sponsor concludes that some or all of the federal 
subsidy related to prescription drug costs included in the accumu­
lated postretirement benefit obligation should be recognized imme­
diately as a component of income from continuing operations, is any 
amount recognized reported as a separate line item on the face of the 
income statement or statement of activities? ____
[FSP FAS 106-1, par. 11 (AC P40.864)]
Note: FSP FAS 106-2 superseded FSP FAS 106-1. Except for certain non­
public entities, FSP FAS 106-2 is effective for the first interim or annual 
period beginning after June 15, 2004. For a nonpublic entity, as defined in 
SFAS 87, that sponsors one or more defined benefit postretirement health 
care plans that provide prescription drug coverage but of which no plan 
has more than 100 participants, FSP FAS 106-2 is effective for fiscal years 
beginning after December 15, 2004. Earlier application is encouraged in 
financial statements for any period including or following enactment of 
the Act that have not yet been issued as of May 19, 2004.
[FSP FAS 106-2 (AC P40.880)]
★♦ 22. Until an employer is able to determine whether benefits provided by 
its plan are actuarially equivalent, do the financial statements for 
interim or annual periods disclose:
a. The existence of the Act?
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b. The fact that measures of the accumulated postretirement benefit 
obligation or net periodic postretirement benefit cost do not reflect 
any amount associated with the subsidy because the employer is 
unable to conclude whether the benefits provided by the plan are 
actuarially equivalent to Medicare Part D under the Act? ____  ___
[FSP FAS 106-2, par. 20 (AC P40.877)]
23. In interim and annual financial statements for the first period in which 
an employer includes the effects of the subsidy in measuring the 
accumulated postretirement benefit obligation and the first period in 
which an employer includes the effects of the subsidy in measuring 
net periodic postretirement benefit cost, do disclosures include:
a. The reduction in the accumulated postretirement benefit obliga­
tion for the subsidy related to benefits attributed to past service? ____ ___
b. The effect of the subsidy on the measurement of net periodic
postretirement benefit cost for the current period? ____  ___
c. Any other disclosures required by paragraph 5(r) of SFAS 132
(revised 2003)? ____  ___
[FSP FAS 106-2, par. 21 (AC P40.878)]
24. For purposes of the disclosures required by paragraphs 5(a) and 5(f) 
of SFAS 132 (revised 2003), are the gross benefit payments (paid and 
expected, respectively), including prescription drug benefits, and 
separately the gross amount of the subsidy receipts (received and
expected, respectively) disclosed? ____ ___
[FSP FAS 106-2, par. 22 (AC P40.879)]
J. Related Organizations and Economic Dependency
1. Related parties and economic dependency:
a. If the reporting entity controls a separate not-for-profit entity 
through a form other than majority ownership or voting interest, 
has an economic interest in that other entity, and consolidated 
financial statements are not presented, do the notes to the financial 
statements include the following disclosures:
(1) Identification of the other entity and the nature of its relation­
ship with the reporting entity that results in control? ____  ___
(2) Summarized financial data of the other entity, including total 
assets, liabilities, net assets, revenue, and expenses; and re­
sources that are held for the benefit of the reporting entity or
that are under its control? ____  ___
(3) Disclosures set forth in SFAS 57 (see Question 2g below)? ____  ___
[AAG, par. 11.12] \
b. In cases where the entity has control (other than through owner­
ship or sole corporate membership) or an economic interest in 
another entity, but not both, has the entity made the required
disclosures set forth in SFAS 57 (see Question 2g below)? ____  ___
[AAG, par. 11.13]
c. If consolidated financial statements are presented and they in­
clude a controlled not-for-profit organization, are the following 
disclosed:
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(1) Restrictions made by entities outside of the reporting entity
on distributions from the controlled not-for-profit organiza­
tion to the reporting entity? and ____  ___
(2) Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity? ____  ___
[AAG, par. 11.15]
d. Are significant relationships and transactions not in the ordinary 
course of business with directors, management, medical staff, etc.
disclosed in the financial statements? ____  ___
[AAG, par. 11.35]
e. If representations about transactions with related parties are 
made, do they avoid the implication that the related party trans­
actions were consummated at arm's length, or if such implications
are made, can they be substantiated? ____  ___
[SFAS 57, par. 3 (AC R36.103)]
f. If (d) the reporting entity and one or more other enterprises are
under common ownership or management control and (b) the 
existence of the control could result in operating results or finan­
cial position of the reporting entity being significantly different 
from that if the enterprise were autonomous, is the nature of the 
controlled relationships disclosed (even if there are no transac­
tions between the enterprises)? ____  ___
[SFAS 57, pars. 2 and 4 (AC R36.102 and .104)]
g. For related-party transactions, do disclosures include:
(1) The nature of the relationships involved? ____  ___
(2) For each period for which an income statement/statement of 
operations is presented:
(i) A description of the transaction, including transac­
tions to which no amounts or nominal amounts were
ascribed? ____  ___
(ii) Other information deemed necessary to an under­
standing of the effects of the transaction on the financial
statements? ____  ___
(iii) The dollar amount of transactions? ____  ___
(iv) The effect of any changes in the method of establishing
the terms from that used in the preceding period? ____  ___
(3) Amounts due from or to related parties as of the date of each 
balance sheet presented and, if not otherwise apparent, the
terms and manner of settlement? ____  ___
[SFAS 57, par. 2 (AC R36.102)]
(4) The information required by paragraph 49 of SFAS 109? ____  ___
[SFAS 109, par. 288(s) (AC R36.102)]
K. Risks and Uncertainties
1. Are the following disclosed:
a. A description of the principal services performed by the health
care provider and the revenue sources for the entity's services? ____  ___
b. The fact that financial statements prepared in accordance with
GAAP require the use of management's estimates? ____  ___
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c. If the reporting entity operates in more than one business, is the 
relative importance of its operations in each business and the basis 
for the determination (for example, assets, revenues, or earnings) 
disclosed? ____  ____  ____
[SOP 94-6, pars. 10 and 11]
★♦2. If known information available before the financial statements are 
issued indicates (1) it is at least reasonably possible that the estimate(s) 
used in preparing the financial statements will change in the near 
term, and (2) the effect(s) of the change will be material, are the 
following disclosed:
a. The nature of uncertainties inherent in estimates used to deter­
mine the carrying amounts of assets and liabilities, or used to
disclose gain or loss contingencies? ____  ____  ____
b. That a material change in the estimate could occur in the near term? ____  ____  ____
[SOP 94-6, pars. 12-14]
3. If the estimate in Question 2 above involves a loss contingency cov­
ered by SFAS 5, Accounting for Contingencies, do disclosures include 
an estimate of the possible loss or range of loss, or state that such an
estimate cannot be made?2 ____  ____  ____
2 If risk reduction techniques are used to mitigate losses or the uncertainty that may result from certain events, these disclosures are 
encouraged but not required. [SOP 94-6, par. 15]
[SOP 94-6, par. 14]
4. If, based on information known to management before the financial 
statements are issued, (1) the concentration existed at the date of the 
financial statements, (2) the concentration made the enterprise vulner­
able to the risk of near-term severe impact, and (3) it is at least 
reasonably possible that the events that could cause the severe impact 
will occur in the near term, are the following disclosed:
a. Concentrations in the volume of the business transacted with 
a particular customer (patient), supplier, lender, grantor, or
contributor? ____  ____  ____
b. Concentrations in revenue from particular services provided or
fund-raising events? ____  ____  ____
c. Concentrations in the available sources of supply of labor, serv­
ices, or of applicable licenses necessary to provide services? ____  ____  ____
d. Concentrations in the market or geographical area in which an 
entity conducts its operations, including the carrying amounts of
net assets and their locations? ____  ____ ____
e. Concentrations of labor subject to collective bargaining agree­
ments, including the percentage of the labor force covered by a 
collective bargaining agreement and the percentage of the labor 
force covered by a collective bargaining agreement that will expire
within one year? ____  ____  ____
f. Information adequate to inform users of the general nature of the
risk associated with the concentration? ____  ____ ____
[SOP 94-6, pars. 21-24]
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♦ L. Segment Information
Note: Public business enterprises are required to provide the disclosures 
described in SFAS 131, Disclosures about Segments of an Enterprise and 
Related Information, and nonpublic business enterprises are encouraged to 
do so.
1. Are the following items disclosed for each reportable segment for each 
period for which an income statement is presented:
a. General information as described in SFAS 131, paragraph 26?
b. Information about profit or loss (including certain revenues and 
expenses included in profit or loss), segment assets, and the basis 
of measurement, as described in SFAS 131, paragraphs 27-31?
c. Reconciliations of the totals of segment revenues, reported profit 
or loss, assets, and other significant items to corresponding enter­
prise amounts as described in SFAS 131, paragraph 32?
d. Interim period information as described in SFAS 131, paragraph 33? 
[SFAS 131, pars. 25-33, as amended by SFAS 135, par. 4 (AC 
S30.124-.132)]
Note: Reconciliations of balance sheet amounts for reportable segments 
to consolidated balance sheet amounts are required only for each year for 
which a balance sheet is presented.
[SFAS 131, par. 25, as amended by SFAS 135, par. 4(x) (AC S30.124)]
2. If an enterprise changes the structure of its internal organization in a 
manner that changes the composition of its reportable segments, has 
it disclosed whether it has restated the corresponding items of seg­
ment information for earlier periods?
[SFAS 131, par. 34 (AC S30.133)]
3. If segment information is not restated to reflect a change in the 
composition of reportable segments, is current year segment informa­
tion under both the old basis and the new basis of segmentation 
disclosed, unless it is impracticable to do so?
[SFAS 131, par. 35 (AC S30.134)]
4. For all enterprises subject to SFAS 131, including those that have a 
single reportable segment, are the following enterprise-wide items 
disclosed:
a. Revenues from external customers for each product and service or 
each group of similar products and services unless it is impracti­
cable to do so?
b. Geographic information as described in paragraph 38 unless it is 
impracticable to do so?
c. Information about the extent of the enterprise's reliance on its 
major customers as described in paragraph 39?
[SFAS 131, pars. 36-39 (AC S30.135-.138)]
5. If the information described in Questions 4a and 4b above has not been 
disclosed because it is impracticable, is that fact disclosed?
[SFAS 131, pars. 37 and 38 (AC S30.136-.137)]
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M. Subsequent Events
★ 1. Are subsequent events that provide evidence about conditions that
did not exist at the date of the balance sheet, but arose subsequent to 
that date, adequately disclosed to keep the financial statements from 
being misleading?
[SFAS 5, par. 11 (AC C59.112); APB 16 (AC B50.120); SAS 1, secs. 
560.05-.07, .09, and 561.01-10, as amended by SAS 98 (AU 560.05-.07, 
.09, and 561.01-.10)]
♦ 2. Are subsequent events that provide evidence about conditions that
did not exist at the date of the balance sheet, but arose subsequent to 
that date, adequately disclosed to keep the financial statements from 
being misleading?
[SFAS 5, par. 11 (AC C59.112); SAS 1, secs. 560.05-.07, .09, and 561.01- 
.10, as amended by SAS 98 (AU 560.05-.07, .09, and 561.01-.10)]
Note: Consider the appropriateness of dual dating the auditor's report if 
a subsequent event is disclosed in the financial statements.
[SAS 1, sec. 530.05 (AU 530.05)]
N. Stock-Based Compensation/Share-Based Payment
Note: If the provisions of SFAS 123(R), Share-Based Payment, are in effect 
or are applied, replace Questions 1 through 9 with Questions 10 through 
14. SFAS 123(R) replaces SFAS 123, Accounting for Stock-Based Compensa­
tion, supersedes APB 25, Accounting for Stock Issued to Employees, and 
amends APB 28, Interim Financial Reporting. The provisions of SFAS 123(R) 
are effective (a) for public entities that do not file as small business 
issuers—as of the beginning of the first interim or annual reporting period 
that begins after June 15, 2005; (b) for public entities that file as small 
business issuers—as of the beginning of the first interim or annual report­
ing period that begins after December 15, 2005; and (c) for nonpublic 
entities—as of the beginning of the first annual reporting period that 
begins after December 15, 2005. See paragraphs 69 through 85 of SFAS 
123(R) for further effective date and transition information. Early adop­
tion for interim or annual periods for which financial statements or interim 
reports have not been issued is encouraged.
[SFAS 123(R), pars. 3 and 69-85]
♦ 1. If an entity continues to apply APB 25 in accounting for its stock-based
compensation arrangements, is the pro forma net income and, if 
presented, earnings per share (determined as if the fair value based 
method had been applied in measuring compensation cost) prominently 
disclosed?
[SFAS 123, par. 11, SFAS 123, par. 45, as amended by SFAS 148, par. 
2(e) (AC C36.110 and .144)]
♦ 2. If an entity has one or more stock-based compensation plans, is a
description of the plan(s), including the general terms of awards 
under the plan(s), disclosed?
[SFAS 123, par. 46 (AC C36.145)]
♦ 3. Is the information in paragraph 47 of SFAS 123 disclosed for each year
for which an income statement is presented?
[SFAS 123, par. 47a-f (AC C36.146)]
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♦ 4. If an entity grants options under multiple stock-based employee
compensation plans, are the items in paragraph 47 disclosed sepa­
rately for different types of awards to the extent that the differences 
in the characteristics of the awards make separate disclosure impor­
tant to an understanding of the entity's use of stock-based compen­
sation?
[SFAS 123, par. 47 (AC C36.146)]
♦ 5. Are the following disclosed for options outstanding at the date of the
latest statement of financial position presented:
a. The range of exercise prices?
b. The weighted-average exercise price?
c. The weighted-average remaining contractual life?
[SFAS 123, par. 48 (AC C36.147)]
♦ 6. If the range of exercise prices is wide, are they segregated into ranges?
[SFAS 123, par. 48 (AC C36.147)]
♦ 7. Are the following disclosed for each range identified in Question 6:
a. The number, weighted-average exercise price, and weighted- 
average remaining contractual life of options outstanding?
b. The number and weighted-average exercise price of options cur­
rently exercisable?
[SFAS 123, par. 48 (AC C36.147)]
♦ 8. Is the following information disclosed in the "Summary of Significant
Accounting Policies" or its equivalent:
a. The method used—either the intrinsic value method or the fair 
value based method—to account for stock-based employee com­
pensation in each period presented?
b. For an entity that adopts the fair value recognition provisions of 
SFAS 148 for all financial statements in which the period of adop­
tion is presented, a description of the method of reporting the 
change in accounting principle?
c. If awards of stock-based employee compensation were outstand­
ing and accounted for under the intrinsic value method of APB 25 
for any period for which an income statement is presented, a 
tabular presentation of the following information for all periods 
presented—
(1) Net income and basic and diluted earnings per share as 
reported?
(2) The stock-based employee compensation cost, net of related 
tax effects, included in the determination of net income as 
reported?
(3) The stock-based employee compensation cost, net of related 
tax effects, that would have been included in the determina­
tion of net income if the fair value based method had been 
applied to all awards?
(4) Pro forma net income as if the fair value based method had 
been applied to all awards?
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(5) Pro forma basic and diluted earnings per share as if the fair 
value based method had been applied to all awards? 
[SFAS 123, par. 45, as amended by SFAS 148, par. 2(e) (AC 
C36.144)]
♦ 9. Is the following information about stock-based employee compensa­
tion costs disclosed prominently and in tabular form for all periods 
presented if awards of stock-based employee compensation were 
outstanding and accounted for under the intrinsic value method of 
APB 25 for any period for which an income statement is presented:
a. Net income and basic and diluted earnings per share as reported?
b. The stock-based employee compensation cost, net of related tax 
effects, included in the determination of net income as reported?
c. The stock-based employee compensation cost, net of related tax 
effects, that would have been included in the determination of net 
income if the fair value based method had been applied to all awards?
d. Pro forma net income as if the fair value based method had been 
applied to all awards?
e. Pro forma basic and diluted earnings per share as if the fair value 
based method had been applied to all awards?
[APB 28, par. 30, as amended by SFAS 148, par. 3 (AC I73.146)]
♦ 10. If the entity has one or more share-based payment arrangements, does
it disclose information that enables users of the financial statements 
to understand:
a. The nature and terms of such arrangements that existed during 
the period and the potential effects of those arrangements on 
shareholders?
b. The effect of compensation cost arising from share-based payment 
arrangements on the income statement?
c. The method of estimating the fair value of the goods or services 
received, or the fair value of the equity instruments granted (or 
offered to grant), during the period?
d. The cash flow effects resulting from share-based payment arrange­
ments?
[SFAS 123(R), par. 64 (AC C35.164)]
Note: Paragraph A240 of SFAS 123(R) includes minimum information 
needed to achieve the disclosure objectives in Question 10. The minimum 
information disclosures in paragraph A240 are presented in Question 11. 
In some circumstances, an entity may need to disclose information beyond 
that listed in paragraph A240 to achieve the disclosure objectives.
[SFAS 123(R), pars. 64 and A240 (AC C35.164)] 
♦ 11. Does the entity disclose:
a. A description of the share-based payment arrangement(s), includ­
ing the general terms of awards under the arrangement(s)?
b. The method used for measuring compensation cost from share­
based payment arrangements with employees?
c. For the most recent year for which an income statement is provided, 
the number and weighted-average exercise prices (or conversion 
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ratios) for each of the following groups of share options (or share 
units):
(1) Those outstanding at the beginning of the year?
(2) Those outstanding at the end of the year?
(3) Those exercisable or convertible at the end of the year?
(4) Those granted during the year?
(5) Those exercised or converted during the year?
(6) Those forfeited during the year?
(7) Those expired during the year?
d. For the most recent year for which an income statement is pro­
vided, the number and weighted-average grant-date fair value 
(calculated value for a nonpublic entity that uses that method; 
intrinsic value if a reasonable estimate of fair value is not possible) 
of equity instruments not specified in Question 11c for each of the 
following groups of equity instruments:
(1) Those nonvested at the beginning of the year?
(2) Those nonvested at the end of the year?
(3) Those granted during the year?
(4) Those vested during the year?
(5) Those forfeited during the year?
e. For each year an income statement is provided:
(1) Weighted-average grant-date fair value (calculated value for 
a nonpublic entity that uses that method; intrinsic value if 
reasonable estimate of fair value is not possible) of equity 
options or other equity instruments granted during the year?
(2) Total intrinsic value of options exercised (or share units con­
verted), share-based liabilities paid, and total fair value of 
shares vested during the year?
f. For fully vested share options (or share units) and share options 
expected to vest at the date of the latest statement of financial 
position:
(1) Number, weighted-average exercise price (or conversion ra­
tio), aggregate intrinsic value, and weighted-average remain­
ing contractual term of options (or share units) outstanding?
(2) Number, weighted-average exercise price (or conversion ra­
tio), aggregate intrinsic value (except for nonpublic entities) 
and weighted-average remaining contractual term of options 
(or share units) currently exercisable (or convertible)?
g. For each year an income statement is presented, a description of 
the method used during the year to estimate fair value (or calcu­
lated value) of awards under share-based payment arrangements? 
(Note: Not required if intrinsic value is used pursuant to para­
graphs 24 and 25 of SFAS 123(R).)
h. For each year an income statement is presented, a description of 
significant assumptions used during the year to estimate fair value 
(or calculated value) of share-based compensation awards, includ­
ing, if applicable: (Note: Not required if intrinsic value is used 
pursuant to paragraphs 24 and 25 of SFAS 123(R).)
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(1) Expected term of share options and similar instruments, in­
cluding discussion of the method used to incorporate the 
contractual term of the instruments and employees' expected 
exercise and post-vesting employment termination behavior 
into the fair value (or calculated value) of the instrument?
(2) Expected volatility of the entity's shares and the method used 
to estimate it?
(3) The range of expected volatilities used and weighted-average 
expected volatility if a method that employs different vola­
tilities during the contractual term is used?
(4) For a nonpublic entity that uses the calculated value method, 
the reasons why it is not practicable to estimate expected 
volatility of its share price, the appropriate industry sector 
index selected, reasons for selecting the particular index, and 
how historical volatility was calculated using that index?
(5) Expected dividends?
(6) If a method that employs different dividend rates during the 
contractual term is used, the range of expected dividends 
used and weighted-average expected dividends?
(7) Risk free rates?
(8) If a method that employs different risk-free rates is used, the 
range of risk-free rates used?
(9) Discount for post-vesting restrictions and method for esti­
mating it?
Note: If an entity grants equity or liability instruments under multiple 
share-based payment arrangements with employees, the information in 
Questions 11a through 11h is presented separately for different types of 
awards to the extent the differences in the characteristics of the awards 
make separate disclosure important to understanding the use of share­
based compensation.
[SFAS 123(R), pars. 65 and A240 (AC C35.399A)]
i. For each year an income statement is presented:
(1) Total compensation cost for share-based payment arrange­
ments (a) recognized in income as well as total recognized tax 
benefit related thereto and (b) total compensation cost capi­
talized as part of asset cost?
(2) Description of significant modifications?
j. As of the latest balance sheet date presented, total compensation 
cost related to nonvested awards not yet recognized and the 
weighted-average period over which is it expected to be recog­
nized?
k. If not separately disclosed elsewhere, amount of cash received 
from exercise of share options and similar instruments granted 
under share-based payment arrangements and the tax benefit 
realized from stock options exercised during the annual period?
l. If not separately disclosed elsewhere, amount of cash used to 
settle equity instruments granted under share-based payment 
arrangements?
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m. Description of policy, if any, for issuing shares (including the 
source) upon share option exercise (or share unit conversion)?
n. If the entity expects to repurchase shares in the following annual 
period, an estimate of the amount (or range if more appropriate) 
of shares to be repurchased during that period?
[SFAS 123(R), par. A240 (AC C35.399A)]
♦ 12. If the entity acquires goods or services other than employee services
in share-based payment transactions, does it provide disclosures 
similar to those required by paragraph 64 of SFAS 123(R) (Question 
10 above) to the extent that those disclosures are important to an 
understanding of the effects of those transactions on the financial 
statements?
[SFAS 123(R), par. 65 (AC C35.165)]
♦ 13. In the period that SFAS 123(R) is adopted, does the entity disclose the
effect of the change from applying the original provisions of SFAS 
123 on income from continuing operations, income before income 
taxes, net income, cash flow from operations, cash flow from financ­
ing activities, and basic and diluted earnings per share? 
[SFAS 123(R), par. 84]
♦ 14. In the period that SFAS 123(R) is adopted, if awards under share­
based payment arrangements with employees are accounted for un­
der the intrinsic value method of APB 25 for any reporting period for 
which an income statement is presented, and if the entity is a public 
entity, does it continue to provide the tabular presentation of the 
following information that was required by paragraph 45 of SFAS 123 
for all those periods:
a. Net income and basic and diluted earnings per share as reported?
b. The share-based employee compensation cost, net of related tax 
effects, included in net income as reported?
c. The share-based employee compensation cost, net of related tax 
effects, that would have been included in net income if the fair­
value-based method had been applied to all awards?
d. Pro forma net income as if the fair-value-based method had been 
applied to all awards?
e. Pro forma basic and diluted earnings per share as if the fair-value­
based method had been applied to all awards?
[SFAS 123(R), par. 84]
Note: Entities may disclose supplemental information believed useful to 
investors and creditors, in addition to the information required by SFAS 
123(R), provided the supplemental information is reasonable and does not 
lessen the prominence and credibility of required information.
[SFAS 123(R), par. A242 (AC C35.399C)]
O. Transfers of Financial Assets
★♦1. If it is not practicable to estimate the fair value of certain assets 
obtained or liabilities incurred in transfers of financial assets during 
the period, are those items and the reasons why it is not practicable to 
estimate fair value described in the notes to the financial statements? 
[SFAS 140, par. 17d (AC F39.110)]
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2. Is the policy for requiring collateral or other security disclosed if the 
reporting entity has entered into securities lending transactions? 
[SFAS 140, par. 17a(1) (AC F39.110)]
3. If the entity has pledged any of its assets as collateral that are not 
reclassified and separately reported in the statement of financial 
position pursuant to paragraph 15a of SFAS 140, is the carrying 
amount and classification of those assets as of the date of the latest 
statement of financial position presented?
[SFAS 140, par. 17a(2) (AC F39.110)]
4. If the entity has accepted collateral that it is permitted by contract or 
custom to sell or repledge, is the fair value, as of the date of each 
statement of financial position presented, of that collateral and of the 
portion of that collateral that it has sold or repledged disclosed? 
[SFAS 140, par. 17a(3) (AC F39.110)]
5. Is information about the sources and uses of that collateral, as of the 
date of each statement of financial position presented, disclosed? 
[SFAS 140, par. 17a(3) (AC F39.110)]
P. Long-Lived Assets and Disposal Groups to Be Disposed Of
Reporting Discontinued Operations
1. Are the results of operations of a component of an entity (as that phrase 
is defined in SFAS 144) that either has been disposed of or is classified 
as held for sale reported in discontinued operations in accordance 
with paragraph 43 of SFAS 144 (Questions 6, 7, 8, and 9 below) if both 
of the following conditions are met:
a. The operations and cash flows of the component have been (or will 
be) eliminated from the ongoing operations of the entity as a result 
of the disposal transaction?
b. The entity will not have any significant continuing involvement in 
the operations of the component after the disposal transaction? 
[SFAS 144, par. 42 (AC I14.102)]
2. If the occurrence of a significant event or circumstance at any time 
during the assessment period results in an expectation that the criteria 
in paragraph 42 of SFAS 144 will be met by the end of the assessment 
period, are the component's operations presented as discontinued 
operations?
[EITF 03-13, par. 13]
★♦3. Is the following information disclosed in the notes to the financial 
statements for each discontinued operation that generates continuing 
cash flows:
a. The nature of the activities that give rise to continuing cash flows?
b. The period of time continuing cash flows are expected to be 
generated?
c. The principal factors used to conclude that the expected continu­
ing cash flows are not direct cash flows of the disposed compo­
nent?
[EITF 03-13, par. 17]
★♦4. For each discontinued operation in which the ongoing entity will 
engage in a "continuation of activities" with the disposed component 
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after its disposal and for which the amounts presented in continuing 
operations after the disposal transaction include a continuation of 
revenues and expenses that were intercompany transactions (elimi­
nated in consolidated financial statements) before the disposal trans­
action, are the intercompany amounts before the disposal transaction 
disclosed for all periods presented?
[EITF 03-13, par. 17]
5. Are the types of continuing involvement, if any, that the entity will 
have after the disposal transaction disclosed and is that information 
disclosed in the period in which operations are initially classified as 
discontinued?
[EITF 03-13, par. 17]
Note: EITF 03-13, Applying the Conditions in Paragraph 42 of FASB State­
ment No. 144, Accounting for the Impairment or Disposal of Long-Lived 
Assets, in Determining Whether to Report Discontinued Operations, should be 
applied to a component of an enterprise that is either disposed of or 
classified as held for sale in fiscal periods beginning after December 15, 
2004. Operating results related to a component that is disposed of or 
classified as held for sale within an enterprise's fiscal year that includes 
the date EITF 03-13 is ratified (November 30, 2004) may be classified to 
reflect the consensus.
[EITF 03-13, pars. 18-19]
6. In a period in which a component of an entity either has been disposed 
of or is classified as held for sale, does the income statement of a 
business enterprise or statement of activities of a not-for-profit organi­
zation for current and prior periods report the results of operations of 
the component, including any gain or loss recognized in accordance 
with paragraph 37 of SFAS 144, in discontinued operations?
[SFAS 144, par. 43 (AC I14.103)]
7. Are the results of operations of a component classified as held for sale 
reported in discontinued operations in the period(s) in which they 
occur?
[SFAS 144, par. 43 (AC I14.103)]
★♦8. Are the results of discontinued operations, less applicable income 
taxes (benefit), reported as a separate component of income before 
extraordinary items and the cumulative effect of accounting changes 
(if applicable)?
[SFAS 144, par. 43 (AC I14.103)]
9. Is the gain or loss recognized on the disposal disclosed either on the 
face of the income statement or in the notes to the financial statements? 
[SFAS 144, par. 43 (AC I14.103)]
★♦10. Are adjustments to amounts previously reported in discontinued 
operations that are directly related to the disposal of a component of 
an entity in a prior period classified separately in the current period 
in discontinued operations?
[SFAS 144, par. 44 (AC I14.104)]
★♦11. Are the nature and amount of such adjustments (as discussed in 
Question 6 above) disclosed?
[SFAS 144, par. 44 (AC I14.104)]
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Reporting Disposal Gains or Losses in Continuing Operations
★♦ 12. Is a gain or loss, that is recognized on the sale of a long-lived asset 
(disposal group) that is not a component of an entity, included in 
income from continuing operations before income taxes in the income 
statement of a business enterprise and in income from continuing 
operations in the statement of activities of a not-for-profit organization? 
[SFAS 144, par. 45 (AC D60.118)]
13. If a subtotal such as "income from operations" is presented, does it 
include the amounts of those gains or losses considered in Question 
8 above?
[SFAS 144, par. 45 (AC D60.118)]
Reporting a Long-Lived Asset or Disposal Group Sold or Classified as 
Held for Sale
★♦14. If the criteria of paragraph 30 of SFAS 144 are met (and thus a 
long-lived asset is classified as held for sale) after the balance sheet 
date but before issuance of the financial statements, does the long- 
lived asset continue to be classified as held and used in those financial 
statements when issued and is the information required by paragraph 
47(a) of SFAS 144 (Question 19a below) disclosed in the notes to the 
financial statements?
[SFAS 144, par. 33 (AC D60.110)]
★♦15. Is a long-lived asset that is classified as held for sale presented 
separately in the statement of financial position?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 16. Are the assets and liabilities of a disposal group that is classified as 
held for sale presented separately in the asset and liability sections, 
respectively, of the statement of financial position?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 17. Are those assets and liabilities considered in Question 12 above, not 
offset and presented as a single amount?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 18. Are the major classes of assets and liabilities that are classified as held 
for sale separately disclosed either on the face of the statement of 
financial position or in the notes to financial statements?
[SFAS 144, par. 46 (AC D60.119)]
★♦ 19. Is the following information disclosed in the notes to the financial 
statements that cover the period in which a long-lived asset (disposal 
group) either has been sold or is classified as held for sale:
a. A description of the facts and circumstances leading to the ex­
pected disposal, the expected manner and timing of that disposal, 
and, if not separately presented on the face of the statement, the 
carrying amount(s) of the major classes of assets and liabilities 
included as part of a disposal group?
b. The gain or loss recognized in accordance with paragraph 37 of 
SFAS 144 and if not separately presented on the face of the income 
statement, the caption in the income statement or statement of 
activities that includes that gain or loss?
c. If applicable, amounts of revenue and pretax profit or loss re­
ported in discontinued operations?
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d. If applicable, the segment in which the long-lived asset (disposal 
group) is reported under SFAS 131?
[SFAS 144, par. 47 (AC D60.120 and 114.105)]
★♦20. If either paragraph 38 or 40 of SFAS 144 applies, is a description of the facts 
and circumstances leading to the decision to change the plan to sell the 
long-lived asset (disposal group) and its effect on the results of operations 
for the period and any prior periods presented disclosed in the notes to the 
financial statements that include the period of that decision?
[SFAS 144, par. 48 (AC D60.121 and I14.106)]
★♦21. If a long-lived asset is to be disposed of other than by sale, does it 
continue to be classified as held and used until it is disposed of? 
[SFAS 144, par. 27 (AC D60.104)]
Q. Asset Retirement Obligations
★♦1. Is the following information about its asset retirement obligations 
disclosed:
a. A general description of the asset retirement obligations and the 
associated long-lived assets?
b. The fair value of assets that are legally restricted for purposes of 
settling asset retirement obligations?
c. A reconciliation of the beginning and ending aggregate carrying 
amount of asset retirement obligations showing separately the 
changes attributable to (1) liabilities incurred in the current period,
(2) liabilities settled in the current period, (3) accretion expense, 
and (4) revisions in estimated cash flows, whenever there is a 
significant change in one or more of those four components during 
the reporting period?
[SFAS 143, par. 22 (AC A50.122)]
★♦ 2. If the fair value of an asset retirement obligation cannot be reasonably 
estimated is that fact and the reasons therefore disclosed?
[SFAS 143, par. 22 (AC A50.122)]
★♦3. In addition to the disclosures required by paragraphs 19 (c), 19 (d), 
and 21 of APB 20, is the liability for the asset retirement obligation 
computed on a pro forma basis disclosed in the footnotes for the 
beginning of the earliest year presented and at the end of all years 
presented as if SFAS 143 and FASBI 47 had been applied during all 
periods affected?
[SFAS 143, par. 27; FASBI 47, par. 11]
Notes: FASBI 47, Accounting for Conditional Asset Retirement Obligations— 
an interpretation of FASB Statement No. 143, is effective no later than the end 
of fiscal years ending after December 15, 2005 (December 31, 2005 for 
calendar-year enterprises). Early adoption is encouraged.
[FASBI 47, par. 8]
SFAS 154, Accounting Changes and Error Corrections, which supersedes APB 
20, is effective for accounting changes made in fiscal years beginning after 
December 15, 2005. SFAS 154 does not change the transition provisions of 
any existing accounting pronouncements, including those in a transition 
phase as of the effective date of SFAS 154.
[SFAS 154, par. 27]
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R. Impaired Loans
1. Is the following information about loans that meet the definition of 
impaired loans in SFAS 114 disclosed as of the date of each balance 
sheet presented:
a. The total recorded investment in impaired loans? ____  ___
b. The amount of that recorded investment for which there is a 
related allowance for credit losses determined in accordance with
SFAS 114 and the amount of that allowance? ____  ___
c. The amount of that recorded investment for which there is no 
related allowance for credit losses determined in accordance with
SFAS 114? ____  ___
[SFAS 118, par. 6i (AC 108.118a)]
2. Is the policy for recognizing interest income on impaired loans, in­
cluding how cash receipts are handled, disclosed? ____  ___
[SFAS 118, par. 6i (AC I08.118b)]
★♦3. Are the following disclosures made for each period for which an
income statement/statement of operations is presented:
a. The average recorded investment in the impaired loans during the
period? ____  ___
b. The related amount of interest income recognized during the time
within the period that the loans were considered impaired? ____  ___
c. Unless not practicable, the amount of interest income recognized 
using a cash-basis method of accounting during the time within
the period that the loans were impaired? ____  ___
d. Activity in the total allowance for credit losses related to loans, 
including the balance in the allowance for credit losses account at 
the beginning and end of each period, additions charged to opera­
tions, direct write-downs charged against the allowance, and re­
coveries of amounts previously charged off? (Note: The total 
allowance for credit losses related to loans includes those amounts 
that have been determined in accordance with SFAS 5 and SFAS
114.) ____  ___
[SFAS 118, par. 6i (AC I08, 118c, and .118A)]
S. Impairment of Long-Lived Assets to Be Held and Used
1. Is an impairment loss recognized for a long-lived asset (asset group) 
to be held and used included in income from continuing operations 
before income taxes in the income statement of a business enterprise 
and in income from continuing operations in the statement of activi­
ties of a not-for-profit organization? ____  ___
[SFAS 144, par. 25 (AC I08.160)]
★♦2. Is the following information disclosed in the notes to the financial 
statements that include the period in which an impairment loss is 
recognized:
a. A description of the impaired long-lived asset (asset group) and 
the facts and circumstances leading to the impairment? ____  ___
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b. If not separately presented on the face of the statement, the amount 
of the impairment loss and the caption in the income statement or 
statement of activities that includes that loss?
c. The method or methods for determining fair value (whether based 
on a quoted market price, prices for similar assets, or another 
valuation technique)?
d. If applicable, the segment in which the impaired long-lived asset 
(asset group) is reported under SFAS 131, Disclosures about Seg­
ments of an Enterprise and Related Information?
[SFAS 144, par. 26 (AC I08.161)]
T. Lessor Leases
1. For sales-type and direct financing leases, do disclosures include:
a. The components of the net investment in sales-type and direct 
financing leases as of each balance-sheet date:
(1) Future minimum lease payments to be received, with sepa­
rate deductions for (a) amounts representing executory costs, 
including any profit thereon, included in minimum lease 
payments and (b) the accumulated allowance for uncollect­
ible minimum lease payments receivable? ____
(2) The unguaranteed residual values accruing to the benefit of
the lessor? ____
(3) For direct financing leases only, initial direct costs? ____
(4) Unearned income? ____
b. Future minimum lease payments to be received for each of the five
succeeding fiscal years as of the latest balance sheet presented? ____
c. Total contingent rentals included in income for each period for
which an income statement is presented? ____
[SFAS 13, par. 23a, as amended by SFAS 91, par. 25 (AC L10.119a)]
2. For operating leases, do disclosures include:
a. Cost and carrying amount (if different) of property on lease or held
for leasing by major classes of property according to nature or 
function and the amount of accumulated depreciation in total as 
of the date of the latest balance sheet/statement of financial posi­
tion presented? ____
b. Minimum future rentals on noncancelable leases as of the date of 
the latest balance sheet presented in the aggregate and for each of
the five succeeding fiscal years? ____
c. Total contingent rentals included in income for each period for
which an income statement/ statement of operations is presented? ____
[SFAS 13, par. 23b (AC L10.119b)]
★♦3. Do disclosures include a general description of the lessor's leasing 
arrangements? ____
[SFAS 13, par. 23 (AC L10.119c)]
4. For investments in leveraged leases, do disclosures include:
a. In the balance sheet, the amount of deferred taxes presented 
separately from the remainder of the net investment? ____
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b. In the income statement or the notes thereto, separate presentation 
(from each other) of pretax income from the leveraged lease, the 
tax effect of pretax income, and the amount of investment tax 
credit recognized as income during the period?
c. When leveraged leasing is a significant part of the lessor's business 
activities in terms of revenue, net income, or assets, the compo­
nents of the net investment balance in leveraged leases in the notes 
to the financial statements?
[SFAS 13, par. 47 (AC L10.149)]
5. For leasing transactions with related parties, are the nature and extent 
of the transaction disclosed?
[SFAS 13, par. 29 (AC L10.125)]
★♦6. For contingent rental income:
a. Has disclosure been made of the lessor's accounting policy for 
contingent rental income?
b. If the lessor accrues contingent rental income prior to the lessee's 
achievement of the specified target (provided achievement of that 
target is considered probable), has disclosure been made of the 
impact on rental income as if the lessor's accounting policy was to 
defer contingent rental income until the specified target is met? 
[EITF 98-9]
U. Lessee Leases
1. For capital leases do disclosures include:
a. Gross amounts of assets recorded by major classes, as of the date 
of each balance sheet/statement of financial position presented? 
[SFAS 13, par. 16a.i. (AC L10.112a(1))]
b. Future minimum lease payments, as of the date of the latest 
balance sheet/statement of financial position presented, in total 
and for each of the next five years, with separate deductions for 
executory costs, including any profit thereon, included in the 
minimum lease payments, and for the amount of the imputed 
interest necessary to reduce net minimum lease payments to pre­
sent value?
[SFAS 13, pars. 10 and 16a.ii. (AC L10.106 and .112a(2))]
c. Total future minimum sublease rentals to be received in the future 
under noncancelable subleases as of the date of the latest balance 
sheet/statement of financial position presented?
[SFAS 13, par. 16a.iii (AC L10.112a(3))]
d. Total contingent rentals actually incurred for each period presented? 
[SFAS 13, par. 16a.iv (AC L10.112a(4))]
e. Assets recorded under capital leases and the related accumulated 
amortization, and obligations under those leases identified sepa­
rately in the balance sheet/statement of financial position or a note? 
[SFAS 13, pars. 13 and 16 (AC L10.112a(5))]
f. Amount of amortization of capital lease assets or the fact that the 
amortization of capital lease assets is included in depreciation 
expense?
[SFAS 13, par. 13 (AC L10.112a(5))]
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2. For operating leases that have initial or remaining noncancelable lease 
terms in excess of one year, do disclosures include:
a. Future minimum rental payments required as of the latest balance 
sheet/statement of financial position presented in total and for 
each of the next five years?
b. Total future minimum rentals under noncancelable subleases as 
of the date of the latest balance sheet/statement of financial posi­
tion presented?
[SFAS 13, par. 16b (AC L10.112b)]
3. For all operating leases, do disclosures include rental expense for each 
period presented, with separate amounts for minimum rentals, con­
tingent rentals, and sublease rentals?
[SFAS 13, par. 16c (AC L10.112c)]
★♦4. Do disclosures include a general description of the lessee's leasing 
arrangements including, but not limited to:
a. Bases for determination of contingent rentals?
b. Existence and terms of any renewal or purchase options or escala­
tion clauses?
c. Restrictive covenants?
[SFAS 13, par. 16d (AC L10.112d)]
5. Is the nature and extent of leasing transactions with related parties 
disclosed?
[SFAS 13, par. 29 (AC L10.125)]
★♦6. If material, is the accounting policy used in recognizing amounts 
related to a modification of an operating lease (that does not change 
the lease classification) disclosed?
[EITF 95-17]
Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
1. Is the estimated amount of advance fees expected to be refunded to 
current residents reported as a liability?
[AAG, par. 14.22]
2. Is the remaining amount of advance fees reported in the balance sheet 
as deferred revenue?
[AAG, par. 14.22]
3. Are the following disclosed:
a. The gross amount of contractual refund obligations under existing 
contracts?
b. The CCRC's refund policy? 
[AAG, par. 14.22]
4. Are amounts refunded disclosed in the statement of cash flows as a 
financing transaction?
[AAG, par. 14.22]
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5. Is the amortization method for deferred revenue disclosed? 
[AAG, par. 14.23]
B. Fees Refundable to Residents Only From Reoccupancy Proceeds of a 
Contract Holder's Unit
1. Are the following reported as deferred revenue:
a. The portion of fees to be paid to current residents or their desig­
nees, only to the extent of a contract holder's unit reoccupancy 
proceeds, if law and management policy and practice support the 
withholding of refunds under this condition?
b. Similar amounts received from new residents in excess of the 
amount to be paid to previous residents or their designees? 
[AAG, par. 14.25]
C. Nonrefundable Advance Fees
1. Are nonrefundable advance fees reported as deferred revenue? 
[AAG, par. 14.26]
★♦2. Is unamortized deferred revenue reported as revenue upon a resi­
dent's death or contract termination?
[AAG, par. 14.23]
D. Obligation to Provide Future Services and Use of Facilities to Current 
Residents
1. If the obligation to provide future services and use of facilities to 
current residents under continuing-care contracts results in a liability, 
are the following disclosed:
a. The carrying amount of the liability that is presented at present 
value in the financial statements (if not separately disclosed in the 
balance sheet/statement of financial position)?
b. The interest rate used to discount that liability? 
[AAG, par. 14.31]
E. Costs of Acquiring Initial Continuing-Care Contracts
★♦1. Are continuing-care contract acquisition costs expensed if incurred 
after (a) the CCRC is substantially occupied or (b) one year following 
completion?
[AAG, par. 14.33]
F. Other
★♦1. Do the notes to the financial statements of the CCRC include a 
description of the CCRC and the nature of the related continuing-care 
contracts entered into by the CCRC?
[AAG, par. 14.35]
★♦2. Do the notes to the financial statements of the CCRC include the 
statutory escrow or similar requirements?
[AAG, par. 14.35]
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OMB Circular A-133 Presentation Requirements
1. Does the schedule of expenditures of federal awards disclose the basis 
of accounting and the significant accounting policies used in prepar­
ing the schedule?
[AAG-SLA, par. 7.05]
2. Did the auditee prepare a schedule of expenditures of federal awards 
for the period covered by the auditee's financial statements that, at a 
minimum:
a. Lists individual federal programs by federal agency?
b. Include, for federal awards received as a subrecipient, the name 
of the pass-through entity and the identifying number assigned by 
the pass-through entity?
c. Provide the total federal awards expended for each individual 
federal program and the CFDA number or other identifying num­
ber when the CFDA information is not available?
d. Include notes that describe the significant accounting policies used 
in preparing the schedule?
e. For federal awards received as a pass-through entity, identify, to 
the extent practical, the total amount provided to subrecipients 
from each federal program?
f. Include, in either the schedule or a note to the schedule, the value 
of federal awards expended in the form of noncash assistance, the 
amount of insurance in effect during the year, and loans or loan 
guarantees outstanding at year end?
[AAG-SLA, par. 7.06]
3. If nonfederal data are presented in the schedule of expenditures of 
federal awards:
a. Are the nonfederal data segregated and clearly designated as 
nonfederal?
b. Is the title of the schedule modified to indicate that nonfederal 
awards are included?
[AAG-SLA, par. 7.09]
4. If the auditee is unable to obtain the CFDA number, does the schedule 
include:
a. A statement that the CFDA number is not available?
b. The program's name and, if available, other identifying numbers? 
[AAG-SLA, par. 7.10]
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Auditors' Reports Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid. This checklist contains the basic requirements for reporting on 
an audit of the financial statements in accordance with AICPA professional standards (GAAS) and Public 
Company Accounting Oversight Board (PCAOB) Auditing Standard No. 1, References in Auditors' Reports to 
the Standards of the Public Company Accounting Oversight Board. It does not contain all requirements for reports 
required to be issued in audits in accordance with government auditing standards ("Yellow Book"), with 
the audit requirements of OMB Circular A-133 ('Single Audits'), or PCAOB professional standards.
.02 Explanation of References:
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
SSARS = AICPA Statements on Standards for Accounting and Review Services
AR = Reference to section number in AICPA Professional Standards (vol. 2)
PCAOB AS = PCAOB Auditing Standards
.03 Checklist Questionnaire:
Yes No N/A
1. Is each financial statement audited specifically identified in the intro­
ductory paragraph of the auditor's report?
[SAS 58, par. 6 (AU 508.06)]
2. Do the titles of the financial statements referred to in the introductory 
paragraph of the auditor's report match the titles of the financial 
statement presented?
[Generally Accepted]
3. Do the dates of the financial statements referred to in the introductory 
paragraph of the auditor's report match the dates of the financial 
statements presented?
[Generally Accepted]
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4. Is the report appropriately addressed?
[SAS 58, par. 9 (AU 508.09)]
5. Does the auditor's report include:
a. A title that includes the word "independent"? 
[SAS 58, par. 8a (AU 508.08a)]
b. A statement that the financial statements identified in the report 
were audited?
[SAS 58, par. 8b (AU 508.08b)]
c. A statement that the financial statements are the responsibility of 
management and that the auditor's responsibility is to express an 
opinion on the financial statements based on his or her audit? 
[SAS 58, par. 8c (AU 508.08c)]
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d. For audits of nonissuers, a statement that the audit was conducted 
in accordance with generally accepted auditing standards and an 
identification of the United States of America as the country of 
origin of those standards (for example, auditing standards gener­
ally accepted in the United States of America or U.S. generally 
accepted auditing standards)?
[SAS 58, par. 8d, as amended by SAS 93 (AU 508.08d)]
Note: Issuers, as defined by the Sarbanes-Oxley Act of 2002, and other 
entities when prescribed by the rules of the Securities and Exchange 
Commission (SEC) (collectively referred to in this section of the checklist 
as "issuers" or "issuer"), and their public accounting firms are subject to 
the rules and standards of the PCAOB, as appropriate.
e. For audits of issuers, a statement that the audit was conducted in 
accordance with the standards of the Public Company Accounting 
Oversight Board (United States)?
[PCAOB AS 1, App., par. 3]
f. A statement that those standards require that the auditor plan and 
perform the audit to obtain reasonable assurance about whether 
the financial statements are free of material misstatement?
[SAS 58, par. 8e, as amended by SAS 93 (AU 508.08e)]
g. A statement that an audit includes examining, on a test basis, 
evidence supporting the amounts and disclosures in the financial 
statements; assessing the accounting principles used and signifi­
cant estimates made by management; and evaluating the overall 
financial statement presentation?
[SAS 58, par. 8f (AU 508.08f)]
h. A statement that the auditor believes that his or her audit provides 
a reasonable basis for his or her opinion?
[SAS 58, par. 8g (AU 508.08g)]
i. An opinion as to whether the financial statements present fairly, 
in all material respects, the financial position of the reporting 
entity as of the balance sheet date and the results of its operations 
and its cash flows for the period then ended in conformity with 
generally accepted accounting principles? The opinion should 
include an identification of the United States of America as the 
country of origin of those accounting principles (for example, 
accounting principles generally accepted in the United States of 
America or U.S. generally accepted accounting principles). 
[SAS 58, par. 8h, as amended by SAS 93 (AU 508.08h)]
j. The manual or printed signature of the auditor's firm? 
[SAS 58, par. 8i (AU 508.08i)]
k. The date of the audit report? 
[SAS 58, par. 8j (AU 508.08j)]
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Note: Issuers, as defined by the Sarbanes-Oxley Act of 2002, and other 
entities when prescribed by the rules of the SEC (collectively referred to 
in this section of the checklist as "issuers" or "issuer"), and their public 
accounting firms are subject to the rules and standards of the PCAOB, as 
appropriate.
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l. For audits of issuers, the city and state (or city and country for 
non-U.S. auditors) from which the auditor's report is issued? ____  ____  ____
[PCAOB AS 1, App., par. 3]
6. If a subsequent event disclosed in the financial statements occurs after
completion of fieldwork but before the issuance of the related finan­
cial statements, has the need for dual-dating of the report been con­
sidered? ____  ____  ____
[SAS 1, sec. 530, pars. 3-5, as amended (AU 530.03-.05)]
7. If the accountant is not independent, is a compilation report indi­
cating the lack of independence issued (non-public companies
only)? ____  ____  ____
[SAS 26, par. 10 (AU 504.10); SSARS 1, pars. 21 and 37 (AR 100.19 and 
.44)]
8. If the opinion is based in part on the report of another auditor:
a. Does the introductory paragraph of the standard report disclose 
the fact that the opinion is based, in part, on the report of other
auditors? ____  ____  ____
b. Does the opinion paragraph include a reference to the report of
the other auditor? ____  ____  ____
[SAS 58, pars. 11a, 12, and 13 (AU 508.11a, .12, and .13)]
9. If, to prevent the financial statements from being misleading because
of unusual circumstances, the financial statements contain a depar­
ture from an accounting principle promulgated by a body designated 
by the AICPA Council to establish such principles, does the report 
include, in a separate paragraph or paragraphs, the information re­
quired by Rule 203 of the Code of Professional Conduct of the AICPA? ____  ____ ____
[SAS 58, pars. 11b and 15 (AU 508.111b and .15)]
10. If there is substantial doubt about the entity's ability to continue as a 
going concern:
a. Does the report include an explanatory paragraph, following the
opinion paragraph, to reflect that conclusion? ____  ____  ____
b. Is that conclusion expressed through the use of the phrase "sub­
stantial doubt about its (the entity's) ability to continue as a going 
concern" or similar wording that includes the terms substantial
doubt and going concern? ____  ____  ____
[SAS 58, par. 11c (AU 508.11c); SAS 59, as amended by SAS 64, par.
12 (AU 341.12)]
Practice Tip
In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion 
concerning the existence of substantial doubt about the entity's ability to continue as a going concern. See 
SAS 77 for an example.
[SAS 59, as amended by SAS 77 (AU 341.13, fn. 5)]
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11. If there has been a material change between periods in accounting 
principles or in the method of their application that has a material effect 
on the comparability of the reporting entity's financial statements:
a. Does the report include an explanatory paragraph, following the 
opinion paragraph, that refers to the change?
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b. Does the explanatory paragraph identify the nature of the change 
and refer the reader to the note to the financial statements that 
discusses the change in detail?
[SAS 58, as amended by SAS 79, pars. 11d and 16 (AU 508.11d and 
.16)]
c. If the change in the accounting principle is a change in reporting 
entity that did not result from a transaction or an event, is an 
explanatory paragraph included in the auditor's report? (Note: A 
change in the reporting entity resulting from a transaction or 
event, such as a pooling of interests, or the creation, cessation, or 
complete or partial purchase or disposition of a subsidiary or other 
business unit, does not require that an explanatory paragraph 
about consistency be included in the auditor's report.)
[SAS No. 88, par. 8, AU 420.08]
12. If in an updated report, the opinion is different from the opinion 
previously expressed on the financial statements of a prior period:
a. Does the report include an explanatory paragraph, preceding the 
opinion paragraph, that discloses all of the substantive reasons for 
the different opinion?
b. Does the explanatory paragraph disclose:
(1) The date of the auditor's previous report?
(2) The type of opinion previously expressed?
(3) The circumstances or events that caused the auditor to ex­
press a different opinion?
(4) That the auditor's updated opinion on the financial state­
ments of the prior period is different from his or her previous 
opinion on those statements?
[SAS 58, as amended by SAS 79, pars. 11e and 69 (AU 508.11e 
and .69)]
13. If financial statements of a prior period (presented for comparative 
purposes) have been audited by a predecessor auditor whose report 
is not presented:
a. Does the introductory paragraph of the report indicate:
(1) That the financial statements of the prior period were audited 
by another auditor?
(2) The date of the predecessor auditor's report?
(3) The type of report issued by the predecessor auditor?
(4) If the report was other than a standard report, the substantive 
reasons therefor, including a description of the nature of and 
reasons for the explanatory paragraph added to the predeces­
sor's report or his or her opinion qualification?
b. If the financial statements have been restated, does the introduc­
tory paragraph indicate that the predecessor auditor reported on 
the financial statements of the prior period before restatement? 
[SAS 58, as amended by SAS 79, pars. 11e and 74 (AU 508.11e and .74)]
14. If selected quarterly financial data required by SEC Regulation S-K 
has been omitted or has not been reviewed, does the report include 
an additional paragraph stating that fact?
[SAS 58, par. 11f (AU 508.11f); SAS 100, par. 50 (AU 722.50)]
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15. If supplementary information required by GAAP has been omitted, 
the presentation of such information departs materially from pre­
scribed guidelines, the auditor is unable to complete prescribed pro­
cedures with respect to such information, or the auditor is unable to 
remove substantial doubt about whether the supplementary informa­
tion conforms to prescribed guidelines, does the report include an 
additional paragraph stating that fact?
[SAS 58, par. 11g (AU 508.11g); SAS 52, par. 8, as amended by SAS 98 
(AU 558.08)]
16. If other information in a document containing audited financial state­
ments is materially inconsistent with information appearing in the 
financial statements, has it been determined whether the financial 
statements, the auditor's report, or both require revision?
[SAS 58, par. 11h (AU 508.11h); SAS 8, par. 4 (AU 550.04)]
17. If the auditor decides to emphasize a matter regarding the financial 
statements in the report, is the explanatory information presented in 
a separate paragraph that avoids use of phrases such as "with the 
foregoing (following) explanation"?
[SAS 58, pars. 11 and 19, as amended by SAS 79 (AU 508.11 and .19); 
Interpretation 3 of SAS 1, sec. 410 (AU 9410.18); Interpretation 1 of 
SAS 57 (AU 9342.03)]
18. If it has not been possible to conduct the audit in accordance with 
GAAS or to apply all of the procedures considered necessary in the 
circumstances, has consideration been given to the need to issue a 
qualified opinion or to disclaim an opinion?
[SAS 58, as amended by SAS 79, par. 22 (AU 508.22)]
19. If a qualified opinion is to be expressed because of a scope limitation:
a. Are all of the substantive reasons for the qualification disclosed in one 
or more explanatory paragraphs preceding the opinion paragraph?
b. Does the qualified opinion include the word except or exception in 
a phrase such as except for or with the exception of?
c. Is the situation described and referred to in both the scope and 
opinion paragraphs?
d. Does the wording in the opinion paragraph indicate that the 
qualification pertains to the possible effects on the financial state­
ments and not the scope limitation itself?
[SAS 58, as amended by SAS 79, pars. 21-27 (AU 508.21-.27)]
Practice Tips
Scope limitations include situations in which the auditor is unable to obtain sufficient evidential matter to 
support management's assertions about the nature of a matter involving an uncertainty and its presentation 
or disclosure in the financial statements.
[SAS 58, as amended by SAS 79, par. 31 (AU 508.31)]
SOP 00-1, Auditing Health Care Third-Party Revenues and Related Receivables, discusses auditing matters to 
consider in testing third-party revenues and related receivables, and provides guidance regarding the 
sufficiency of evidential matter (SOP 00-1, pars. 16-21).
FSP §11,300.03
106 Health Care Organizations
Yes No N/A
Note: Consult the Topical Index to the AICPA Professional Standards 
under "Scope of Audit—Limitations" for additional references to specific 
types of scope limitations that could result in either a qualified or dis­
claimer of opinion.
20. If an opinion is disclaimed because of a scope limitation:
a. Are all of the substantive reasons for the disclaimer stated in a 
separate paragraph or paragraphs?
b. Does the report state that the scope of the audit was not sufficient 
to warrant the expression of an opinion?
c. Does the report avoid identifying procedures that were performed?
d. Is the scope paragraph omitted?
e. If there are reservations about fair presentation of the financial 
statements in conformity with GAAP, are they described in the 
report?
[SAS 58, as amended by SAS 79, pars. 62 and 63 (AU 508.62-.63)]
21. If the financial statements are materially affected by a departure from 
GAAP (including inadequate disclosure, inappropriate accounting 
principles, and unreasonable accounting estimates), has considera­
tion been given to the need to issue a qualified opinion or an adverse 
opinion?
[SAS 58, as amended by SAS 79, par. 35 (AU 508.35)1
Note: SOP 00-1, Auditing Health Care Third-Party Revenues and Related 
Receivables, discusses auditing matters to consider in testing third-party 
revenues and related receivables, and provides guidance regarding the 
sufficiency of evidential matter and reporting on financial statements of 
health care entities exposed to material uncertainties. Paragraphs 22-37 
specifically address potential departures from GAAP related to estimates 
and uncertainties that fall into three categories: unreasonable accounting 
estimates; inappropriate accounting principles; and inadequate disclosure.
22. If a qualified opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons that have led to the conclusion that 
there is a departure from GAAP disclosed in one or more separate 
explanatory paragraphs preceding the opinion paragraph?
b. Does the qualified opinion include the word except or exception in 
a phrase such as except for or with the exception of and a reference to 
the explanatory paragraph?
c. Does the explanatory paragraph disclose the principle effects of 
the departure on financial position, results of operations, and cash 
flows, if practicable, or state that the effects are not reasonably 
determinable, if not practicable to do so?
[SAS 58, as amended by SAS 79, pars. 21, 37, and 38 (AU 508.21, 
.37, and .38)]
23. If an adverse opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons for the adverse opinion disclosed
in one or more separate explanatory paragraphs preceding the 
opinion paragraph?
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b. Does the explanatory paragraph disclose the principle effects of
the departure on financial position, results of operations, and cash
flows, if practicable, or state that the effects are not reasonably
determinable, if not practicable to do so? ____  ____  ____
c. State that the financial statements do not present fairly the finan­
cial position, or results of operations or cash flows in conformity
with GAAP? ____  ____  ____
[SAS 58, as amended by SAS 79, pars. 58 and 59 (AU 508.58 and .59)]
Note: Consult the Topical Index to the AICPA Professional Standards 
under "Departures From Established Principles," "Adverse Opinions," 
and "Qualified Opinions" for additional references to specific types of 
GAAP departures that could result in either a qualified or adverse opinion.
24. If information accompanies the basic financial statements and audi­
tor's report in an auditor-submitted document, is it accompanied by 
a report that:
a. States that the audit was performed for the purpose of forming an 
opinion on the basic financial statements taken as a whole?
b. Specifically identifies the accompanying information?
c. States that the accompanying information is presented for pur­
poses of additional analysis and is not a required part of the basic 
financial statements?
d. Includes either an opinion on whether the accompanying informa­
tion is fairly stated in all material respects in relation to the basic 
financial statements taken as a whole or a disclaimer of opinion 
(depending on whether the information was subjected to the 
auditing procedures applied in the audit of the basic financial 
statements)?
[SAS 29, par. 6 (AU 551.06)]
Practice Tip
SAS 87, Restricting the Use of an Auditor's Report, provides guidance to auditors in determining whether an 
engagement requires a restricted-use report and, if so, what elements to include in that report.
Practice Tip
PCAOB Conforming Amendments To PCAOB Interim Standards Resulting from the Adoption of PCAOB Auditing 
Standard No. 2, "An Audit of Internal Control Over Financial Reporting Performed In Conjunction With An 
Audit Of Financial Statements," amend SAS 58 to include reporting requirements when performing an 
integrated audit of financial statements and internal control over financial reporting in accordance with 
PCAOB Standards.
Note: The PCAOB establishes standards for audits of issuers, as defined 
by the Sarbanes-Oxley Act of 2002, and other entities when prescribed by 
the rules of the SEC, collectively referred to in this section of the checklist 
as "issuers."
FSP §11,300.03
108 Health Care Organizations
Yes No N/A
Practice Tips
Auditing Interpretation 17, "Clarification in the Audit Report of the Extent of Testing of Internal Control 
Over Financial Reporting in Accordance With Generally Accepted Auditing Standards," of SAS 58, provides 
for audits of nonissuers an example of additional language that may be added to an auditor's standard report 
to explain that an audit includes consideration of internal control over financial reporting as a basis for 
designing audit procedures but not for the purpose of expressing an opinion on the effectiveness of internal 
control over financial reporting.
[Interpretation 17 of SAS 58 (AU 9508.85-88)]
Auditing Interpretation 18, "Reference to PCAOB Standards in an Audit Report on a Nonissuer," of SAS 58, 
provides guidance on the appropriate referencing of PCAOB auditing standards in audit reports for those 
auditors who are engaged to perform an audit in accordance with PCAOB standards when auditing 
nonissuers.
[Interpretation 18 of SAS 58 (AU 9508.89-92)]
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FSP Section 11,400
Auditors' Reports on Audits Performed in 
Accordance With Government Auditing 
Standards and Circular A-133 Checklist
.01 Government Auditing Standards (also referred to as the Yellow Book), issued by the Comptroller 
General of the United States of the Government Accountability Office (GAO), applies to the audits of 
governmental entities, programs, activities, and functions, and of governmental assistance administered by 
contractors, not-for-profit organizations (NPOs), and other nongovernmental entities, when required by 
statute or other mandates or when auditors hold themselves out as following those standards.1 The Single 
Audit Act Amendments of 1996 (the Single Audit Act) and Office of Management and Budget (OMB) Circular 
A-133, Audits of States, Local Governments, and Non-Profit Organizations (Circular A-133), require a single or 
program-specific audit for entities that expend $500,000 or more of federal awards in a fiscal year. The Single 
Audit Act requires single audits and program-specific audits of federal awards to be performed in accordance 
with Government Auditing Standards. Similarly, Government Auditing Standards requires the use of its standards 
when auditing compliance with regulations relating to federal award expenditures and other governmental 
financial assistance in conjunction with or as a byproduct of a financial statement audit.
1 As discussed in paragraph 4.24 of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits, paragraph 
5.07 of Government Auditing Standards acknowledges that an auditee may need a financial statement audit for purposes other than to 
comply with a requirement calling for an audit in accordance with Government Auditing Standards. For example, the auditee may need 
a financial statement audit to issue bonds. In that case, Government Auditing Standards permits auditors to issue a separate report on the 
financial statements conforming only to the requirements of generally accepted auditing standards (GAAS).
.02 This checklist has two parts: Part I is for auditor's reports on financial statement audits performed in 
accordance with Government Auditing Standards. (This checklist does not address the performance auditing 
or attestation standards of Government Auditing Standards. It also does not address types of financial audits 
other than financial statement audits, except for Circular A-133 audits.) Part II contains the additional 
requirements for auditor's reports on audits performed in accordance with the Single Audit Act and Circular 
A-133. For audits performed in accordance with Circular A-133, both Parts I and II of this checklist must be 
completed. Illustrative auditor's reports on financial statement audits performed in accordance with Govern­
ment Auditing Standards and illustrative auditor's reports and an illustrative schedule of findings and 
questioned costs for Circular A-133 audits are in the AICPA Audit Guide Government Auditing Standards 
and Circular A-133 Audits.
.03 The OMB issues an annual Circular A-133 compliance supplement for conducting single audits. That 
supplement is available from the Government Printing Office by calling (202) 512-1800 and on the OMB's 
Web site at www.whitehouse.gov/omb/grants/grants_circulars.html. The AICPA issues an annual Audit 
Risk Alert, Government Auditing Standards and Circular A-133 Audits, as a complement to the Audit Guide 
Government Auditing Standards and Circular A-133 Audits. The AICPA also has issued a related practice aid, 
Auditing Recipients of Federal Awards: Practical Guidance for Applying OMB Circular A-133, Third Edition 
(product no. 006621).
.04 The Public Accounting Oversight Board (PCAOB) establishes standards for audits of "issuers," as 
that term is defined by the Sarbanes-Oxley Act of 2002 (the Act) or whose audit is prescribed by the rules of 
the Securities and Exchange Commission (SEC). Other entities are referred to as "nonissuers." Because health 
care organizations generally are nonissuers, this section of this checklist does not address PCAOB standards. 1
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However, the auditee may be an issuer or the auditor may be engaged to audit and report on the effectiveness 
of a nonissuer's internal control over financial reporting in accordance with PCAOB auditing standards. In 
those cases, the auditor should modify this checklist considering the guidance in PCAOB standards, the GAO 
Internet Notice at www.gao.gov/govaud/ybk01.htm titled Guidance on Complying with Government Audit­
ing Standards Reporting Requirements for the Report on Internal Control for Audits of Certain Entities Subject to 
the Requirements of the Sarbanes-Oxley Act of 2002 and Government Auditing Standards, and Auditing 
Interpretation 18, "Reference to PCAOB Standards in an Audit Report on a Nonissuer," of SAS 58, as 
amended (AU 9508.89-92), as well as the discussion in the Notice to Readers and Appendix A to Chapter 4 
of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits.
.05 Explanation of References:
A-133 = Office of Management and Budget (OMB) Circular A-133, Audits of States, Local
Governments, and Non-Profit Organizations (June 1997 Revision)
GAS = General Accounting Office 1994 revision to Government Auditing Standards, as
amended through Amendment 3, Independence
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
AAG-SLA = AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits
(with conforming changes as of May 1, 2005)
.06 Checklist Questionnaire:
Yes No N/A
Part I—Reports on Audits Performed in Accordance With
Government Auditing Standards
1. In a financial statement audit performed in accordance with Govern­
ment Auditing Standards, has the auditor issued the following reports:
a. A report on the entity's financial statements that provides an
opinion or disclaimer of opinion on the financial statements? ____  ____  ____
[GAS, par. 5.03; AAG-SLA, pars. 4.03 and 4.21]
b. A report on internal control over financial reporting and on com­
pliance and other matters based on an audit of financial statements
performed in accordance with Government Auditing Standards? ____  ____  ____
[GAS, pars. 5.08 and 5.12; AAG-SLA, pars. 4.03, 4.07, and 4.25]
Report on the Financial Statements
2. In addition to the elements listed in the checklist for the auditor's 
report on the financial statements at FSP section 11,300, does the 
auditor's report on the financial statements contain:2
2 If an auditee prepares financial statements in conformity with comprehensive bases of accounting other than generally accepted 
accounting principles (GAAP), known as other comprehensive bases of accounting, or OCBOA, the auditor still is required to express or 
disclaim an opinion and should follow the reporting in SAS 62 (AU 623), as amended. [AAG-SLA, par. 4.21h, fn. 21]
3 When personal, external, and organizational impairments to independence exist, a government auditor who cannot decline to 
perform the work because of a legislative requirement or for other reasons should report the impairment in the scope section of the 
auditor's report. [GAS, par. 3.05; AAG-SLA, par. 4.21d, fn. 20]
a. A statement that the audit was conducted in accordance with the 
standards applicable to financial audits contained in Government 
Auditing Standards, issued by the Comptroller General of the 
United States?3 ____  ____  ____
[GAS, par. 5.05; AAG-SLA, pars. 4.04a, 4.21d, and 4.23]
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b. A reference to the separate report on internal control over 
financial reporting and on compliance with certain provisions 
of laws, regulations, contracts, and grant agreements and other 
matters prepared in accordance with Government Auditing Stand­
ards,4 which includes:
4 If the reporting on internal control over financial reporting and on compliance and other matters is included in the report on the 
financial statements, the reference to the separate report is not required. The Audit Guide Government Auditing Standards and Circular 
A-133 Audits recommends separate reporting. [AAG-SLA, pars. 4.04b and 4.21i]
5 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial 
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion 
on internal control over financial reporting or on compliance in the Government Auditing Standards report. [AAG-SLA, pars. 4.04b, fn. 6 
and 4.21i]
(1) A statement that the purpose of that report is to describe the 
scope of testing of internal control over financial reporting 
and compliance and the results of that testing, and not to 
provide an opinion on the internal control over financial
reporting or on compliance?5 ____  ____  ____
(2) A statement that the separate report is an integral part of an 
audit performed in accordance with Government Auditing 
Standards and should be considered in assessing the results of
the audit? ____  ____  ____
[GAS, par. 5.08; AAG-SLA, pars. 4.04b and 4.21i]
3. If the auditor does not follow an applicable standard of Government 
Auditing Standards, does the scope section of the report disclose the 
standard that was not followed, the reasons therefore, and how not 
following the standard affected, or could have affected, the results of
the audit? ____  ____  ____
[GAS, par. 5.06; AAG-SLA, par. 4.23]
4. If a material organizational unit is not required to have an audit in 
accordance with Government Auditing Standards, has the scope para­
graph of the report on the financial statements been modified to 
indicate the portion of the entity that was not audited in accordance
with Government Auditing Standards'? ____  ____ ____
[AAG-SLA, pars. 4.37 and 4.38]
Report on Internal Control Over Financial Reporting and On Compli­
ance and Other Matters Based on an Audit Performed in Accordance 
With Government Auditing Standards
5. Does the auditor's report on internal control over financial reporting 
and on compliance and other matters conform to the standard report
language illustrated in AAG-SLA? ____  ____  ____
[AAG-SLA, par. 4.44, Exs. 4-3 and 4-4]
6. Does the auditor's report on internal control over financial reporting
and on compliance and other matters contain:
a. A statement that the auditor has audited the financial statements 
of the auditee and a reference to the auditor's report on the 
financial statements, including a description of any departure 
from the standard report (for example, a qualified opinion, a 
modification as to consistency because of a change in accounting 
principle, or a reference to the report of other auditors)? ____  ____  ____
[AAG-SLA, pars. 4.26a and 4.44, Ex. 4-3, fn. 24]
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b. A statement that the audit was conducted in accordance with 
GAAS (with an identification of the United States of America as 
the country of origin of those standards) and with the standards 
applicable to financial audits contained in Government Auditing 
Standards, issued by the Comptroller General of the United 
States?6
c. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over financial reporting 
in order to determine the auditing procedures for the purpose of 
expressing an opinion on the financial statements and not to provide 
an opinion on the internal control over financial reporting?7
d. If applicable, a statement that reportable conditions were noted 
and the definition of a reportable condition?
e. If no reportable conditions are noted, a statement that the auditor's 
consideration of the internal control over financial reporting 
would not necessarily disclose all matters in the internal control 
that might be material weaknesses; if reportable conditions are 
noted, a statement that the auditor's consideration of the internal 
control over financial reporting would not necessarily disclose all 
matters in the internal control that might be reportable conditions 
and, accordingly, would not necessarily disclose all reportable 
conditions that are also considered to be material weaknesses?
f. If applicable, a description of the reportable conditions noted 
(including the views of responsible officials and their planned 
corrective action) or a reference to a separate schedule in which 
the reportable conditions, views of responsible officials, and their 
planned corrective action are described?8
g. The definition of a material weakness?
h. If applicable, a statement about whether the auditor believes any 
of the reportable conditions noted are material weaknesses and, if 
they are, that identifies which reportable conditions are consid­
ered material weaknesses?9 (If there are no reportable conditions 
noted, a statement is made that no material weaknesses were 
noted.)
i. A statement that as part of obtaining reasonable assurance about 
whether the auditee's financial statements are free of material 
misstatement, the auditor performed tests of the auditee's compli­
ance with certain provisions of laws, regulations, contracts, and 
grant agreements, noncompliance with which could have a direct 
and material effect on the determination of financial statement 
amounts?
6 See footnote 3. [GAS, par. 3.05; AAG-SLA, par. 4.26b, fn. 27]
7 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial 
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion 
on internal control over financial reporting. [AAG-SLA, par. 4.26c, fn. 28]
8 For an audit in accordance with Circular A-133, all findings, including those required to be reported under Government Auditing 
Standards, should be included in the schedule of findings and questioned costs. Therefore, for such audits, this report should refer to 
the schedule of findings and questioned costs. See the questions about that schedule in Part II of this checklist. [AAG-SLA, pars. 4.26f, 
fn. 29 and 12.17]
9 In reporting reportable conditions, the auditor should identify those that are individually or in the aggregate material weaknesses. 
[GAS, par. 5.14; AAG-SLA, par. 4.08]
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j. A statement that providing an opinion on compliance with those 
provisions was not an objective of the audit and that, accordingly, 
the auditor does not express such an opinion?10 11
k. A statement that notes whether the results of tests disclosed in­
stances of noncompliance or other matters (certain fraud and 
abuse) that are required to be reported under Government Auditing 
Standards and, if they are, describes the instances of noncompli­
ance and other matters (including the views of responsible officials 
and their planned corrective action) or refers to the separate sched­
ule in which the noncompliance and other matters, views of 
responsible officials, and their planned corrective action are de­
scribed?11
10 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial 
reporting or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion 
on compliance. [AAG-SLA, par. 4.26i, fn. 30]
11 See footnote 8. [AAG-SLA, par. 4.26k, fn. 32]
12 For an audit in accordance with Circular A-133, this reference should include federal awarding agencies and, if applicable, 
pass-through entities. [AAG-SLA, pars. 4.26m, fn. 34 and 12.17]
13 This paragraph conforms to SAS 87, Restricting the Use of an Auditor’s Report (AU 532). See SAS 87 for additional guidance on 
restricted-use reports. [AAG-SLA, par. 4.26m, fn. 35]
[AAG-SLA, par. 4.26]
l. If applicable, a statement that additional matters were communi­
cated to the auditee in a management letter?
[AAG-SLA, pars. 4.26l, 4.35, and 4.44, Ex. 4-3, fn. 30 and Ex. 4-4, 
fn. 46]
m. A separate paragraph at the end of the report stating that the report 
is intended solely for the information and use of the audit 
committee, management and specified legislative or regulatory 
bodies12 and is not intended to be and should not be used by 
anyone other than these specified parties?13
n. The manual or printed signature of the auditor's firm?
o. The date of the auditor's report? 
[AAG-SLA, par. 4.26]
7. Does the report carry the same date as the report on the financial 
statements?
[AAG-SLA, par. 4.26o]
8. If a material organizational unit is not required to have an audit in 
accordance with Government Auditing Standards, has the scope para­
graph of the report been modified to indicate the portion of the entity 
that was not audited in accordance with Government Auditing Stand­
ards?
[AAG-SLA, pars. 4.37 and 4.39]
9. If certain pertinent information is prohibited from general disclosure 
(as it may be by federal, state, or local laws or regulations), does the 
auditor's report state the nature of the information omitted and the 
requirement that makes the omission necessary?
[GAS, par. 5.31; AAG-SLA, par. 4.04e]
10. Does the language in the compliance and other matters section of the 
report refer to findings that do or may include fraud and abuse? (That
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language should appear in all reports, even if the report does not 
describe or refer to findings of fraud or abuse or even if the only 
findings of fraud or abuse are described in or referred to from the 
section on internal control over financial reporting.) ____  ____  ____
[AAG-SLA, par. 4.291
11. Are findings that relate to both internal control over financial report­
ing and to compliance reported in or referred to from both the section 
of the report concerning internal control over financial reporting and 
in the section of the report concerning compliance and other matters? 
(The reporting in one section of the report or schedule may be in 
summary form with a reference to a detailed reporting in the other
section.) ____  ____ ____
[AAG-SLA, par. 4.281
12. Are findings of fraud and abuse reported in or referred to from the 
compliance and other matters section of the report, unless the primary 
nature of the finding is a reportable condition in internal control? 
(Auditors should present or refer to findings of fraud and abuse that 
represent reportable conditions in internal control in the internal
control section.) ____  ____ ____
[AAG-SLA, par. 4.291
13. Do the reported findings include all identified deficiencies in internal 
control over financial reporting considered to be reportable conditions 
and all fraud and illegal acts (unless clearly inconsequential),14 156and 
material violations of provisions of contracts or grant agreements and
14 In an audit conducted in accordance with Circular A-133, the auditor should apply a financial statement materiality consideration 
in reporting in the Government Auditing Standards report fraud and illegal acts involving federal awards that are subject to Circular 
A-133 reporting. [AAG-SLA, pars. 4.15, 12.16, and 12.33]
15 Although Government Auditing Standards uses the term significant in its reporting standard for violations of provisions of contracts 
or grant agreements and abuse, footnote 47 to paragraph 4.18 of Government Auditing Standards states that it considers the terms material 
and significant to be synonymous. For consistency, the Audit Guide Government Auditing Standards and Circular A-133 Audits and this 
checklist use the term material when discussing that standard. [AAG-SLA, par. 4.04c, fn. 8]
16 Government Auditing Standards requires this reporting even if the auditor disclaims an opinion on the financial statements. 
Government Auditing Standards also provides reporting requirements for other findings of internal control deficiencies, fraud, illegal 
acts, violations of provisions of contracts or grants agreements, and abuse; see Questions 18 and 19.
material abuse that has occurred or is likely to have occurred?15,16 ____  ____ ____
[GAS, par. 5.12; AAG-SLA, pars. 4.04c, 4.08, 4.15, 4.16, 4.27, and 12.33]
a. Does the auditor limit the public reporting of fraud, illegal acts, 
violations of provisions of contracts or grant agreements, or abuse 
to matters that would not compromise investigative or legal pro­
ceedings? ____  ____  ____
[GAS, par. 5.25; AAG-SLA, par. 4.20] 
14. Does each finding include a reference number? (For example, findings 
identified and reported in the audit of fiscal year 20X1 could be
assigned reference numbers 20X1-1, 20X1-2, and so forth.) ____  ____  ____
[AAG-SLA, par. 4.32]
15. Do the reported findings place the findings in proper perspective (or 
context) by describing the work performed that resulted in the find­
ing? (The identified instances should be related to the population or 
the number of cases examined and be quantified in terms of dollar
value, if appropriate.) ____  ____  ____
[GAS, pars. 5.14 and 5.18; AAG-SLA, par. 4.30]
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a. When reporting instances of fraud, illegal acts, violations of pro­
visions of contracts or grant agreements, or abuse, are the results 
projected? (If the results cannot be projected, conclusions in the 
findings should be limited to the items tested.) ____  ____  ____
[GAS, par. 5.18; AAG-SLA, par. 4.30]
16. To the extent possible, do the reported findings present criteria,
condition, cause, effect, and recommendation? ____  ____  ____
[GAS, pars. 5.15 and 5.19; AAG-SLA, par. 4.31]
17. Does the auditor's report include the views of responsible officials 
concerning the findings, conclusions, and recommendations, as well
as planned corrective actions?17,18 ____  ____  ____
[GAS, par. 5.26; AAG-SLA, pars. 4.04d and 4.33]
a. If the auditee's views oppose the report's findings, conclusions, or 
recommendations, and are not, in the auditor's opinion, valid—or 
if the planned corrective actions do not adequately address the 
auditor's recommendations—does the report state reasons for 
disagreeing with the comments or planned corrective actions? ____  ____  ____
[GAS, par. 5.30; AAG-SLA, par. 4.33]
Other Reporting and Communication Considerations
18. Does the management letter communicate the following unless 
clearly inconsequential—deficiencies in internal control that are not 
reportable conditions, immaterial violations of provisions of contracts
or grant agreements, and immaterial abuse?17 89 ____  ____ ____
17 In an audit in accordance with Circular A-133, the auditee is required to submit a corrective action plan. For those audits, 
depending on the status of the development of the corrective action plan at the time the auditor's reports are released, the auditor may 
be able to refer to the corrective action plan to satisfy as the required presentation of the auditee's views and planned corrective actions. 
See the questions about the reporting of auditee views and the corrective action plan in Part II of this checklist. [AAG-SLA, par. 4.33, fn. 
39]
18 The auditor is required to extend a reasonable effort to obtain and report auditee views and planned corrective actions. Government 
Auditing Standards does not require the auditor to delay or withhold the release of the report if the auditee does not provide the 
necessary information on a timely basis. If, however, the auditee does not provide the necessary information by the time the report is 
released, the report should indicate the status of the auditee's response. [AAG-SLA, par. 4.34]
19 Generally, Government Auditing Standards requires the auditor to evaluate findings for the purpose of communication in the 
management letter based on their consequence to the financial statements or other financial data significant to the audit objectives. In 
an audit in accordance with Circular A-133, however, the auditor should evaluate findings involving federal awards for the purpose of 
that communication based only on their consequence to the financial statements. Further, the auditor should not communicate such 
findings in the management letter if they are otherwise reported as audit findings in accordance with Circular A-133. [AAG-SLA, pars. 
4.35, fn. 40 and 12.25]
[GAS, pars. 5.16 and 5.20; AAG-SLA, pars. 4.17 and 4.35]
a. Are the management letter discussions worded so that readers can 
distinguish those matters that are required to be included by 
GAAS or Government Auditing Standards from matters that are 
recommendations for improvements or information about "best
practices"? ____  ____ ____
[AAG-SLA, par. 4.36]
b. Does the management letter not include personal identification or
other potentially sensitive matters? ____  ____  ____
[AAG-SLA, par. 4.42]
19. Has the auditor used professional judgment to determine whether 
and how to communicate to auditee officials deficiencies in internal
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control, fraud, illegal acts, violations of provisions of contracts or 
grant agreements, and abuse that are clearly inconsequential?20 ____  ____  ____
20 GAAS require that whenever the auditor has determined that there is evidence that fraud may exist, the auditor should bring that 
matter to the attention of an appropriate level of management, even if the matter might be considered inconsequential. [SAS 99, par. 79 
(AU 316.79); AAG-SLA, pars. 4.11 and 4.35, fn. 42]
[GAS, pars. 5.16 and 5.20; AAG-SLA, par. 4.35]
20. Has the auditor reported fraud, illegal acts, violations of provisions 
of contracts or grant agreements, and abuse directly to parties outside 
of the auditee in the situations required by Government Auditing 
Standards, even if the auditor has resigned or been dismissed from the
audit? ____  ____  ____
[GAS, pars. 5.21-5.25; AAG-SLA, pars. 4.18-4.20]
21. Has the auditor communicated the following information, preferably 
in a writing such as the engagement letter, to officials of the audited 
entity and to the individuals contracting for or requesting the audit 
during the planning stages of the audit:
a. The auditor's responsibilities for testing and reporting on internal 
control over financial reporting and on compliance with laws,
regulations, and provisions of contracts or grant agreements? ____  ____  ____
b. The nature of any additional testing of internal control and com­
pliance required by laws, regulations, and provisions of contracts 
or grant agreements or otherwise requested, and whether the 
auditor is planning on providing an opinion on internal control 
over financial reporting or on compliance with laws, regulations,
and provisions of contracts or grant agreements? ____ ____  ____
c. A contrasting of the responsibilities in Questions a and b above
with other audits of internal control and compliance? ____  ____  ____
d. Potential restrictions on the auditor's reports? ____  ____  ____
[GAS, pars. 4.06-4.11; AAG-SLA, pars. 2.18 and 2.19]
e. Additional relevant topics, such as the auditor's fieldwork and
reporting responsibilities for fraud and abuse? ____  ____ ____
[AAG-SLA, par. 2.18]
22. If an audit is terminated before it is complete, is the reason for 
terminating the audit communicated to auditee management, the 
entity requesting the audit, and other appropriate officials, preferably
in writing? ____  ____  ____
[GAS, par. 4.09; AAG-SLA, par. 2.20]
23. If the auditor is:
a. A government auditor, does the auditor submit the auditor's 
reports to the appropriate officials of the audited entity, appropri­
ate officials of the organizations requiring or arranging for the 
audits (unless legal restrictions prevent it), and other officials who 
have legal oversight authority or who may be responsible for 
acting on audit findings and recommendations and to others
authorized to receive such reports? ____  ____  ____
b. A nongovernment auditor, does the auditor clarify report distri­
bution responsibilities with the party contracting for the audit and
follow the agreements reached? ____  ____  ____
[GAS, par. 5.34; AAG-SLA, par. 4.04/]
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24. Unless the report is restricted by law or regulation, or contains privi­
leged and confidential information, does the auditor clarify that cop­
ies are made available for public inspection? (That clarification should 
be made in the engagement letter and may also be made in correspon­
dence that transmits the reports to the auditee and other recipients.) ____ ____ ____
[GAS, par. 5.34; AAG-SLA, par. 4.04f and fn. 10]
Part II—Reports on Audits Performed in Accordance With 
Circular A-133
1. In an audit performed in accordance with Circular A-133, has the 
auditor issued the following reports in addition to those in Part I of 
this checklist:21
21 Because of the requirements of Government Auditing Standards, the auditor also has other reporting and communication responsi­
bilities in a Circular A-133 audit. See the questions in the section titled "Other Reporting and Communication Considerations" in Part 
I of this checklist.
a. A report on the supplementary schedule of expenditures of
federal awards? ____  ____  ____
b. A report on compliance with requirements applicable to each
major program and on internal control over compliance in accord­
ance with Circular A-133? ____  ____  ____
c. A schedule of findings and questioned costs? ____  ____  ____
[A-133, sec. 505; AAG-SLA, par. 12.07]
Report on the Supplementary Schedule of Expenditures of 
Federal Awards
2. Is the report on the schedule (a) included in the auditor's report on the 
financial statements, (b) included in the report on compliance with 
requirements applicable to each major program and on internal con­
trol over compliance in accordance with Circular A-133, or (c) issued
as a stand-alone report? ____  ____  ____
[AAG-SLA, pars. 12.12, 12.15, 12.24, and 12.28]
3. If the report on the financial statements refers to the work of other 
auditors, has the auditor considered the need to refer to the major 
federal programs audited by other auditors in the report on the
schedule? ____  ____  ____
[AAG-SLA, par. 12.29]
4. If the report on the schedule is included in the auditor's report on the 
financial statements or in the Circular A-133 report on compliance and 
on internal control over compliance, does it:
a. Conform to the standard report language illustrated in AAG-SLA? ____  ____  ____
[AAG-SLA, pars. 12.14 and 12.54, Ex. 12-1, fn. 5]
b. Identify the schedule of expenditures of federal awards as accom­
panying supplementary information by descriptive title or by
page number of the document? ____  ____  ____
c. Contain a statement that the audit was conducted for the purpose 
of forming an opinion on the basic financial statements taken as a 
whole and that the schedule is presented for purposes of additional
analysis and is not a required part of the financial statements? ____  ____  ____
[AAG-SLA, pars. 12.12 and 12.54, Ex. 12-1, fn. 5]
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d. Contain an opinion or a disclaimer of opinion as to whether the 
Schedule is fairly stated, in all material respects, in relation to the 
financial statements taken as a whole?
[AAG-SLA, pars. 12.10, 12.12, and 12.54, Ex. 12-1, fn. 5]
e. Carry the same date as the report on the financial statements, even 
if that requires a dual date on the Circular A-133 report on com­
pliance and on internal control over compliance?
[AAG-SLA, pars. 12.26 and 12.28]
f. Consider the effect of any modifications to this report? 
[AAG-SLA, par. 12.14, fn. 10]
5. If the report on the schedule is issued as a stand-alone report, is the 
guidance of SAS 58 (AU 508) followed in issuing that report?
a. Does the report carry the same date as the Circular A-133 report 
on compliance and on internal control over compliance? 
[AAG-SLA, par. 12.28]
Report on Compliance With Requirements Applicable to Each Major 
Program and on Internal Control Over Compliance in Accordance With 
Circular A-133
6. Does the report conform to the standard report language illustrated 
in AAG-SLA?
[AAG-SLA, par. 12.54, Exs. 12-1-12-4]
7. Does the report contain the following elements:
a. A statement that the auditor has audited the compliance of the 
auditee with the types of compliance requirements described in 
the OMB Circular A-133 Compliance Supplement that are applicable 
to each of its major programs?
b. A statement that the auditee's major programs are identified in the 
summary of the auditor's results section of the accompanying 
schedule of findings and questioned costs?
c. A statement that compliance with the requirements of laws, regu­
lations, contracts, and grants applicable to each of the auditee's 
major federal programs is the responsibility of the auditee's man­
agement, and that the auditor's responsibility is to express an 
opinion on the auditee's compliance based on the audit?
d. A statement that the audit of compliance was conducted in accord­
ance with GAAS (with an identification of the United States of 
America as the country of origin of those standards), the standards 
applicable to financial audits contained in Government Auditing 
Standards issued by the Comptroller General of the United States, 
and Circular A-133?
e. A statement that those standards and Circular A-133 require that 
the auditor plan and perform the audit to obtain reasonable assur­
ance about whether noncompliance with the types of compliance 
requirements that could have a direct and material effect on a 
major federal program occurred?
f. A statement that an audit includes examining, on a test basis, 
evidence about the auditee's compliance with those requirements 
and performing such other procedures as the auditor considered 
necessary in the circumstances?
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g. A statement that the auditor believes that the audit provides a
reasonable basis for the auditor's opinion? ____  ___
h. A statement that the audit does not provide a legal determination
of the auditee's compliance with those requirements? ____  ___
i. If instances of noncompliance are noted that result in an opinion 
modification, a reference to a description in the accompanying 
schedule of findings and questioned costs, including:
(1) The reference number(s) of the finding(s)? ____  ___
(2) An identification of the type(s) of compliance requirements
and related major program(s)? ____  ___
(3) A statement that compliance with such requirements is nec­
essary, in the auditor's opinion, for the auditee to comply
with the requirements applicable to the program(s)? ____  ___
j. An opinion on whether the auditee complied, in all material
respects, with the types of compliance requirements that are ap­
plicable to each of its major federal programs? ____  ___
k. If applicable, a statement that the results of the auditing proce­
dures disclosed instances of noncompliance that are required to 
be reported in accordance with Circular A-133 and a reference to 
the schedule of findings and questioned costs in which they are
described? ____  ___
l. A statement that the auditee's management is responsible for 
establishing and maintaining effective internal control over com­
pliance with the requirements of laws, regulations, contracts, and
grants applicable to federal programs? ____  ___
m. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over compliance with 
requirements that could have a direct and material effect on a 
major federal program, to determine the auditing procedures for 
the purpose of expressing an opinion on compliance and to test 
and report on the internal control over compliance in accordance
with Circular A-133? ____  ___
n. If applicable, a statement that reportable conditions were noted
and the definition of a reportable condition? ____  ___
o. If applicable, a reference to a description of reportable conditions 
noted in the accompanying schedule of findings and questioned
costs, including the reference number of the finding(s)? ____  ___
p. If no reportable conditions are noted, a statement that the auditor's 
consideration of the internal control over compliance would not 
necessarily disclose all matters in internal control that might be 
material weaknesses; if reportable conditions are noted, a state­
ment that the auditor's consideration of the internal control over 
compliance would not necessarily disclose all matters in the inter­
nal control that might be reportable conditions and, accordingly, 
would not necessarily disclose all reportable conditions that are
also considered to be material weaknesses? ____  ___
q. The definition of a material weakness? ____  ___
r. If applicable, a statement about whether the auditor believes any
of the reportable conditions noted are material weaknesses and, if 
they are, a reference to a description of the material weaknesses in 
the schedule of findings and questioned costs, including the reference 
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number of the finding(s)? (If there are no reportable conditions, a 
statement should be made that no material weaknesses were 
noted.)
s. A separate paragraph at the end of the report stating that the report 
is intended solely for the information and use of the audit commit­
tee, management, specified legislative or regulatory bodies, fed­
eral awarding agencies, and (if applicable) pass-through entities 
and is not intended to be and should not be used by anyone other 
than these specified parties?22
t. The manual or printed signature of the auditor's firm?
u. The date of the auditor's report? 
[AAG-SLA, par. 12.23]
22 See footnote 13. [AAG-SLA, par. 12.23s, fn. 18]
8. If the audit of the auditee's compliance with requirements applicable 
to a major program detects material instances of noncompliance with 
those requirements, does the auditor's report express a qualified or 
adverse opinion?
[AAG-SLA, par. 12.19]
9. Have scope limitations on the auditor's testing of the auditee's com­
pliance with laws, regulations, and the provisions of contracts or grant 
agreements been considered in the opinion on compliance with re­
quirements applicable to each major program?
[AAG-SLA, pars. 12.20-12.22]
10. Have the cumulative effects of all instances of noncompliance with 
federal programs and scope limitations been considered in the opin­
ion on the financial statements?
[AAG-SLA, pars. 12.19 and 12.20]
11. If there are abuse findings reported in the federal awards section of 
the schedule of findings and questioned costs that do not otherwise 
meet the Circular A-133 requirements for reporting as findings, has 
the auditor considered the need to modify the report on compliance 
and on internal control over compliance?
[AAG-SLA, par. 12.36]
12. Is the report dated the same as or later than the date of the auditor's 
report on the financial statements?
a. If the report is dated later than the date of the auditor's report on 
the financial statements, have appropriate subsequent events pro­
cedures been performed?
[AAG-SLA, par. 12.27]
13. If the audit of federal awards does not encompass the entirety of the 
auditee's operations expending federal awards, are the operations 
that are not included identified in a separate paragraph following the 
first paragraph of the report?
[AAG-SLA, par. 12.30]
14. If the report on the financial statements refers to the work of other 
auditors, has the auditor considered the need to refer to the major 
federal programs audited by other auditors in the report on compli­
ance and on internal control over compliance?
[AAG-SLA, par. 12.29]
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Schedule of Findings and Questioned Costs
15. Does the report conform to the standard report language illustrated
in AAG-SLA? ____  ___
[AAG-SLA, par. 12.54, Ex. 12-5]
16. Is the report presented even if there are no findings to report? (In a 
situation in which there are no findings or questioned costs, the 
auditor should prepare the summary of auditor's results section of 
the schedule and either omit the other sections or include them,
indicating that no matters were reported.) ____  ___
[AAG-SLA, par. 12.40]
17. Does the report contain the following three sections:
a. A summary of the auditor's results? ____  ___
b. Findings related to the financial statements that are required to be
reported in accordance with Government Auditing Standards? (See 
the questions about those findings in Part I of this checklist.) ____  ___
c. Findings and questioned costs for federal awards? ____  ___
[AAG-SLA, pars. 12.31 and 12.40]
18. Does the summary of auditor's results include:
a. The type of report the auditor issued on the financial statements 
of the auditee (that is, unqualified opinion, qualified opinion,
adverse opinion, or disclaimer of opinion)? ____  ___
[AAG-SLA, par. 12.32a]
b. Where applicable, a statement that reportable conditions in inter­
nal control were disclosed by the audit of the financial statements
and whether any such conditions were material weaknesses? ____  ___
c. A statement on whether the audit disclosed any noncompliance
that is material to the financial statements? ____  ___
d. Where applicable, a statement that reportable conditions in the 
internal control over major programs were disclosed by the audit
and whether any such conditions were material weaknesses? ____  ___
[AAG-SLA, par. 12.32a]
e. The type of report the auditor issued on compliance for major 
programs (that is, unqualified opinion, qualified opinion, adverse 
opinion, or disclaimer of opinion)? (If the audit report for one or 
more major programs is other than unqualified, indicate the type
of report issued for each program.) ____  ___
[AAG-SLA, pars. 12.32a and 12.54, Ex. 12-5, fn. 27]
f. A statement on whether the audit disclosed any audit findings that
the auditor is required to report under Circular A-133? (See Ques­
tion 20 below.) ____  ___
g. An identification of major programs? ____  ___
h. The dollar threshold used to distinguish between type A and type
B programs? ____  ___
i. A statement on whether the auditee qualified as a low-risk auditee? ____ ___
[AAG-SLA, par. 12.32a]
19. If there are abuse findings reported in the federal awards section of the 
schedule of findings and questioned costs that do not otherwise meet the 
Circular A-133 requirements for reporting as findings, has the auditor
considered the need to modify the summary of the auditor's results? ____  ___
[AAG-SLA, par. 12.36]
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20. Are the following reported as audit findings related to federal awards:
a. Reportable conditions and material weaknesses in internal control 
over major programs? (The auditor should identify reportable con­
ditions that are individually or cumulatively material weaknesses.)
b. Material noncompliance with the provisions of laws, regulations, 
contracts, or grant agreements related to a major program?
c. Known questioned costs that are greater than $10,000 for a type of 
compliance requirement for a major program?
d. Known questioned costs when likely questioned costs are greater 
than $10,000 for a type of compliance requirement for a major 
program?
e. Known questioned costs that are greater than $10,000 for pro­
grams that are not audited as major?
f. The circumstances concerning why the auditor's report on com­
pliance for major programs is other than an unqualified opinion, 
if not otherwise reported as an audit finding?
g. Known fraud affecting a federal award, if not otherwise reported 
as an audit finding? (An audit finding is not required if the fraud 
was reported outside the entity as required by GAS.)
[A-133, sec. 510(a); AAG-SLA, par. 12.35]
h. Instances of material misrepresentation by the auditee of the status 
of any prior audit findings?
[A-133, sec. 510(a); AAG-SLA, pars. 12.35 and 12.42]
i. Abuse involving federal awards that is material to a major program? 
[AAG-SLA, par. 12.36]
21. Does the audit finding detail include:
a. A reference number? (For example, findings identified and re­
ported in the audit of fiscal year 20X1 would be assigned reference 
numbers 20X1-1, 20X1-2, and so forth.)
[A-133, sec. 510(c); AAG-SLA, par. 12.39]
b. Identification of the federal program and specific federal award, 
including CFDA title and number, federal award number and 
year, name of the federal agency, and name of the applicable 
pass-through entity?23 24
23 When information such as the CFDA title and number or the federal award number is not available, the auditor should provide 
the best information available to describe the federal award. (Chapter 7 of AAG-SLA discusses an alternative for presentation if a CFDA 
number is not available.) [A-133, sec. 510(b)(1); AAG-SLA, par. 12.37a]
24 Where appropriate, the instances identified should be related to the universe and the number of cases examined and be quantified 
in terms of the dollar value. [A-133, sec. 510(b)(5); AAG-SLA, par. 12.37e]
c. The criteria or specific requirement upon which the audit finding 
is based, including the statutory, regulatory, or other citation?
d. The condition found, including facts that support the deficiency 
identified in the audit finding?
e. Identification of questioned costs and how they were computed?
f. Information to provide a proper perspective for judging the preva­
lence and consequences of the audit findings?24
g. The possible asserted effect of the condition?
h. Recommendations to prevent future occurrences of the deficiency? 
[A-133, sec. 510(b); AAG-SLA, par. 12.37]
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22. Do the audit findings related to federal awards also meet the presen­
tation requirements of Government Auditing Standards? (See the Ques­
tions about those presentation requirements in Part I of this checklist.) ____  ____  ____
[AAG-SLA, par. 12.38]
23. Are audit findings that relate to federal awards:
a. And that relate to the same issue presented as one finding? ____  ____  ____
b. Organized by federal agency or pass-through entity, where practical? ____  ____ ____
[A-133, sec. 505(d)(3)(f) and (ii); AAG-SLA, par. 12.32c]
24. Are audit findings that relate to both the financial statements and the 
federal awards reported in both sections of the schedule (an alterna­
tive is to report the finding in one section of the schedule in summary 
form, with a reference to a detailed reporting in the other section of
the schedule)? ____  ____  ____
[A-133, sec. 505(d)(3); AAG-SLA, par. 12.32c]
25. Do the findings report the views of responsible officials concerning 
the findings, conclusions, and recommendations, as well as planned 
corrective actions, as required by Government Auditing Standards, or 
refer to the corrective action plan, depending on the status of the 
development of the corrective action plan at the time the auditor's
reports are released?25 ____  ____  ____
25 See footnote 18.
26 The data collection form and related instructions are available from the Federal Audit Clearinghouse's (FAC's) Internet site at 
http://harvester.census.gov/sac or by calling the FAC at (888) 222-9907. The form number is SF-SAC. The FAC prefers to receive the 
data collection form via an online Internet Data Entry System (IDES). The Office of Management and Budget periodically revises the 
data collection form and its accompanying instructions. Auditors should exercise caution to make sure they use the version of the form 
and instructions that applies to the fiscal year audited. [AAG-SLA, par. 12.46 and fn. 27]
[AAG-SLA, pars. 12.34 and 12.38]
a. If the auditee's comments oppose the report's findings, conclusions, 
or recommendations, and are not, in the auditors' opinion, valid—or 
if the planned corrective actions do not adequately address the 
auditors' recommendations—does the federal awards section of the 
schedule of findings and questioned costs state the auditor's reasons 
for disagreeing with the comments or planned corrective actions? ____  ____  ____
[A-133, sec. 510(b)(8); AAG-SLA, par. 12.38, fn. 25]
26. Do the audit report and any attached or referenced schedules not 
include names, Social Security numbers, other personal identification,
or other potentially sensitive matters? ____  ____  ____
[AAG-SLA, par. 12.53]
Data Collection Form26
27. Has the auditor completed the appropriate parts of the data collection
form? ____  ____  ____
28. Has the auditor signed the form and dated it as of the date on which
the auditor completes and signs the form? ____  ____ ____
[AAG-SLA, par. 12.45]
29. Does the information on the data collection form agree to the infor­
mation in the auditor's reports and the summary of auditor's results
in the schedule of findings and questioned costs? ____  ____  ____
[Federal Audit Clearinghouse, Data Collection Form No. SF-SAC]
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Program-Specific Audits
Practice Tip
When an auditee expends federal awards under only one federal program (excluding research and devel­
opment) and the federal program's laws, regulations, or grant agreements do not require a financial 
statement audit of the auditee, the auditee may elect to have a program-specific audit. A program-specific 
audit may not be elected for research and development unless all federal awards expended were received 
from the same federal agency (or the same federal agency and the same pass-through entity) and that federal 
agency (or pass-through entity, in the case of a subrecipient) approves a program-specific audit in advance. 
[A-133, sec. 200; AAG-SLA, par. 13.02]
30. If a program-specific audit guide is available and current with regard 
to the program's compliance requirements, has the auditor issued the 
reports required by the guide?
[A-133, sec. 235(a); AAG-SLA, par. 13.04]
31. If a program-specific audit guide is not available or not current with 
regard to the program's compliance requirements, has the auditor issued 
the following reports:27,28
a. A report on the federal program's financial statements that provides 
an opinion or disclaimer of opinion on the financial statements?
b. A report on compliance with requirements applicable to the federal 
program and on the internal control over compliance in accordance 
with the program-specific audit option under Circular A-133?
c. A schedule of findings and questioned costs for the program? 
[A-133, sec. 235(b)(4); AAG-SLA, pars. 13.08 and 13.09]
32. Do the reports conform to the standard report language illustrated in 
AAG-SLA?
[AAG-SLA, pars. 12.54, Ex. 12-5 and 13.16, Exs. 13-1-13-2)]
27 If the financial statement(s) of the program present only the activity of the federal program, the auditor is not required to issue a 
separate report to meet the reporting requirements of GAS. However, if the financial statement(s) of the federal program present more 
than the program's activity the auditor should issue a separate GAS report and modify it so that it refers only to the financial 
statement(s) of the federal program. [AAG-SLA, par. 13.10]
28 See footnote 21.
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Illustrative Financial Statements
.01 The following illustrative financial statements demonstrate the practical applications of the reporting 
practices discussed in the June 1996 AICPA Audit and Accounting Guide Health Care Organizations with 
conforming changes as of May 1, 2005 (the Guide). The checklists and illustrative financial statements do not 
include all disclosures and presentation items promulgated. Pronouncements deemed remote for audits of 
health care providers are not included in this document. Specific types of health care organizations have been 
selected to illustrate a wide diversity of reporting practices; it is not intended that these illustrations represent 
either the only types of disclosure or the only statement formats that would be appropriate. Health care 
providers are urged to develop financial statement formats that are appropriate for their individual 
circumstances while being consistent with the accounting and reporting practices discussed in the Guide.
This section contains illustrative financial statements, prepared using the illustrative financial statements in 
the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of May 1, 
2005), for the following types of health care organizations:
• Not-for-Profit Hospital
• For-Profit Nursing Home
• Not-for-Profit Continuing Care Retirement Community
• Not-for-Profit Home Health Agency
• Not-for-Profit Health Maintenance Organization
• Not-for-Profit Ambulatory Care Organization
These illustrative financial statements are not intended to include items that should be accounted for under 
the requirements of SFAS 133, Accounting for Derivative Instruments and Hedging Activities, as amended, and 
do not reflect the requirements of SFAS 133. SFAS 133, among other matters, amends the disclosure 
requirements for securities in SFAS 115, Accounting for Certain Investments in Debt and Equity Securities (see 
paragraph 534 of SFAS 133). In reporting disclosures about investments in securities, investor-owned entities 
should comply primarily with the requirements of paragraphs 6, 17, 19, 20, 21, and 22 of SFAS 115, as 
amended. Other disclosure requirements for investments in securities may also be applicable. Practitioners 
should refer to SFAS 133, as amended, for guidance on reporting derivative instruments and hedging 
activities.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NOT-FOR-PROFIT HOSPITAL
.02
Sample Not-for-Profit Hospital
Balance Sheets
December 31, 20X7 and 20X6
(in thousands)
20X7 20X6
Assets
Current assets:
Cash and cash equivalents $ 4,758 $ 5,877
Short-term investments 15,836 10,740
Assets limited as to use 970 1,300
Patient accounts receivable, net of allowance for doubtful
accounts of $2,500 in 20X7 and $2,400 in 20X6 15,100 14,194
Other current assets 2,670 2,856
Total current assets 39,334 34,967
Interest in net assets of Sample Hospital Foundation’ 510 462
Assets limited as to use:
Internally designated for capital acquisition 12,000 12,500
Held by trustee 6,949 7,341
18,949 19,841
Less amount required to meet current obligations (970) (1,300)
17,979 18,541
Long-term investments 4,680 4,680
Long-term investments restricted for capital acquisition 320 520
Property and equipment, net 51,038 50,492
Other assets 1,185 908
Total assets $115,046 $110,570
(continued)
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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See accompanying notes to financial statements.
20X7 20X6
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt $ 1,470 $ 1,750
Accounts payable and accrued expenses 5,818 5,382
Estimated third-party payor settlements 2,143 1,942
Other current liabilities 1,969 2,114
Total current liabilities 11,400 11,188
Long-term debt, net of current portion 23,144 24,014
Other liabilities 3,953 3,166
Total liabilities 38,497 38,368
Net assets:
Unrestricted 70,846 66,199
Temporarily restricted 2,115 2,470
Permanently restricted 3,588 3,533
Total net assets 76,549 72,202
Total liabilities and net assets $115,046 $110,570
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FORMAT A 
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7 20X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other revenue 2,601 5,212
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 99,207 95,104
Expenses:
Operating expenses 88,521 80,585
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Allowance for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Operating income 1,152 5,814
Other income:
Investment income 3,900 3,025
Other expense:
Loss from extinguishment of debt (500)
Excess of revenues over expenses 4,552 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Change in interest in net assets of Sample Hospital
Foundation* 283 536
Transfers to parent (688) (3,051)
Increase in unrestricted net assets $ 4,647 $ 6,699
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
See accompanying notes to financial statements.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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FORMAT B 
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7 20X6
Unrestricted revenues, gains and other support: 
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other, primarily investment income 6,501 8,237
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 103,107 98,129
Expenses:
Salaries and benefits 53,900 49,938
Medical supplies and drugs 26,532 22,121
Insurance 8,089 8,526
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Allowance for bad debts 1,000 1,300
Loss from extinguishment of debt 500
Other 2,000 1,300
Total expenses 98,555 89,290
Excess of revenues, gains, and other support over expenses 4,552 8,839
Change in net unrealized gains and losses on other than 
trading securities 300 375
Net assets released from restrictions used for purchase of 
property and equipment 200
Change in interest in net assets of Sample Hospital 
Foundation’ 283 536
Transfers to parent (688) (3,051)
Increase in unrestricted net assets $ 4,647 $ 6,699
See accompanying notes to financial statements.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
130 Health Care Organizations
.05
Sample Not-for-Profit Hospital 
Statements of Changes in Net Assets 
Years Ended December 31, 20X7 and 20X6 
(in thousands)
20X7 20X6
Unrestricted net assets:
Excess of revenues over expenses $ 4,552 $ 8,839
Net unrealized gains on investments, other than trading 
securities 300 375
Change in interest in net assets of Sample Hospital 
Foundation* 283 536
Transfers to parent (688) (3,051)
Net assets released from restrictions used for purchase 
of property and equipment 200
Increase in unrestricted net assets 4,647 6,699
Temporarily restricted net assets: 
Contributions for charity care 140 996
Net realized and unrealized gains on investments 5 8
Net assets released from restrictions (500)
Increase (decrease) in temporarily restricted net assets (355) 1,004
Permanently restricted net assets: 
Contributions for endowment funds 50 411
Net realized and unrealized gains on investments 5 2
Increase in permanently restricted net assets 55 413
Increase in net assets 4,347 8,116
Net assets, beginning of year 72,202 64,086
Net assets, end of year $76,549 $72,202
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in Note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
See accompanying notes to financial statements.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.20 for contributions restricted to property acquisitions. Readers should be aware that SFAS 136 is silent on this
classification. The AICPA has released a group of Technical Practice Aids (TPAs) (TIS section 6400.36 through .42) that address
recognition of the interests in the net assets of financially interrelated organizations and the classification of the changes in those
interests. TPAs are nonauthoritative and are not sources of established accounting principles as described in SAS 69, The Meaning of
Present Fairly in Conformity With Generally Accepted Accounting Principles.
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Sample Not-for-Profit Hospital
Statements of Cash Flows (Indirect Method)
Years Ended December 31, 20X7 and 20X6
(in thousands)
Cash flows from operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net 
cash provided by operating activities:
Loss from extinguishment of debt
Depreciation and amortization
Net realized and unrealized gains on investments, 
other than trading
Undistributed portion of change in interest in net 
assets of Sample Hospital Foundation
Transfers to parent
Allowance for bad debts
Restricted contributions and investment income 
received
(Increase) decrease in:
Patient accounts receivable
Trading securities
Other current assets
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Proceeds from sale of investments
Purchase of investments
Capital expenditures
Net cash used in investing activities
Cash flows from financing activities:
Transfers to parent
Proceeds from restricted contributions and restricted 
investment income
Payments on long-term debt
Payments on capital lease obligations
Proceeds from issuance of long-term debt
Net cash used in financing activities
Net (decrease) increase in cash and cash equivalents 
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental Disclosures of Cash Flow Information:
20X7 20X6
$ 4,347
500
$ 8,116
4,782 4,280
(450) (575)
(48) (51)
688 3,051
1,000 1,300
(290) (413)
(1,906) (2,036)
215
186 (2,481)
(277) (190)
436 679
201 305
(145) (257)
787 (128)
10,026 11,600
45,100 50,650
(48,869) (52,800)
(4,728) (5,860)
(8,497) (8,010)
(688) (3,051)
290 413
(24,700) (804)
(150) (100)
22,600 500
(2,648) (3,042)
(1,119) 548
5,877 5,329
$ 4,758 $ 5,877
The Hospital entered into capital lease obligations in the amount of $600,000 for new 
equipment in 20X7.
Cash paid for interest (net of amount capitalized) in 20X7 and 20X6 was $1,780,000 
and $1,856,000, respectively.
See accompanying notes to financial statements.
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Sample Not-for-Profit Hospital 
Notes to Financial Statements 
December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies1
1 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Not-for-Profit Hospital (the Hospital), located in Tulsa, Oklahoma, 
is a not-for-profit acute care hospital. The Hospital provides inpatient, outpatient and emergency 
care services for residents of northeastern Oklahoma. Admitting physicians are primarily practi­
tioners in the local area. The Hospital was incorporated in Oklahoma in 20X1 and is affiliated with 
the Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly 
liquid debt instruments with original maturities of three months or less.
The Hospital routinely invests its surplus operating funds in money market mutual funds. These 
funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all 
investments in debt securities are measured at fair value in the balance sheet. Investment income 
or loss (including realized gains and losses on investments, interest and dividends) is included in 
the excess of revenues over expenses unless the income or loss is restricted by donor or law. 
Unrealized gains and losses on investments are excluded from the excess of revenues over 
expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under 
indenture agreements and designated assets set aside by the Board of Trustees for future capital 
improvements, over which the Board retains control and may at its discretion subsequently use 
for other purposes. Amounts required to meet current liabilities of the hospital have been 
reclassified in the balance sheet at December 31, 20X7 and 20X6.
Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation 
is provided over the estimated useful life of each class of depreciable asset and is computed using 
the straight-line method. Equipment under capital lease obligations is amortized on the straight- 
line method over the shorter period of the lease term or the estimated useful life of the equipment. 
Such amortization is included in depreciation and amortization in the financial statements. 
Interest cost incurred on borrowed funds during the period of construction of capital assets is 
capitalized as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted 
support, and are excluded from the excess of revenues over expenses, unless explicit donor 
stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit 
restrictions that specify how the assets are to be used and gifts of cash or other assets that must 
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be used to acquire long-lived assets are reported as restricted support. Absent explicit donor 
stipulations about how long those long-lived assets must be maintained, expirations of donor 
restrictions are reported when the donated or acquired long-lived assets are placed in service.
Temporarily and permanently restricted net assets. Temporarily restricted net assets are those whose 
use by the Hospital has been limited by donors to a specific time period or purpose. Permanently 
restricted net assets have been restricted by donors to be maintained by the Hospital in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over ex­
penses. Changes in unrestricted net assets which are excluded from excess of revenues over expenses, 
consistent with industry practice, include unrealized gains and losses on investments other than 
trading securities, permanent transfers of assets to and from affiliates for other than goods and 
services, and contributions of long-lived assets (including assets acquired using contributions which 
by donor restriction were to be used for the purposes of acquiring such assets).
Net patient service revenue. The Hospital has agreements with third-party payors that provide 
for payments to the Hospital at amounts different from its established rates. Payment arrange­
ments include prospectively determined rates per discharge, reimbursed costs, discounted 
charges, and per diem payments. Net patient service revenue is reported at the estimated net 
realizable amounts from patients, third-party payors, and others for services rendered, including 
estimated retroactive adjustments under reimbursement agreements with third-party payors. 
Retroactive adjustments are accrued on an estimated basis in the period the related services are 
rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The Hospital has agreements with various Health Maintenance Organizations 
(HMOs) to provide medical services to subscribing participants. Under these agreements, the Hospital 
receives monthly capitation payments based on the number of each HMO's participants, regardless 
of services actually performed by the Hospital. In addition, the HMOs make fee-for-service payments 
to the Hospital for certain covered services based upon discounted fee schedules.
Charity care. The Hospital provides care to patients who meet certain criteria under its charity 
care policy without charge or at amounts less than its established rates. Because the Hospital does 
not pursue collection of amounts determined to qualify as charity care, they are not reported as 
revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the Hospital are 
reported at fair value at the date the promise is received. Conditional promises to give and 
indications of intentions to give are reported at fair value at the date the gift is received. The gifts 
are reported as either temporarily or permanently restricted support if they are received with 
donor stipulations that limit the use of the donated assets. When a donor restriction expires, that 
is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily 
restricted net assets are reclassified as unrestricted net assets and reported in the statement of 
operations as net assets released from restrictions. Donor-restricted contributions whose restric­
tions are met within the same year as received are reported as unrestricted contributions in the 
accompanying financial statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes 
estimates of the ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The Hospital is a not-for-profit corporation and has been recognized as tax- 
exempt pursuant to Sec. 501(c)(3) of the Internal Revenue Code.
2. Net Patient Service Revenue
The Hospital has agreements with third-party payors that provide for payments to the Hospital 
at amounts different from its established rates. A summary of the payment arrangements with 
major third-party payors follows:
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• Medicare. Inpatient acute care services and outpatient services rendered to Medicare 
program beneficiaries are paid at prospectively determined rates. These rates vary 
according to a patient classification system that is based on clinical, diagnostic, and other 
factors. Inpatient nonacute services, and defined capital and medical education costs 
related to Medicare beneficiaries are paid based on a cost reimbursement methodology. 
The Hospital is reimbursed for cost reimbursable items at a tentative rate with final 
settlement determined after submission of annual cost reports by the Hospital and audits 
thereof by the Medicare fiscal intermediary. Beginning in 20X3, the Hospital claimed 
Medicare payments based on an interpretation of certain "disproportionate share" rules. 
The intermediary disagreed and declined to pay the excess reimbursement claimed under 
that interpretation. Through 1996, the Hospital has not included the claimed excess in net 
patient revenues pending resolution of the matter. In 20X7, the intermediary accepted the 
claims and paid the outstanding claims, including $950,000 applicable to 20X6 and $300,000 
applicable to 20X5 and prior, which has been included in 20X7 net revenues.
• Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries 
are reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at 
a tentative rate with final settlement determined after submission of annual cost reports 
by the Hospital and audits thereof by the Medicaid fiscal intermediary.
Revenue from the Medicare and Medicaid programs accounted for approximately XX 
percent and XX percent, respectively, of the Hospital's net patient revenue for the year 
ended 20X7, and XX percent and XX percent, respectively, of the Hospital's net patient 
revenue, for the year ended 20X6. Laws and regulations governing the Medicare and 
Medicaid programs are extremely complex and subject to interpretation. As a result, there 
is at least a reasonable possibility that recorded estimates will change by a material amount 
in the near term. The 20X6 net patient service revenue increased approximately $XXX due 
to removal of allowances previously estimated that are no longer necessary as a result of 
final settlements and years that are no longer subject to audits, reviews, and investigations. 
The 20X7 net patient service revenue decreased approximately $XXX due to prior-year 
retroactive adjustments in excess of amounts previously estimated.
The Hospital also has entered into payment agreements with certain commercial insurance 
carriers, health maintenance organizations, and preferred provider organizations. The basis for 
payment to the Hospital under these agreements includes prospectively determined rates per 
discharge, discounts from established charges, and prospectively determined daily rates.
3. Investments
Assets Limited as to Use
The composition of assets limited as to use at December 31, 20X7 and 20X6, is set forth in the 
following table. Investments are stated at fair value.
20X7 20X6
Internally designated for capital acquisition: 
Cash $ 545,000 $ 350,000
U.S. Treasury obligations 11,435,000 12,115,000
Interest receivable 20,000 35,000
12,000,000 12,500,000
Held by trustee under indenture agreement: 
Cash and short-term investments 352,000 260,000
U.S. Treasury obligation 6,505,000 7,007,000
Interest receivable 92,000 74,000
6,949,000 7,341,000
$18,949,000 $19,841,000
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Other Investments
Other investments, stated at fair value, at December 31, 20X7 and 20X6, include:
20X7 20X6
Trading:
U.S. Corporate Bonds $ 1,260,000 $ 1,475,000
Other:
U.S. Treasury obligations $19,266,000 $14,233,000
Interest receivable 310,000 232,000
20,836,000 15,940,000
Less:
Long-term investments 4,680,000 4,680,000
Long-term investments restricted for capital acquisitions 320,000 520,000
Short-term investments $15,836,000 $10,740,000
Investment income and gains for assets limited as to use, cash equivalents, and other invest­
ments are comprised of the following for the years ending December 31, 20X7 and 20X6:
20X7 20X6
Income:
Interest income $3,585,000 $2,725,000
Realized gains on sales of securities 150,000 200,000
Unrealized gains on trading securities 165,000 100,000
$3,900,000 $3,025,000
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities $ 300,000 $ 375,000
4. Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7 20X6
Land $ 3,000,000 $ 3,000,000
Land improvements 472,000 472,000
Buildings and improvements 46,852,000 46,636,000
Equipment 29,190,000 26,260,000
Equipment under capital lease obligations 2,851,000
82,365,000
2,752,000
79,120,000
Less accumulated depreciation and amortization 34,928,000
47,437,000
30,661,000
48,459,000
Construction in progress 3,601,000 2,033,000
Property and equipment, net $51,038,000 $50,492,000
Depreciation expense for the years ended December 31, 20X7 and 20X6 amounted to approxi­
mately $4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease 
obligations was $689,000 and $453,000 at December 31, 20X7 and 20X6, respectively. Construction 
contracts of approximately $7,885,000 exist for the remodeling of Hospital facilities. At December 
31, 20X7, the remaining commitment on these contracts approximated $4,625,000.
5. Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 20X7 and 20X6, 
follows:
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20X7 20X6
7.25 percent 20X7 Tax-Exempt Revenue Bonds, principal mat­
uring in varying annual amounts, due November 1, 20XX, 
collateralized by a pledge of the Hospital's gross receipts $21,479,000
8.50 percent 20X2 Tax-Exempt Revenue Bonds, principal 
maturing in varying annual amounts, due June 1, 20XX $22,016,000
7.75 percent mortgage loan, principal maturing in varying 
annual amounts, due January 20XX, collateralized by a 
mortgage on certain property and equipment 2,010,000 2,127,000
7.75 percent note payable, payable in monthly installments 
of $12,000, including interest, due March 20XX, unsecured 125,000 671,000
Capital lease obligations, at varying rates of imputed interest from
6.8 percent to 9.3 percent collateralized by leased equipment 1,000,000 950,000
24,614,000 25,764,000
Less current portion 1,470,000 1,750,000
$23,144,000 $24,014,000
Under the terms of the 20X7 and 20X2 revenue bond indentures, the Hospital is required to 
maintain certain deposits with a trustee. Such deposits are included with assets limited as to use. 
The revenue note indenture also places limits on the incurrence of additional borrowings and 
requires that the Hospital satisfy certain measures of financial performance as long as the notes 
are outstanding.
Scheduled principal repayments on long-term debt and payments on capital lease obligations 
are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter
Less amount representing interest under 
capital leases obligations
Long-Term 
Debt
$ 970,000
912,000 
983,000 
1,060,000 
1,143,000 
18,546,000 
$23,614,000
Capital Leases 
Obligations
$ 550,000
260,000
260,000
45,000
1,115,000
115,000 
$1,000,000
A summary of interest cost and investment income on borrowed funds held by the trustee under 
the 20X7 and 20X2 revenue bond indentures during the years ended December 31, 20X7 and 20X6, 
follows:
Interest cost:
Capitalized
Charged to operations 
Total
Investment income:
Capitalized
Credited to other revenue
Total
20X7 20X6
$ 740,000 $ 700,000
1,752,000 1,825,000
$2,492,000 $2,525,000
$ 505,000 $ 663,000
330,000 386,000
$ 835,000 $1,049,000
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6. Temporarily and Permanently Restricted Net Assets
Temporarily restricted net assets are available for the following purposes or periods at Decem­
ber 31, 20X7 and 20X6:
20X7 20X6
Health care services
Purchase of equipment $ 320,000 $ 520,000
Indigent care 840,000 950,000
Health education 350,000 400,000
For periods after December 31, 20X9 605,000 600,000
$2,115,000 $2,470,000
Permanently restricted net assets at December 31, 20X7 and 20X6, are restricted to:
20X7 20X6
Investments to be held in perpetuity, the income 
from which is expendable to support health care 
services (reported as operating income) $2,973,000 $2,923,000
Endowment requiring income to be added to 
original gift until fund value is $1,500,000 615,000 610,000
$3,588,000 $3,533,000
During 20X7, net assets were released from donor restrictions by incurring expenses satisfying 
the restricted purposes of indigent care and health care education in the amounts of $250,000 and 
$50,000, respectively.
7. Medical Malpractice Claims
The Hospital purchases professional and general liability insurance to cover medical malprac­
tice claims. There are known claims and incidents that may result in the assertion of additional 
claims, as well as claims from unknown incidents that may be asserted arising from services 
provided to patients. The Hospital has employed independent actuaries to estimate the ultimate 
costs, if any, of the settlement of such claims. Accrued malpractice losses have been discounted 
at 7 percent and in management's opinion provide an adequate reserve for loss contingencies.
On March 15, 20X7, a patient filed a suit against the Hospital for malpractice during care received 
as an inpatient. The Hospital believes it has meritorious defenses against the suit; however, the 
ultimate resolution of the matter could result in a loss. The patient has claimed $16 million in 
actual damages. Under state law, punitive damages are determined at trial. The Hospital main­
tains insurance coverage for malpractice claims. The coverage does not include punitive damages 
awards. Trial is scheduled to occur within the next year.
8. Pension and Other Postretirement Benefit Plans2, 2 †
2 The disclosures for pensions and other postretirement benefits in this note to the illustrative financial statements have been modified to 
reflect the requirements of SFAS 132, Employers' Disclosures about Pensions and Other Postretirement Benefits (revised 2003). SFAS 132 (revised 
2003) is effective for fiscal years ending after December 15, 2003, with certain exceptions. Interim-period disclosures are effective for interim 
periods beginning after December 15, 2003. The provisions of SFAS 132 remain in effect until the provisions of SFAS 132 (revised 2003) are 
adopted. This note to the financial statements illustrates the financial statement disclosures about pension and postretirement benefit plans 
for a public entity. Readers should refer to SFAS 132 (revised 2003) when considering disclosure requirements for nonpublic entities.
† Readers may also need to consider the accounting and disclosure requirements of FASB Staff Position (FSP) 106-1, Accounting and Disclosure 
Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, and 106-2, Accounting and Disclosure Requirements 
Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, when an employer provides postretirement prescription drug 
coverage. FSP 106-2, which supersedes FSP 106-1, is effective, with exception for certain nonpublic entities, for the first interim or annual period 
beginning after June 15, 2004. For a nonpublic entity, as defined in SFAS 87, Employers' Accounting for Pensions, that sponsors one or more defined 
benefit postretirement health care plans that provide prescription drug coverage but of which no plan has more than 100 participants, FSP 106-2 
is effective for fiscal years beginning after December 15, 2004. Earlier application is encouraged.
Note: The following two paragraphs are encouraged but not required.
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The Hospital has a defined benefit pension plan covering substantially all of its employees. The 
plan benefits are based on years of service and the employees' compensation during the last five 
years of covered employment. Contributions are intended to provide not only for benefits 
attributed to service to date but also for those expected to be earned in the future.
The Hospital also sponsors two defined benefit postretirement plans that cover both salaried 
and nonsalaried employees. One plan provides medical and dental benefits, and the other 
provides for the payment of life insurance premiums. The postretirement health care plan is 
contributory, with retiree contributions adjusted annually; the life insurance plan is noncontribu­
tory. The accounting for the health care plan anticipates future cost-sharing changes to the written 
plan that are consistent with the Hospital's expressed intent to increase retiree contributions each 
year to 50 percent of the excess of the expected general inflation rate over 6 percent. Beginning in 
20X7, the Hospital adopted a funding policy for its postretirement health care plan similar to its 
funding policy for its life insurance plan—an amount equal to a level percentage of the employees' 
salaries is contributed to the plan annually. For 20X7, that percentage was 4.25, and the aggregate 
contribution for both plans was $34,000.
The Hospital uses a December 31 measurement date for its plans.
The following table sets forth the changes in benefit obligations, changes in plan assets and 
components of net periodic benefit cost for both the pension plan and the other postretirement 
benefit plans:
Pension Benefits Other Benefits
20X7 20X6 20X7 20X6
Change in benefit obligation:
Benefit obligation at beginning of year $ 9,710 $ 9,700 $585 $500
Service cost 905 770 14 15
Interest cost 700 650 50 44
Plan participants' contributions 
Actuarial gain
Benefits paid
(20) 
(375) (1,410)
34
(7) 
(66)
34
(8)
Benefit obligation at end of year 10,920 9,710 610 585
Change in plan assets:
Fair value of plan assets at beginning of year 9,800 9,610 89 40
Actual return on plan assets 759 810 4 4
Employer contribution 866 790 39 19
Plan participants' contributions 
Benefits paid (375) (1,410)
34 
(66)
34
(8)
Fair value of plan assets at end of year 11,050 9,800 100 89
Funded status 130 90 (510) (496)
Unrecognized net actuarial gain (30) (40) (30) (40)
Unrecognized prior service cost 50 55 16 19
Unrecognized transition obligation
Unrecognized transition asset
Prepaid (accrued) benefit cost
(15)
$ 135
(20)
$ 85
445
$ (79)
470
$ (47)
The accumulated benefit obligation for the defined benefit pension plan was $XXX and $XXX at 
December 31, 20X7, and 20X6, respectively.
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Pension Benefits Other Benefits
20X7 20X6 20X7 20X6
Components of net periodic benefit cost:
Service cost $905 $770 $14 $15
Interest cost 700 650 50 44
Expected return on plan assets (784) (769) (6) (3)
Amortization of prior service cost 5 7 3 2
Recognized net actuarial gain (5) (2) (15) (1)
Amortization of transition obligation 25 25
Amortization of transition asset (5) (1)
Net periodic benefit cost $816 $655 $71 $82
Additional Information
Assumptions
Pension Benefits Other Benefits
20X7 20X6 20X7 20X6
Weighted-average assumptions used to determine
benefit obligations at December 31:
Discount rate 7.00% 7.00% 7.00% 7.00%
Rate of compensation increase 6.00% 6.00%
Pension Benefits
20X7 20X6
Other Benefits
20X7 20X6
Weighted-average assumptions used to determine net 
periodic benefit cost for years ended December 31: 
Discount rate
Expected long-term return on plan assets
Rate of compensation increase 
7.00% 7.00%
8.00% 8.00%
6.00% 6.00%
7.00% 7.00%
6.60% 6.60%
(Entity specific narrative description of the basis used to determine the overall expected long-term 
rate of return on assets, as described in paragraph 5(d)(3) of SFAS 132, Employers' Disclosures About 
Pensions and Other Postretirement Benefits (revised 2003) would be included here.)
20X7 20X6
Assumed health care cost trend rates at December 31:
Health care cost trend rate assumed for next year 7% 7%
Rate to which the cost trend rate is assumed to decline
(the ultimate trend rate) 5% 5%
Year that the rate reaches the ultimate trend rate 20Y2 20Y2
Assumed health care cost trend rates have a significant effect on the amounts reported for the 
health care plans. A one-percentage-point change in assumed health care cost trend rates would 
have the following effects:
Effect on total of service and interest cost
Effect on postretirement benefit obligation
1-Percentage- 
Point Increase
$13
73
1-Percentage- 
Point Decrease
$(11) 
(67)
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Plan Assets
The composition of plan assets at December 31, 20X7, and 20X6, is as follows:
Pension Benefits Other Benefits
20X7 20X6 20X7 20X6
Asset Category
Equity securities XX% XX% XX% XX%
Debt securities XX XX XX XX
Real estate XX XX XX XX
Other XX XX XX XX
Total 100% 100% 100% 100%
(Entity specific narrative description of investment policies and strategies for plan assets, includ­
ing weighted-average target asset allocations [if used as part of those policies and strategies] as 
described in paragraph 5(d)(2) of SFAS 132 (revised 2003) would be included here.)
Cash Flows
Contributions
The Hospital expects to contribute $XXX to its pension plan and $XXX to its other postretirement 
benefit plan in 20X8.
Estimated Future Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are ex­
pected to be paid:
Pension
Benefits
Other
Benefits
20X8 $XXX $XXX
20X9 XXX XXX
20Y0 XXX XXX
20Y1 XXX XXX
20Y2 XXX XXX
Years 20Y3-20Y7 XXX XXX
9. Concentrations of Credit Risk
The Hospital grants credit without collateral to its patients, most of whom are local residents 
and are insured under third-party payor agreements. The mix of receivables from patients and 
third-party payors at December 31, 20X7 and 20X6, was as follows:
20X7 20X6
Medicare 51% 53%
Medicaid 17 14
Blue Cross 18 17
Other third-party payors 7 9
Patients 7 7
100% 100%
10. Commitments and Contingencies
Operating leases. The Hospital leases various equipment and facilities under operating leases 
expiring at various dates through April 20Y2. Total rental expense in 20X7 and 20X6 for all 
operating leases was approximately $859,000 and $770,000, respectively.
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The following is a schedule by year of future minimum lease payments under operating leases 
as of December 31, 20X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31, Amount
20X8
20X9
20Y0
20Y1
20Y2
$517,000
506,000
459,000
375,000
343,000
Litigation. The Hospital is involved in litigation and regulatory investigations arising in the 
course of business. After consultation with legal counsel, management estimates that these 
matters will be resolved without material adverse effect on the Hospital's future financial position 
or results from operations.
Allowance for doubtful accounts. Beginning in 20X5, the Hospital has provided care under an 
agreement with Associated HMO. The HMO currently owes the Hospital $950,000, substantially 
all of which is overdue. The Hospital has notified the HMO that further services under the contract 
cannot be provided without payment on the outstanding balance. The HMO has assured the 
Hospital that additional funds are being obtained in order to pay the overdue balance and 
continue service under the agreement, however, if the HMO is unable to make payments, 
additional allowances for bad debts would need to be accrued.
11. Related Party Transactions
During the years ended December 31, 20X7 and 20X6, the Hospital contributed capital to Sample 
Health System, an affiliate with some board members in common with the Hospital, in the 
amounts of $688,000 and $3,051,000, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health 
System, was established to solicit contributions from the general public solely for the funding of 
capital acquisitions by the Hospital. Funds are distributed to the Hospital as determined by the 
Foundation's Board of Directors. A summary of the foundation's assets, liabilities, net assets, 
results of operations, and changes in net assets follows. The Hospital's interest in the net assets 
of the Foundation is reported as a non-current asset in the balance sheets.
December 31,
20X6 20X7
Assets, principally cash and cash equivalents $521,000 $472,000
Liabilities 11,000 10,000
Unrestricted net assets 510,000 462,000
Total liabilities and net assets $521,000 $472,000
Support and revenue $269,000 $535,000
Expenses
Distributions to Sample Hospital for property acquisitions 235,000 485,000
Other 13,000 16,000
Total expenses 248,000 501,000
Excess of support and revenue over expenses 21,000 34,000
Other changes in net assets 27,000 17,000
Unrestricted net assets, beginning of year 462,000 411,000
Unrestricted net assets, end of year $510,000 $462,000
Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts 
were paid after the end of each year.
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12. Functional Expenses
The Hospital provides general health care services to residents within its geographic location. 
Expenses related to providing these services are as follows (in thousands):
December 31,
20X7 20X6
Health care services $86,000 $78,647
General and administrative 12,055
$98,055
10,643
$89,290
13. Fair Value of Financial Instruments
The following methods and assumptions were used by the Hospital in estimating the fair value 
of its financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash 
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on 
quoted market prices, if available, or estimated using quoted market prices for similar securities.
Assets limited as to use: These assets consist primarily of cash and short-term investments and 
interest receivable. The carrying amount reported in the balance sheet is fair value.
Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for 
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for 
estimated third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the Hospital's revenue notes are based on current traded value. 
The fair value of the Hospital's remaining long-term debt is estimated using discounted cash 
flow analyses, based on the Hospital's current incremental borrowing rates for similar types 
of borrowing arrangements.
The carrying amounts and fair values of the Hospital's financial instruments at December 31, 20X7 
and 20X6, are as follows (In thousands):
20X7 20X6
Carrying 
Amount Fair Value
Carrying 
Amount Fair Value
Cash and cash equivalents $ 4,758 $ 4,758 $ 5,877 $ 5,877
Short-term investments 15,836 15,836 10,740 10,740
Assets limited as to use 18,949 18,949 19,841 19,841
Long-term investments 4,680 4,680 4,680 4,680
Long-term investments restricted 
for capital acquisition 320 320 520 520
Accounts payable and 
accrued expenses 5,818 5,818 5,382 5,382
Estimated third-party 
payor settlements 2,143 2,143 1,942 1,942
Long-term debt 24,614 23,980 25,764 24,918
14. Promises to Contribute
At December 31, 20X7, the Hospital had received $1,500,000 of conditional promises to contrib­
ute to the building of a new facility for outpatient services. These contributions will be recorded 
as temporarily restricted support when received. The Hospital had no material outstanding 
unconditional promises of support at December 31, 20X7.
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15. Charity Care
The amount of charges foregone for services and supplies furnished under the Hospital's charity 
care policy aggregated approximately $4,500,000 and $4,100,000 in 20X7 and 20X6, respectively.
16. Subsequent Event
On February 9, 20X8, the Hospital signed a contract in the amount of $1,050,000 for the purchase 
of certain real estate.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
.08
Sample For-Profit Nursing Home, Inc.
Balance Sheets
December 31, 20X5 and 20X4
20X5 20X4
Assets
Current assets:
Cash and cash equivalents $ 95,000 $ 129,000
Investments 150,000
Assets limited as to use 50,000 50,000
Patient accounts receivable, net of allowance 
for doubtful accounts of $6,700 in 20X5 and
$5,300 in 20X4 162,000 152,000
Estimated third-party payor settlements 71,000 62,000
Interest receivable 7,000
Supplies 47,000 43,000
Prepaid expenses 3,000 2,000
Deferred tax asset 12,000 14,000
Total current assets 597,000 452,000
Assets limited as to use, net of amount required
for current liabilities 173,000 150,000
Property and equipment:
Land 205,000 205,000
Land improvements 37,000 32,000
Buildings 1,399,000 1,399,000
Furniture, fixtures, and equipment 228,000 189,000
1,869,000 1,825,000
Less accumulated depreciation 210,000 141,000
Property and equipment, net 1,659,000 1,684,000
Other assets 150,000 127,000
Total assets $2,579,000 $2,413,000
Liabilities and Shareholders' Equity
Current liabilities:
Current maturities of long-term debt $ 50,000 $ 50,000
Accounts payable 78,000 52,000
Accrued expenses 175,000 188,000
Deposits from patients 50,000 45,000
Other current liabilities 74,000 15,000
Total current liabilities 427,000 350,000
Deferred tax liability 6,000 14,000
Long-term debt, net of current maturities 1,700,000 1,750,000
Shareholders' equity:
Common stock, $20 par value; authorized 
5,000 shares; issued and outstanding
3,500 shares 70,000 70,000
Retained earnings 376,000 229,000
Total shareholders' equity 446,000 299,000
Total liabilities and shareholders' equity $2,579,000 $2,413,000
See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc. 
Statements of Income and Retained Earnings 
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Revenue:
Net patient service revenue $2,163,000 $1,949,000
Other revenue 67,000 22,000
Interest on investments held by trustee 13,000 7,000
Total revenue 2,243,000 1,978,000
Expenses:
Salaries and benefits 969,000 919,000
Medical supplies and drugs 511,000 499,000
Insurance and other 216,000 176,000
Provision for bad debts 92,000 83,000
Depreciation 69,000 57,000
Interest 164,000 172,000
Total expenses 2,021,000 1,906,000
Operating income 222,000 72,000
Nonoperating income:
Other interest income 5,000
Income before provision for income taxes 227,000 72,000
Provision for income taxes 80,000 29,000
Net income 147,000 43,000
Retained earnings, beginning of year 229,000 186,000
Retained earnings, end of year $ 376,000 $ 229,000
See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc. 
Statements of Cash Flows
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Cash flows from operating activities:
Cash received from residents and third-party payors $2,019,000 $1,796,000
Cash received from others 67,000 22,000
Cash paid to employees and suppliers (1,679,000) (1,495,000)
Interest and dividends received 10,000 10,000
Interest paid (160,000) (170,000)
Taxes paid (29,000) (30,000)
Deposits received from patients 35,000 15,000
Deposits refunded to patients (30,000) (20,000)
Net cash provided by operating activities 233,000 128,000
Cash flows from investing activities: 
Purchase of investments (150,000)
Proceeds from sale of property 2,000
Capital expenditures (44,000) (79,000)
Purchase of assets limited as to use (23,000)
Net cash used in investing activities (217,000) (77,000)
Cash flows from financing activities: 
Repayment of long-term debt (50,000) (50,000)
Net cash used in financing activities (50,000) (50,000)
Net increase (decrease) in cash and cash equivalents (34,000) 1,000
Cash and cash equivalents, beginning of year 129,000 128,000
Cash and cash equivalents, end of year $ 95,000 $ 129,000
Reconciliation of net income to net cash 
provided by operating activities:
Net income $ 147,000 $ 43,000
Adjustments to reconcile net income to net cash 
provided by operating activities:
Depreciation 69,000 57,000
Provision for bad debts 92,000 83,000
Loss on sale of property — 11,000
Change in deferred income taxes (6,000) (14,000)
(Increase) decrease in:
Patient accounts receivable (102,000) (41,000)
Other current assets (21,000) (15,000)
Estimated third-party payor settlements (9,000) (10,000)
Interest receivable (7,000) (3,000)
Other assets (7,000) (10,000)
Increase (decrease) in:
Accounts payable and accrued expenses 13,000 43,000
Deposits from patients 5,000 (5,000)
Other current liabilities 59,000 (11,000)
Net cash provided by operating activities $ 233,000 $ 128,000
See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc.
Notes to Financial Statements
December 31, 20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies3
3 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State 
in 20X1 and operates a 128-bed nursing home in Abacus, New State. A summary of the Company's 
significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less, excluding amounts whose use is 
limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified 
as held-to-maturity because the Company has the positive intent and ability to hold the securities 
until maturity. Held-to-maturity securities are carried at cost adjusted for amortization of premi­
ums and accretion of discounts.
Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and 
assets set aside by the Board of Directors for capital improvements are classified as assets limited 
as to use. Amounts required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated 
on the straight-line method over the estimated useful Eves of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 20X1 bonds are being amortized based 
on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable 
amounts from residents, third-party payors, and others for service rendered.
Revenue under third-party payor agreements is subject to audit and retroactive adjustment. 
Provisions for estimated third-party payor settlements are provided in the period the related 
services are rendered. Differences between the estimated amounts accrued and interim and final 
settlements are reported in operations in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently 
payable and those deferred because of temporary differences between the financial statement and tax 
bases of assets and liabilities. These differences consist principally of bad debts and depreciation.
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2. Assets Limited as to Use
Assets limited as to use include:
Assets held by trustee under the Series 20X1 note indenture agreement 
at December 31, 20X5 and 20X4.
20X5 20X4
U.S. Government obligations $150,000 $130,000
Cash 24,000 21,000
Accrued interest income 2,000 2,000
Internally designated by the Board of 
Directors for capital improvements
176,000 153,000
Certificate of deposit $ 45,000 $ 45,000
Accrued interest 2,000 2,000
47,000 47,000
$223,000 $200,000
3. Investments‡
4. Long-Term Debt
Long-term debt at December 31, 20X5 and 20X4, was as follows:
20X5 20X4
9.5 percent bonds payable to the City 
of Abacus, maturing $50,000 annually 
through November 1, 20YY, with a 
final maturity of $1 million on 
November 1, 20YY
Less current maturities
$1,750,000
50,000
$1,700,000
$1,800,000
50,000
$1,750,000
The notes are collateralized by a first-mortgage lien on all property and equipment of the 
Company and a security interest in all of its receipts. The note indenture requires the maintenance 
of certain deposits with a trustee, which are included in assets limited as to use.
Future maturities of long-term debt as of December 31, 20X5, follow:
Year ending December 31, Amount
20X6
20X7
20X8
20X9
20Y0
Thereafter
Total
$ 50,000
50,000
50,000
50,000
50,000
1,500,000
$1,750,000
FSP §11,500.11
* In reporting disclosures about investments in securities, entities should comply primarily with the requirements of paragraphs 6, 
17, 19, 20, 21, and 22 of SFAS 115, as amended. Other disclosure requirements may also be applicable.
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5. Income Taxes
The provisions for income taxes are as follows:
20X5 20X4
Current:
Federal $72,000 $15,000
State 2,000 _______
Total current 74,000 15,000
Deferred:
Federal 6,000 13,000
State _______ 1,000
Total deferred 6,000 14,000
Total provision for income taxes $80,000 $29,000
Deferred income taxes are provided for the temporary differences between the financial report­
ing basis and the tax basis of the Company's assets and liabilities.
For the years ended December 31, 20X5 and 20X4, the effective tax rate approximated the 
statutory rate of 34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance
sheet at December 31, 20X5 and 20X4, follows:
20X5 20X4
Net current assets $12,000 $14,000
Net noncurrent liabilities 6,000 14,000
$ 6,000 $____ 0
Management has determined that no valuation allowance related to deferred tax assets is 
necessary at December 31, 20X5 and 20X4, respectively.
6. Concentration in State Medicaid Program
The Company has 100 of its 128 beds designated for care of patients under the state's Medicaid 
program. The current funding of that program is 90 days behind filed claims. The current state budget 
has no provision for reducing that lag and, while the proposed budget for 20X6 includes additional 
funding, there is no assurance that the final budget will include the needed additional funds.
7. Third Party Rate Adjustments and Revenue
Revenue from the Medicaid program accounted for approximately XX percent for the year ended 
20X5, and XX percent for the year ended 20X4, of the Company's net patient revenue. Laws and 
regulations governing the Medicaid program are extremely complex and subject to interpretation. As 
a result, there is at least a reasonable possibility that recorded estimates will change by a material 
amount in the near term. The 20X5 net patient service revenue increased approximately $XXX due to 
removal of allowances previously estimated that are no longer necessary as a result of final settlements 
and years that are no longer subject to audits, reviews, and investigations. The 20X4 net patient service 
revenue decreased approximately $XXX due to prior-year retroactive adjustments in excess of 
amounts previously estimated.
8. Risks and Uncertainties Disclosures||
9. Pension Plan||
10. Postretirement Benefits||
11. Fair Values of Financial Instruments||
12. Concentrations of Credit Risk||
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|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS 
FOR A CONTINUING CARE RETIREMENT COMMUNITY 
.12
Sample Not-for-Profit Continuing Care Retirement Community
Balance Sheets
December 31, 20X5 and 20X4
20X5 20X4
Assets
Current assets:
Cash $ 375,000 $ 330,000
Assets limited as to use 265,000 170,000
Accounts receivable, net of allowance for 
doubtful accounts of $4,000 in 20X5 and
$5,000 in 20X4 187,000 197,000
Supplies 40,000 21,000
Prepaid expenses 115,000 73,000
Total current assets 982,000 791,000
Assets limited as to use, net of amount required
for current liabilities 1,865,000 1,583,000
Property and equipment, net 14,893,000 15,280,000
Deferred financing costs, net of accumulated 
amortization of $28,000 in 20X5 and
$21,000 in 20X4 83,000 90,000
Total assets $17,823,000 $17,744,000
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt $ 90,000 $ 77,000
Accounts payable 180,000 174,000
Accrued expenses 161,000 178,000
Deposits on unoccupied units 22,000 40,000
Total current liabilities 453,000 469,000
Long-term debt, less current maturities 8,871,000 8,935,000
Refundable fees 59,000 144,000
Estimated obligation to provide future 
services, in excess of amounts received
or to be received 88,000 100,000
Deferred revenue from advance fees 6,304,000 6,585,000
Total liabilities 15,775,000 16,233,000
Net assets:
Unrestricted 1,286,000 833,000
Temporarily restricted 311,000 294,000
Permanently restricted 451,000 384,000
Total net assets 2,048,000 1,511,000
Total liabilities and net assets $17,823,000 $17,744,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Operations
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Revenue, gains, and other support:
Resident services, including amortization 
of advance fees of $935,000 in 20X5 
and $915,000 in 20X4 $3,946,000 $3,152,000
Patient revenue from nonresidents 249,000 275,000
Change in obligation to provide future services 12,000 (82,000)
Contributions 54,000 39,000
Net assets released from restrictions used for 
operations 24,000 50,000
Investment income 29,000 30,000
Other 75,000 68,000
Total revenue, gains, and other support 4,389,000 3,532,000
Expenses:
Salaries and benefits 1,708,000 1,250,000
Medical supplies and drugs 543,000 742,000
Insurance 291,000 311,000
Depreciation 452,000 447,000
Interest 967,000 955,000
Total expenses 3,961,000 3,705,000
Operating income (loss) 428,000 (173,000)
Net assets released from restriction— 
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets $ 453,000 $ (128,000)
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Changes in Net Assets
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Unrestricted net assets:
Operating income (loss) $ 428,000 $ (173,000)
Net assets released from restriction—
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets 453,000 (128,000)
Temporarily restricted net assets:
Contributions 40,000 15,000
Net assets released from restrictions used
for operations (24,000) (50,000)
Net assets released from restriction—
purchase of equipment (25,000) (45,000)
Investment income 26,000 15,000
Increase (decrease) in temporarily restricted
net assets 17,000 (65,000)
Permanently restricted net assets:
Contributions 67,000 52,000
Increase in permanently restricted net assets 67,000 52,000
Increase (decrease) in net assets 537,000 (141,000)
Net assets, beginning of year 1,511,000 1,652,000
Net assets, end of year $2,048,000 $1,511,000
See accompanying notes to financial statements.
FSP §11,500.14
Illustrative Financial Statements 153
.15
Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Cash Flows
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Cash flows from operating activities: 
Cash received from residents and 
third-party payors $3,252,000 $2,341,000
Advance fees received 654,000 857,000
Other receipts from operations 75,000 68,000
Investment income received 68,000 53,000
Contributions received 51,000 44,000
Cash paid to employees and suppliers (2,576,000) (2,040,000)
Interest paid (950,000) (945,000)
Net cash provided by operating activities 574,000 378,000
Cash flows from investing activities:
Purchase of property and equipment (65,000) (250,000)
Purchase of assets limited as to use (377,000) 229,000
Net cash used in investing activities (442,000) (21,000)
Cash flows from financing activities: 
Permanently restricted funds received 67,000 52,000
Refunds of deposits and refundable fees (103,000) (52,000)
Proceeds from issuance of long-term debt 26,000
Principal payments of long-term debt (77,000) (307,000)
Net cash used in financing activities (87,000) (307,000)
Net increase in cash 45,000 50,000
Cash, beginning of year 330,000 280,000
Cash, end of year $ 375,000 $ 330,000
Reconciliation of change in net assets to 
net cash provided by operating activities:
Change in net assets $ 537,000 $ (141,000)
Adjustments to reconcile change in net assets 
to net cash provided by operating activities: 
Advance fees received 654,000 857,000
Restricted net assets received (67,000) (52,000)
Amortization of advance fees (935,000) (915,000)
Loss (gain) on obligation to provide 
future services (12,000) 82,000
Depreciation 452,000 447,000
Amortization of deferred financing costs 7,000 34,000
Provision for bad debts 3,000 3,000
(Increase) decrease in: 
Accounts receivable 7,000 (33,000)
Other assets (61,000) (4,000)
Increase (decrease) in:
Accounts payable and accrued expenses (11,000) 100,000
Net cash provided by operating 
activities $ 574,000 $ 378,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Notes to Financial Statements4
4 SOP 00-1 provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample 
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding 
third-party payments. SOP 00-1 is included in Appendix E to the Guide.
# Does not include all disclosures common to all health care entities.
5 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
December 31, 20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies#,5
Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit 
organization that principally provides housing, health care, and other related services to residents 
through the operation of a retirement facility containing 249 apartments and a 78-bed health care 
facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 20X1. A 
summary of significant accounting policies follows.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, 
interest, and dividends) is included in operating income (loss) unless restricted by donor or law. 
Unrealized gains and losses on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest 
method over the term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the portion 
thereof that is refundable to the resident, are recorded as deferred revenue and are amortized to 
income using the straight-line method over the estimated remaining life expectancy of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net cost 
of future services and the use of facilities to be provided to current residents and compares that amount 
with the balance of deferred revenue from advance fees. If the present value of the net cost of future 
services and the use of facilities exceeds the deferred revenue from advance fees, a liability is recorded 
(obligation to provide future services and use of facilities) with the corresponding charge to income. 
The obligation is discounted at 9 percent, based on the expected long-term rate of return on 
government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor 
restriction expires (that is, when a stipulated time restriction ends or a purpose restriction is 
accomplished), temporarily restricted net assets are reclassified as unrestricted net assets and 
reported in the statement of operations as net assets released from restrictions. Donor-restricted 
contributions whose restrictions are met within the same year as received are reflected as 
unrestricted contributions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted 
support unless explicit donor stipulations specify how the donated assets must be used. Gifts of 
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long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of 
cash or other assets that must be used to acquire long-lived assets are reported as restricted support. 
Absent explicit donor stipulations about how long those long-lived assets must be maintained, the 
CCRC reports expirations of donor restrictions when the donated or acquired long-lived assets are 
placed in service.
Income taxes. The CCRC has been recognized by the Internal Revenue Service as a not-for-profit 
corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from 
federal income taxes pursuant to Sec. 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is re­
corded at its estimated fair value at the date of receipt. Depreciation is computed on the 
straight-line method based on the following estimated useful lives:
Land improvements
Buildings and improvements
Furniture and equipment
20 years
40 years
5-15 years
Operating income (loss). The statement of operations includes operating income (loss). Changes in 
unrestricted net assets which are excluded from operating income (loss), consistent with industry 
practice, include unrealized gains and losses on investments other than trading securities, 
permanent transfers of assets to and from affiliates for other than goods and services, and 
contributions of long-lived assets (including assets acquired using contributions which by donor 
restriction were to be used for the purposes of acquiring such assets).
2. Property and Equipment
A summary of property and equipment at December 31, 20X5 and 20X4, follows:
20X5 20X4
Land $ 557,000 $ 557,000
Land improvements 205,000 203,000
Buildings and improvements 14,573,000 14,564,000
Furniture and equipment 752,000
16,087,000
698,000
16,022,000
Less: accumulated depreciation (1,194,000)
$14,893,000
(742,000)
$15,280,000
3. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
Purchase of equipment 
Charity care
20X5
$169,000
142,000
$311,000
20X4
$152,000
142,000
$294,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted 
purposes or by occurrence of other events specified by donors:
20X5
$24,000
$25,000
20X4
$50,000
$45,000
Charity care
Purchase of equipment
4. Permanently Restricted Net Assets
Permanently restricted net assets are restricted to investment in perpetuity, the income from 
which is expendable to support:
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20X5 20X4
Charity care
Community activities
$168,000 
283,000
$451,000
$168,000
216,000
$384,000
Long-Term Debt
Long-term debt at December 31, 20X5 and 20X4, is as follows:
20X5 20X4
10.75 percent mortgage note payable 
Notes payable to bank—unsecured 
Other
$8,901,000 
34,000 
26,000
$8,965,000 
14,000 
33,000
Less current maturities
8,961,000
90,000
9,012,000
77,000
$8,871,000 $8,935,000
The mortgage note is payable in consecutive monthly installments of principal and interest of 
$85,425 to May 20XX. The note is collateralized by a first mortgage on property and equipment 
with a depreciated cost at December 31, 20X5, of $14,893,000 and by a pledge of all operating 
revenue.
As required by the mortgage note agreement, the CCRC established an initial debt service 
reserve fund of $1,000,000 at April 15, 20X3. All resident fees received thereafter, net of resident 
fee refunds and debt service payments not to exceed $300,000 annually in the first four years and 
$200,000 annually thereafter, are to be added to the debt service reserve fund until the total sum 
of $2,050,000 is accumulated. Since June 1, 20X4, the CCRC has been required to deliver to the 
trustee $5,500 per month to establish maintenance reserves until the aggregate of such payments 
equals a residential unit reserve and a health care center reserve of $240,000 and $90,000, 
respectively. At December 31, 20X5 and 20X4, the trustee held investments aggregating $2,130,000 
and $1,753,000, respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows: 
Year ending December 31, Amount
20X6 $ 90,000
20X7 90,000
20X8 95,000
20X9 105,000
20Y0 105,000
6. Classification of Expenses
20X5 20X4
Program activities 3,368,000 3,135,000
General and administrative 593,000 570,000
$3,961,000 $3,705,000
7. Assets Limited as to Use||
8. Risks and Uncertainties Disclosures||
9. Pension and Other Postretirement Benefit Plans||
10. Fair Values of Financial Instruments||
11. Concentrations of Credit Risk||
12. Investments||
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
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Sample Not-for-Profit Home Health Agency 
Balance Sheets
December 31, 20X5 and 20X4
20X5 20X4
Assets
Current assets:
Cash and cash equivalents $ 74,000 $ 41,000
Investments 147,000 137,000
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 20X5 and $30,000 in 20X4 752,000 476,000
Other receivables 27,000 22,000
Total current assets 1,000,000 676,000
Investments 100,000 100,000
Equipment:
Medical and office equipment 56,000 39,000
Vehicles 50,000 37,000
Less accumulated depreciation
106,000
(45,000)
76,000
(24,000)
Equipment, net 61,000 52,000
Deferred finance charges, net of accumulated amort­
ization of $15,000 in 20X5 and $10,000 in 20X4 20,000 25,000
Total assets $1,181,000 $853,000
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt $ 13,000 $ 13,000
Accounts payable 40,000 21,000
Accrued payroll and vacation costs 496,000 352,000
Estimated third-party payor settlements 28,000 31,000
Advances from third-party payors 70,000 66,000
Total current liabilities 647,000 483,000
Long-term debt, less current maturities 105,000 118,000
Total liabilities 752,000 601,000
Net assets:
Unrestricted 330,000 167,000
Temporarily restricted 9,000 5,000
Permanently restricted 90,000 80,000
Total net assets 429,000 252,000
Total liabilities and net assets $1,181,000 $853,000
See accompanying notes to financial statements.
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FORMAT A 
Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Revenue, gains, and other support: 
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Investment income 13,000 6,000
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,092,000 2,747,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Excess of revenue over expenses and 
change in unrestricted net assets $ 163,000 $ 99,000
See accompanying notes to financial statements.
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FORMAT B
Sample Not-for-Profit Home Health Agency 
Statements of Operations 
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,079,000 2,741,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Operating income 150,000 93,000
Other income:
Investment income 13,000 6,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency 
Statements of Changes in Net Assets 
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Unrestricted net assets:
Excess of revenue over expenses $163,000 $ 99,000
Increase in unrestricted net assets 163,000 99,000
Temporarily restricted net assets:
Contributions 9,000 5,000
Net assets released from restrictions (5,000) —
Increase in temporarily restricted net assets 4,000 5,000
Permanently restricted net assets:
Contributions 10,000 6,000
Increase in permanently restricted net assets 10,000 6,000
Increase in net assets 177,000 110,000
Net assets, beginning of year 252,000 142,000
Net assets, end of year $429,000 $252,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency 
Statements of Cash Flows
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Cash flows from operating activities: 
Cash received from patients and 
third-party payors $3,721,000 $2,542,000
Other receipts from operations 22,000 32,000
Cash paid to employees and suppliers (3,679,000) (2,541,000)
Interest paid (11,000) (14,000)
Nonoperating revenue 23,000 22,000
Net cash provided by operating activities 76,000 41,000
Cash flows from investing activities: 
Purchase of equipment (30,000) (19,000)
Purchase of investments (10,000) (15,000)
Net cash used in investing activities (40,000) (34,000)
Cash flows from financing activities: 
Proceeds from contributions restricted for: 
Endowment 10,000 6,000
Other financing activities:
Payment of long-term debt (13,000) __
Net cash provided by (used in) financing activities (3,000) 6,000
Net increase in cash and cash equivalents 33,000 13,000
Cash and cash equivalents, beginning of year 41,000 28,000
Cash and cash equivalents, end of year $ 74,000 $ 41,000
Reconciliation of change in net assets to net 
cash provided by operating activities:
Change in net assets $ 177,000 $ 110,000
Adjustments to reconcile change in net assets 
to net cash provided by operating activities: 
Increase in permanently restricted net assets (10,000) (6,000)
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Amortization of deferred financing charges 5,000 5,000
(Increase) decrease in: 
Accounts receivable (322,000) (150,000)
Other receivables (5,000) 4,000
Increase (decrease) in:
Accounts payable, accrued payroll, and 
vacation costs 163,000 38,000
Estimated third-party payor settlements 1,000 4,000
Net cash provided by operating activities $ 76,000 $ 41,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency
Notes to Financial Statements
Years Ended December 31, 20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies6
6 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Home Health Agency (the Agency) was incorporated in 20X0 in New 
State as a not-for-profit corporation. The Agency provides health and supportive services to 
individuals at their homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in 
the balance sheet. Investment income (including realized gains and losses on investments, interest and 
dividends) is included in excess of revenues over expenses unless restricted by donor or law. Unrealized 
gains and losses on investments, if any, are excluded from excess of revenues over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line 
method over the estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest 
method over the term of the related financing agreement.
Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor restriction 
expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, 
temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statement 
of operations as net assets released from restrictions. When long-lived assets are placed in service, 
thus satisfying purpose restrictions, the amount is included as a change in net assets, restricted and 
unrestricted. Donor-restricted contributions whose restrictions are met within the same year as 
received are reflected as unrestricted contributions in the accompanying financial statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless 
explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets 
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that 
must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor 
stipulations about how long those long-lived assets must be maintained, the Agency reports expira­
tions of donor restrictions when the donated or acquired long-lived assets are placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to 
pay. Such patients are identified based on financial information obtained from the patient and 
subsequent analysis. Since the Agency does not expect payment, estimated charges for charity 
care are not included in revenue.
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Income taxes. The Agency has been recognized by the Internal Revenue Service as a not-for- 
profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt 
from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over expenses. 
Changes in unrestricted net assets which are excluded from excess of revenue over expenses, consistent 
with industry practice, include unrealized gains and losses on investments other than trading 
securities, permanent transfers of assets to and from affiliates for other than goods and services, and 
contributions of long-lived assets (including assets acquired using contributions which by donor 
restriction were to be used for the purposes of acquiring such assets).
2. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
20X5 20X4
Charity care $ — $5,000
Purchase of equipment 9,000
$9,000 $5,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted 
purposes or by occurrence of other events specified by donors:
Charity care expenditures
20X5 20X4
$5,000 $ —
3. Permanently Restricted Net Assets
Permanently restricted net assets are restricted in perpetuity, the income from which is expend­
able to support:
20X5 20X4
Program A activities $10,000 $ —
Any activities of the Agency 80,000
$90,000
80,000
$80,000
4. Third-Party Rate Adjustments and Revenue
Approximately 38 percent in 20X5 and 37 percent in 20X4 of net patient service revenue was derived 
under federal and state third-party reimbursement programs. These revenues are based, in part, on 
cost reimbursement principles and are subject to audit and retroactive adjustment by the respective 
third-party fiscal intermediaries. Laws and regulations governing these programs are extremely 
complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded 
estimates will change by a material amount in the near term. The 20X5 net patient service revenue 
increased approximately $XXX due to removal of allowances previously estimated that are no longer 
necessary as a result of final settlements and years that are no longer subject to audits, reviews, and 
investigations. The 20X4 net patient service revenue decreased approximately $XXX due to prior-year 
retroactive adjustments in excess of amounts previously estimated.
5. Internally-Designated Assets
The Board of Directors has designated investments aggregating $100,000 to be used for future major 
capital improvements. Those assets are classified in the balance sheet as long-term investments.
FSP §11,500.22
164 Health Care Organizations
6. Long-Term Debt
Long-term debt at December 31, 20X5 and 20X4, is as follows:
20X5 20X4
Note payable to bank, interest at 15 percent, 
payable in monthly installments of $2,200 per 
month, including interest, collateralized by 
equipment with a depreciated cost of $42,000 
Less current maturities
$118,000 $131,000
13,000 13,000
$105,000 $118,000
Scheduled maturities of long-term debt at December 31, 20X5, are as follows:
Year ending December 31, Amount
20X6 $ 13,000
20X7 13,000
20X8 13,000
20X9 13,000
20Y0 13,000
Thereafter 53,000
Total $118,000
7. Classification of Expenses
Program_____________ General and
Total A B C Administrative
Expenses incurred for the 
year ended December 31, 
20X5, were for:
Salaries and benefits $2,714,000 $1,363,000 $699,000 $363,000 $289,000
Medical supplies and drugs 1,042,000 511,000 246,000 285,000
Insurance and other 90,000 58,000 32,000
Provision for bad debts 46,000 16,000 30,000
Depreciation 21,000 5,000 16,000
Interest 16,000 10,000 3,000 3,000
Total expenses $3,929,000 $1,963,000 $978,000 $648,000 $340,000
Expenses incurred for the
year ended December 31,
20X4, were for:
Salaries and benefits $1,835,000 $ 915,000 $463,000 $216,000 $241,000
Medical supplies and drugs 675,000 335,000 211,000 129,000
Insurance and other 83,000 64,000 19,000
Provision for bad debts 21,000 21,000
Depreciation 15,000 6,000 9,000
Interest 19,000 12,000 5,000 2,000
Total expenses $2,648,000 $1,353,000 $679,000 $345,000 $271,000
(The preparer of the financial statements may wish to include a brief description of the types of 
programs.)
8. Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 20X5 and 20X4, 
respectively.
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9. Risks and Uncertainties Disclosures||
10. Pension and Other Postretirement Benefit Plans||
11. Fair Value of Financial Statements||
12. Concentrations of Credit Risk||
13. Investments||
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the not-for-profit hospital and, therefore, are not repeated here.
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FOR A HEALTH MAINTENANCE ORGANIZATION
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Sample Not-for-Profit Health Maintenance Organization
Balance Sheets
June 30, 20X5 and 20X4
20X5 20X4
Assets
Current assets:
Cash and cash equivalents $2,937,000 $1,021,000
Premiums receivable, net of allowance for
doubtful accounts of $36,000 in 20X5
and $42,000 in 20X4 358,000 407,000
Other receivables 263,000 261,000
Supplies 190,000 184,000
Prepaid expenses 197,000 99,000
Total current assets 3,945,000 1,972,000
Property and equipment, net 5,756,000 5,626,000
State guaranty fund deposit 150,000 150,000
Debt issuance costs, net of accumulated
amortization of $42,000 in 20X5 and
$39,000 in 20X4 18,000 21,000
Total assets $9,869,000 $7,769,000
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank $ — $ 44,000
Current maturities of long-term debt 241,000 109,000
Accounts payable—medical services 2,245,000 1,471,000
Other accounts payable and accrued expenses 829,000 661,000
Unearned premium revenue 141,000 202,000
Total current liabilities 3,456,000 2,487,000
Long-term debt, less current maturities 4,295,000 2,382,000
Total liabilities 7,751,000 4,869,000
Net assets—unrestricted 2,118,000 2,900,000
Total liabilities and net assets $9,869,000 $7,769,000
See accompanying notes to financial statements.
FSP §11,500.23
Illustrative Financial Statements 167
.24
Sample Not-for-Profit Health Maintenance Organization 
Statements of Operations and Changes in Net Assets 
Years Ended June 30, 20X5 and 20X4
20X5 20X4
Revenue:
Premiums earned $27,682,000 $22,500,000
Coinsurance 689,000 500,000
Interest and other income 242,000 100,000
Total revenue 28,613,000 23,100,000
Expenses:
Salaries and benefits 16,154,000 13,328,000
Medical supplies and drugs 8,507,000 5,988,000
Insurance 3,963,000 2,463,000
Provision for bad debts 19,000 20,000
Depreciation 367,000 336,000
Interest 385,000 375,000
Total expenses 29,395,000 22,510,000
Operating income (loss) (782,000) 590,000
Net assets, beginning of year 2,900,000 2,310,000
Net assets, end of year $ 2,118,000 $ 2,900,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Health Maintenance Organization 
Statements of Cash Flows
Years Ended June 30, 20X5 and 20X4
20X5 20X4
Cash flows from operating activities:
Cash received from premiums, stop-loss
insurance recoveries, and coinsurance $28,969,000 $24,410,000
Cash paid to employees and to providers
of health care services (28,405,000) (22,818,000)
Interest and other income received 230,000 90,000
Interest paid (382,000) (372,000)
Net cash provided by operating activities 412,000 1,310,000
Cash flows from investing activities:
Capital expenditures (497,000) (121,000)
Net cash used in investing activities (497,000) (121,000)
Cash flows from financing activities:
Proceeds from long-term debt 2,300,000 —
Principal payments on long-term debt (255,000) (1,000,000)
Principal payments on note payable (44,000) —
Net cash provided by (used in)
financing activities 2,001,000 (1,000,000)
Net increase in cash and cash equivalents 1,916,000 189,000
Cash and cash equivalents, beginning of year 1,021,000 832,000
Cash and cash equivalents, end of year $ 2,937,000 $ 1,021,000
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets $ (782,000) $ 590,000
Adjustments to reconcile change in net assets to
net cash provided by operating activities:
Depreciation and amortization 370,000 339,000
Provision for bad debts 19,000 20,000
(Increase) decrease in:
Premiums receivables 30,000 64,000
Other current assets 230,000 (93,000)
Increase (decrease) in:
Accounts payable—medical services 774,000 335,000
Other accounts payable and accrued expenses (168,000) (60,000)
Unearned premium revenue (61,000) 115,000
Net cash provided by operating activities $ 412,000 $ 1,310,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Health Maintenance Organization
Notes to Financial Statements7
7 SOP 00-1 provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample 
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding 
third-party payments. SOP 00-1 is included in appendix E to the Guide.
8 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
June 30, 20X5 and 20X4
1. Organization
The Sample Health Maintenance Organization (the HMO) was incorporated in 20X0 in New 
State as a not-for-profit corporation for the purpose of providing comprehensive health care 
services on a prepaid basis and for the purpose of establishing and operating organized health 
maintenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title 
XIII of the Public Health Service Act.
2. Summary of Significant Accounting Policies8
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, 
first-out) or market.
Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs 
are charged to expense, and betterments are capitalized. Property and equipment costing approxi­
mately $700,000 was financed by health maintenance organization initial development grants 
received in 20X1 and 20X2 from the U.S. Department of Health and Human Services (HHS). This 
property will be owned by the HMO as long as the equipment and facilities are used for projects 
related to the objectives of the Public Health Service Act.
Depreciation is computed using the straight-line method over the estimated useful lives of the 
related assets as follows:
Building
Improvements
Data processing and laboratory
40 years
20-25 years
equipment and automobiles 
Medical equipment 
Office equipment
3-7 years
10 years
5-10 years
Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the 
effective interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for 
the provision of certain medical care services to its members. The HMO compensates these providers 
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on a capitation basis. As part of a cost control incentive program, the HMO retains up to 20 percent 
of the capitation as a risk-sharing fund. In the event of hospital utilization in excess of budget, 
those providers bear the risk to the extent of 15 percent of the capitation fee. Operating expenses 
include all amounts incurred by the HMO under the aforementioned contracts.
The cost of other health care services provided or contracted for is accrued in the period in which 
it is provided to a member based in part on estimates, including an accrual for medical services 
provided but not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the 
employer group or the HMO upon 30 days written notice. Premiums are due monthly and are 
recognized as revenue during the period in which the HMO is obligated to provide services to members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and 
reinsurance recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Sec. 501(c)(4) of the 
Internal Revenue Code; accordingly, no provision for federal income taxes has been made in the 
accompanying financial statements.
3. Property and Equipment
Property and equipment at June 30, 20X5 and 20X4, consists of the following:
20X5 20X4
Land $ 300,000 $ 300,000
Buildings and improvements 5,473,000 5,459,000
Furniture and equipment 1,786,000
7,559,000
1,303,000
7,062,000
Less accumulated depreciation (1,803,000)
$5,756,000
(1,436,000)
$5,626,000
4. Long-Term Debt
Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of 
long-term debt at June 30, 20X5 and 20X4, follows.
20X5 20X4
HHS loan, interest at 7.5 percent, 
payable in monthly installments 
of $50,000, including interest $2,020,000 $ 111,000
HHS loan, interest at 9.25 percent, 
payable in monthly installments 
of $10,000, including interest 1,658,000 1,694,000
Secured equipment loans, payable 
in monthly installments of $15,000, 
including interest 858,000 686,000
Less current maturities
4,536,000
241,000
2,491,000
109,000
$4,295,000 $2,382,000
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Scheduled principal payments on long-term debt are as follows:
Year ending December 31, Amount
20X6 $ 241,000
20X7 259,000
20X8 280,000
20X9 800,000
20Y0 2,956,000
$4,536,000
5. State Guarantee Fund Deposit
In August 20X4 the state in which the HMO is domiciled enacted legislation specifically 
governing HMOs. Under this legislation, the corporation is required to maintain a deposit of 
$150,000 with the director of the division of insurance of the state.
6. Employee Retirement Plan
The HMO has a contributory defined contribution retirement plan covering substantially all 
employees. Expense determined in accordance with the plan formula (4 percent to 10 percent of 
eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 20X5 and 
20X4, respectively.
7. Stop-Loss Insurance
The HMO entered into a stop-loss insurance agreement with an insurance company to limit its 
losses on individual claims. Under the terms of this agreement, the insurance company will 
reimburse the HMO approximately 25 percent of the cost of each member's annual hospital 
services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In 
the event the HMO ceases operations, (a) plan benefits will continue for members who are 
confined in an acute care hospital on the date of insolvency until their discharge, and (b) plan 
benefits will continue for any other member until the end of the contract period for which 
premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insur­
ance expense (Note 9) in 20X5 and 20X4, respectively. Approximately $600,000 and $400,000 in 
stop-loss insurance recoveries are deducted from insurance expense in 20X5 and 20X4, respec­
tively.
Included in other receivables is approximately $50,000 recoverable from insurers.
8. Malpractice Claims
Malpractice claims have been asserted against the HMO by various claimants. The claims are 
in various stages of processing, and some may ultimately be brought to trial. In the opinion of 
counsel, the outcome of these actions will not have a significant effect on the financial position or 
the operating income of the HMO. Incidents occurring through June 30, 20X5, may result in the 
assertion of additional claims. Other claims may be asserted arising from past services provided. 
Management believes that these claims, if asserted, would be settled within the limits of insurance 
coverage.
9. Classification of Expenses
20X5 20X4
Program activities 26,921,000 20,909,000
General and administrative 2,474,000
$29,395,000
1,601,000
$22,510,000
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10. Risks and Uncertainties Disclosures||
11. Pension and Other Postretirement Benefit Plans||
12. Fair Value of Financial Instruments||
13. Concentrations of Credit Risk||
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|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Ambulatory Care, Inc.
Balance Sheets
December 31, 20X5 and 20X4
20X5 20X4
Assets
Current assets:
Cash $ 65,000 $ 76,000
Patient accounts receivable, net of allowance for
doubtful accounts of $15,000 in 20X5 and
$5,000 in 20X4 290,000 278,000
Estimated retroactive adjustments—third-party payors 19,000 32,000
Accounts receivable—other 13,000 8,000
Supplies 21,000 18,000
Prepaid expenses and deposits 5,000 9,000
Total current assets 413,000 421,000
Property and equipment, at cost:
Land 100,000 100,000
Land improvements 322,000 322,000
Buildings 682,000 682,000
Equipment 1,390,000 1,389,000
2,494,000 2,493,000
Less accumulated depreciation 217,000 100,000
Property and equipment, net 2,277,000 2,393,000
Other assets:
Advances receivable 14,000 5,000
Total assets $2,704,000 $2,819,000
Liabilities and Net Assets
Current liabilities:
Notes payable $ 138,000 $ 144,000
Accounts payable 42,000 77,000
Accrued payroll, benefits, and taxes 33,000 22,000
Estimated retroactive adjustments—third-party payors 30,000 24,000
Financing advance from third-party payors — 1,000
Total current liabilities 243,000 268,000
Guarantee liability 10,000 10,000
Total liabilities 253,000 278,000
Net assets—unrestricted 2,451,000 2,541,000
Total liabilities and net assets $2,704,000 $2,819,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Operations and Changes in Net Assets 
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Revenue and gains:
Net patient service revenue $ 860,000 $ 357,000
Other 29,000 15,000
Total revenue and gains 889,000 372,000
Expenses:
Salaries and benefits 485,000 243,000
Medical supplies and drugs 189,000 66,000
Insurance 154,000 98,000
Provision for bad debts 14,000 4,000
Depreciation 117,000 100,000
Interest 20,000 18,000
Total expenses 979,000 529,000
Operating loss (90,000) (157,000)
Net assets, beginning of year 2,541,000 2,698,000
Net assets, end of year $2,451,000 $2,541,000
See accompanying notes to financial statements.
FSP §11,500.28
Illustrative Financial Statements 175
.29
Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Cash Flows 
Years Ended December 31, 20X5 and 20X4
20X5 20X4
Cash flows from operating activities:
Cash received from patients and third-party payors $866,000 $ 368,000
Cash received from others 21,000 6,000
Interest received 3,000 11,000
Interest paid (15,000) (16,000)
Cash paid to employees and suppliers (870,000) (432,000)
Net cash provided by (used in) operating activities 5,000 (63,000)
Cash flows from investing activities: 
Purchase of equipment (1,000) (4,000)
Advances made to XYZ Affiliate (9,000) (5,000)
Net cash used in investing activities (10,000) (9,000)
Cash flows from financing activities: 
Proceeds from notes payable 144,000
Payments on notes payable (6,000) —
Net cash provided by (used in) financing activities (6,000) 144,000
Net increase (decrease) in cash (11,000) 72,000
Cash, beginning of year 76,000 4,000
Cash, end of year $ 65,000 $ 76,000
Reconciliation of change in net assets 
to net cash provided by (used in) 
operating activities:
Change in net assets $(90,000) $(157,000)
Adjustments to reconcile change in net 
assets to net cash provided by (used in) 
operating activities:
Depreciation 117,000 100,000
Provision for bad debts 14,000 4,000
(Increase) decrease in:
Patient accounts receivable (12,000) (19,000)
Other current assets 1,000 (2,000)
Increase (decrease) in:
Accounts payable and accrued payroll, 
benefits, and taxes (24,000) 10,000
Other current liabilities (1,000) 1,000
Net cash provided by (used in) 
operating activities $ 5,000 $ (63,000)
See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc. 
Notes to Financial Statements
December 31, 20X5 and 20X4
1. Description of Organization and Summary of Significant Accounting Policies9
9 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, provides guidance on disclosures that should be included in the summary of significant accounting policies, including 
accounting policies for loans, trade receivables, and doubtful accounts.
Organization. Ambulatory Care, Inc. was incorporated on September 7, 20X3, in New State, to 
operate an ambulatory care health facility to treat or prevent injury and disease, to provide funds 
or to expend funds to further the treatment or prevention of injury or disease, and to develop and 
participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital— 
entered into a members' agreement to develop this ambulatory care center. In accordance with 
this agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambula­
tory Care, Inc. began operations in October 20X3.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method 
over the estimated Eves of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjust­
ments are accrued on an estimated basis in the period the related services are rendered. Net patient 
service revenue is adjusted as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are 
unable to pay. Such patients are identified and related charges are estimated, based on financial 
information obtained from the patient and subsequent analysis. Since management does not 
expect payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a 
not-for-profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and 
is exempt from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
2. Advances Receivable
In May 20X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates 
(XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge 
and bill each patient treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that 
XYZ will collect at least $18,000 per month during the term of this agreement. In any month in 
which XYZ does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to 
XYZ to cover the deficiency. Such advances are to be repaid to the extent XYZ's net cash 
collections exceed the minimum guarantee amount. Management estimates that the advances 
will be fully recovered in 20X8.
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3. Related-Party Transactions
During 20X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals 
(the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc. 
Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. 
The agreement with the managing hospital was to remain in effect through December 31, 20X5, 
but has been extended on a month-to-month basis.
In addition, during 20X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of 
promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 9 
percent in 20X5 and 20X4, respectively). Of the total $144,000 liability, $48,000 is payable on demand 
after November 28, 20X5, to one member hospital, with the remaining portion ($96,000) payable on 
demand after December 8, 20X5, to the other two member hospitals. During 20X5, Ambulatory Care, 
Inc. paid $2,000 to each member hospital, thereby reducing the obligation to $138,000.
4. Revenue From Contracting Agencies
Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, 
and County Indigent Plan patients. Reimbursement for covered services is based on tentative 
payment rates. Final reimbursement is determined after submission of annual cost reports and 
audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments 
are reported in the financial statements in the period that the services are rendered.
Revenue from the Medicare program accounted for approximately XX percent for the year 
ended 20X5, and XX percent for the year ended 20X4, of Ambulatory Care, Inc.'s net patient 
revenue. Laws and regulations governing the Medicare program are extremely complex and 
subject to interpretation. As a result, there is at least a reasonable possibility that recorded 
estimates will change by a material amount in the near term. The 20X5 net patient service 
revenue increased approximately $XXX due to removal of allowances previously estimated 
that are no longer necessary as a result of final settlements and years that are no longer subject 
to audits, reviews, and investigations. The 20X4 net patient service revenue decreased ap­
proximately $XXX due to prior-year retroactive adjustments in excess of amounts previously 
estimated.
5. Charity Care
Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emer­
gency situations. These services, which are excluded from revenues, amounted to $27,000 and 
$13,000 in 20X5 and 20X4, respectively, when measured at Ambulatory Care, Inc.'s established 
rates.
6. Classification of Expenses
Program
General and 
Total A B C Administrative
Expenses incurred for the
year ended December 31,
20X5, were for:
Salaries and benefits $485,000 $216,000 $102,000 $121,000 $46,000
Medical supplies and drugs 189,000 98,000 43,000 48,000 —
Insurance 154,000 79,000 45,000 14,000 16,000
Provision for bad debts 14,000 9,000 — 5,000 —
Depreciation 117,000 100,000 — 17,000 —
Interest 20,000 9,000 — — 11,000
Total expenses $979,000 $511,000 $190,000 $205,000 $73,000
(continued)
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Program
General and
Total A B C Administrative
Expenses incurred for the 
year ended December 31, 
20X4, were for:
Salaries and benefits $243,000 $111,000 $ 46,000 $ 57,000 $29,000
Medical supplies and drugs 66,000 31,000 15,000 20,000 —
Insurance 98,000 45,000 19,000 26,000 8,000
Provision for bad debts 4,000 — 4,000 — —
Depreciation 100,000 56,000 — 44,000 —
Interest 18,000 7,000 — — 11,000
Total expenses $529,000 $250,000 $ 84,000 $147,000 $48,000
(The preparer of the financial statements may wish to include a brief description of the types of 
programs.)
7. Risks and Uncertainties Disclosures||
8. Pension and Other Postretirement Benefit Plans||
9. Fair Value of Financial Instruments||
10. Concentrations of Credit Risk||
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|| The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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